US20040096402A1 - Delivery of aerosols containing small particles through an inhalation route - Google Patents

Delivery of aerosols containing small particles through an inhalation route Download PDF

Info

Publication number
US20040096402A1
US20040096402A1 US10/696,959 US69695903A US2004096402A1 US 20040096402 A1 US20040096402 A1 US 20040096402A1 US 69695903 A US69695903 A US 69695903A US 2004096402 A1 US2004096402 A1 US 2004096402A1
Authority
US
United States
Prior art keywords
compound
drug
particles
aerosol
gas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/696,959
Inventor
Craig Hodges
Peter Lloyd
Daniel Mufson
Daniel Rogers
Martin Wensley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexza Pharmaceuticals Inc
Original Assignee
Alexza Molecular Delivery Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexza Molecular Delivery Corp filed Critical Alexza Molecular Delivery Corp
Priority to US10/696,959 priority Critical patent/US20040096402A1/en
Publication of US20040096402A1 publication Critical patent/US20040096402A1/en
Assigned to ALEXZA PHARMACEUTICALS, INC. reassignment ALEXZA PHARMACEUTICALS, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: ALEXZA MOLECULAR DELIVERY CORPORATION
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/04Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
    • A61M11/041Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
    • A61M11/042Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters electrical
    • A61M11/044Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters electrical with electrodes immersed in the liquid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4468Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/001Particle size control
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10Preparation of respiratory gases or vapours
    • A61M16/1075Preparation of respiratory gases or vapours by influencing the temperature
    • A61M16/109Preparation of respiratory gases or vapours by influencing the temperature the humidifying liquid or the beneficial agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B05SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05BSPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B17/00Apparatus for spraying or atomising liquids or other fluent materials, not covered by the preceding groups
    • B05B17/04Apparatus for spraying or atomising liquids or other fluent materials, not covered by the preceding groups operating with special methods
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B05SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05BSPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B7/00Spraying apparatus for discharge of liquids or other fluent materials from two or more sources, e.g. of liquid and air, of powder and gas
    • B05B7/16Spraying apparatus for discharge of liquids or other fluent materials from two or more sources, e.g. of liquid and air, of powder and gas incorporating means for heating or cooling the material to be sprayed
    • B05B7/1686Spraying apparatus for discharge of liquids or other fluent materials from two or more sources, e.g. of liquid and air, of powder and gas incorporating means for heating or cooling the material to be sprayed involving vaporisation of the material to be sprayed or of an atomising-fluid-generating product
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/003Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
    • A61M2016/0033Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical
    • A61M2016/0039Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical in the inspiratory circuit
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/36General characteristics of the apparatus related to heating or cooling
    • A61M2205/3606General characteristics of the apparatus related to heating or cooling cooled
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/36General characteristics of the apparatus related to heating or cooling
    • A61M2205/3653General characteristics of the apparatus related to heating or cooling by Joule effect, i.e. electric resistance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/36General characteristics of the apparatus related to heating or cooling
    • A61M2205/368General characteristics of the apparatus related to heating or cooling by electromagnetic radiation, e.g. IR waves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/50General characteristics of the apparatus with microprocessors or computers

Definitions

  • the present invention relates to the inhalation delivery of aerosols containing small particles. Specifically, it relates to the delivery of drug containing aerosols having particles with a mass median aerodynamic diameter less than 1 ⁇ for inhalation therapy.
  • the present invention relates to the inhalation delivery of aerosols containing small particles. Specifically, it relates to the delivery of drug containing aerosols having particles with a mass median aerodynamic diameter less than 1 ⁇ for inhalation therapy.
  • the drug containing aerosol contains particles having a mass median aerodynamic diameter between 10 nm and 1 ⁇ .
  • the particles have a mass median aerodynamic diameter between 10 nm and 900 nm. More preferably, the particles have a mass median aerodynamic diameter between 10 nm and 800 nm, 10 nm and 700 nm, 10 nm and 600 nm, 10 nm and 500 nm, 10 nm and 400 nm, 10 nm and 300 nm, 10 nm and 200 nm, or 10 nm and 100 nm.
  • the particles comprise at least 5 percent by weight of drug.
  • the particles comprise at least 10 percent by weight of drug. More preferably, the particles comprise at least 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, 90 percent, 95 percent, 97 percent, 99 percent, 99.5 percent, or 99.97 percent by weight of drug.
  • At least 50 percent by weight of the aerosol is amorphous in form, wherein crystalline forms make up less than 50 percent by weight of the total aerosol weight, regardless of the nature of individual particles.
  • at least 75 percent by weight of the aerosol is amorphous in form. More preferably, at least 90 percent by weight of the aerosol is amorphous in form.
  • the aerosol comprises less than 10 percent by weight of drug degradation products.
  • the particles contain less than 5 percent of drug degradation products. More preferably, the particles contain less than 2.5, 1, 0.5, 0.1 or 0.03 percent by weight of drug degradation products.
  • the mass of the aerosol is at least 0.05 mg.
  • the mass of the aerosol is at least 0.10 mg. More preferably, the mass of the aerosol is at least 0.15 mg, 0.20 mg, or 0.25 mg.
  • the geometric standard deviation around the mass median aerodynamic diameter of the aerosol particles is less than 2.
  • the geometric standard deviation is less than 1.9. More preferably, the geometric standard deviation is less than 1.8, 1.7, 1.6 or 1.5.
  • the drug has a decomposition index less than 0.15.
  • the drug has a decomposition index less than 0.10. More preferably, the drug has a decomposition index less than 0.05.
  • the drug of the aerosol is of one of the following classes: antibiotics, anticonvulsants, antidepressants, antiemetics, antihistamines, antiparkisonian drugs, antipsychotics, anxiolytics, drugs for erectile dysfunction, drugs for migraine headaches, drugs for the treatment of alcoholism, drugs for the treatment of addiction, muscle relaxants, nonsteroidal anti-inflammatories, opioids, other analgesics and stimulants.
  • the drug is an antibiotic
  • it is selected from one of the following compounds: cefinetazole; cefazolin; cephalexin; cefoxitin; cephacetrile; cephaloglycin; cephaloridine; cephalosporins, such as cephalosporin C; cephalotin; cephamycins, such as cephamycin A, cephamycin B, and cephamycin C; cepharin; cephradine; ampicillin; amoxicillin; hetacillin; carfecillin; carindacillin; carbenicillin; amylpenicillin; azidocillin; benzylpenicillin; clometocillin; cloxacillin; cyclacillin; methicillin; nafcillin; 2-pentenylpenicillin; penicillins, such as penicillin N, penicillin O, penicillin S, penicillin V; chlorobutin penicillin; dicloxacillin; diphenicillin; heptylpenicillin
  • the drug is selected from one of the following compounds: gabapentin, tiagabine, and vigabatrin.
  • the drug is selected from one of the following compounds: amitriptyline, amoxapine, benmoxine, butriptyline, clomipramine, desipramine, dosulepin, doxepin, imipramine, kitanserin, lofepramine, medifoxamine, mianserin, maprotoline, mirtazapine, nortriptyline, protriptyline, trimipramine, viloxazine, citalopram, cotinine, duloxetine, fluoxetine, fluvoxamine, milnacipran, nisoxetine, paroxetine, reboxetine, sertraline, tianeptine, acetaphenazine, binedaline, brofaromine, cericlamine, clovoxamine, iproniazid, isocarboxazid, moclobemide, phenyhydrazine, phen
  • the drug is selected from one of the following compounds: alizapride, azasetron, benzquinamide, bromopride, buclizine, chlorpromazine, cinnarizine, clebopride, cyclizine, diphenhydramine, diphenidol, dolasetron methanesulfonate, droperidol, granisetron, hyoscine, lorazepam, metoclopramide, metopimazine, ondansetron, perphenazine, promethazine, prochlorperazine, scopolamine, triethylperazine, trifluoperazine, triflupromazine, trimethobenzamide, tropisetron, domeridone, and palonosetron.
  • alizapride alizapride, azasetron, benzquinamide, bromopride, buclizine, chlorpromazine, cinnarizine, clebopride,
  • the drug is an antihistamine
  • it is selected from one of the following compounds: azatadine, brompheniramine, chlorpheniramine, clemastine, cyproheptadine, dexmedetomidine, diphenhydramine, doxylamine, hydroxyzine, cetrizine, fexofenadine, loratidine, and promethazine.
  • the drug is an antiparkisonian drug
  • it is selected one of the following compounds: amantadine, baclofen, biperiden, benztropine, orphenadrine, procyclidine, trihexyphenidyl, levodopa, carbidopa, selegiline, deprenyl, andropinirole, apomorphine, benserazide, bromocriptine, budipine, cabergoline, dihydroergokryptine, eliprodil, eptastigmine, ergoline pramipexole, galanthamine, lazabemide, lisuride, mazindol, memantine, mofegiline, pergolike, pramipexole, propentofylline, rasagiline, remacemide, spheramine, terguride, entacapone, and tolcapone.
  • the drug is selected from one of the following compounds: acetophenazine, alizapride, amperozide, benperidol, benzquinamide, bromperidol, buramate, butaperazine, carphenazine, carpipramine, chlorpromazine, chlorprothixene, clocapramine, clomacran, clopenthixol, clospirazine, clothiapine, cyamemazine, droperidol, flupenthixol, fluphenazine, fluspirilene, haloperidol, mesoridazine, metofenazate, molindrone, penfluridol, pericyazine, perphenazine, pimozide, pipamerone, piperacetazine, pipotiazine, prochlorperazine, promazine, remoxipride, sert
  • the drug is selected from one of the following compounds: mecloqualone, medetomidine, metomidate, adinazolam, chlordiazepoxide, clobenzepam, flurazepam, lorazepam, loprazolam, midazolam, alpidem, alseroxlon, amphenidone, azacyclonol, bromisovalum, buspirone, calcium N-carboamoylaspartate, captodiamine, capuride, carbcloral, carbromal, chloral betaine, enciprazine, flesinoxan, ipsapiraone, lesopitron, loxapine, methaqualone, methprylon, propanolol, tandospirone, trazadone, zopiclone, and zolpidem.
  • the drug is a drug for erectile dysfunction
  • it is selected from one of the following compounds: cialis (IC351), sildenafil, vardenafil, apomorphine, apomorphine diacetate, phentolamine, and yohimbine.
  • the drug is selected from one of the following compounds: almotriptan, alperopride, codeine, dihydroergotamine, ergotamine, eletriptan, frovatriptan, isometheptene, lidocaine, lisuride, metoclopramide, naratriptan, oxycodone, propoxyphene, rizatriptan, sumatriptan, tolfenamic acid, zolmitriptan, amitriptyline, atenolol, clonidine, cyproheptadine, diltiazem, doxepin, fluoxetine, lisinopril, methysergide, metoprolol, nadolol, nortriptyline, paroxetine, pizotifen, pizotyline, propanolol, protriptyline, sertraline,
  • the drug is a drug for the treatment of alcoholism
  • it is selected from one of the following compounds: naloxone, naltrexone, and disulfiram.
  • the drug is a drug for the treatment of addiction it is buprenorphine.
  • the drug is a muscle relaxant
  • it is selected from one of the following compounds: baclofen, cyclobenzaprine, orphenadrine, quinine, and tizanidine.
  • the drug is selected from one of the following compounds: aceclofenac, alminoprofen, amfenac, aminopropylon, amixetrine, benoxaprofen, bromfenac, bufexamac, carprofen, choline, salicylate, cinchophen, cinmetacin, clopriac, clometacin, diclofenac, etodolac, indoprofen, mazipredone, meclofenamate, piroxicam, pirprofen, and tolfenamate.
  • the drug is an opioid
  • it is selected from one of the following compounds: alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, carbiphene, cipramadol, clonitazene, codeine, dextromoramide, dextropropoxyphene, diamorphine, dihydrocodeine, diphenoxylate, dipipanone, fentanyl, hydromorphone, L-alpha acetyl methadol, lofentanil, levorphanol, meperidine, methadone, meptazinol, metopon, morphine, nalbuphine, nalorphine, oxycodone, papaveretum, pethidine, pentazocine, phenazocine, remifentanil, sufentanil, and tramadol.
  • the drug is an other analgesic it is selected from one of the following compounds: apazone, benzpiperylon, benzydramine, caffeine, clonixin, ethoheptazine, flupirtine, nefopam, orphenadrine, propacetamol, and propoxyphene.
  • the drug is a stimulant
  • it is selected from one of the following compounds: amphetamine, brucine, caffeine, dexfenfluramine, dextroamphetamine, ephedrine, fenfluramine, mazindol, methyphenidate, pemoline, phentermine, and sibutramine.
  • FIG. 1 is a schematic diagram of the overall system for conducting experiments using a laboratory example of a device of the present invention
  • FIG. 2 is a top, right end and front perspective view of the example depicted in FIG. 1;
  • FIG. 3 is a partial cross-sectional and partial schematic side view of the example shown in FIG. 2;
  • FIG. 4 is a partial cross-sectional and partial schematic end view of the example shown in FIG. 2;
  • FIG. 5 is a partial cross-sectional and partial schematic top view of the example shown in FIG. 2;
  • FIG. 6 is a schematic cross-sectional side view of an alternate example of the device of the present invention using an annunciating device
  • FIG. 7 is a top, left end and front perspective views of the removable sub-assembly containing the compound and a movable slide of the example shown in FIG. 2 showing the sub-assembly being mounted within the slide;
  • FIG. 8 is a schematic view of the heating element of the example shown in FIG. 2 showing the electric drive circuit
  • FIG. 9 is a schematic side view of a second example of the present invention using a venturi tube
  • FIG. 10 is a schematic side view of a fourth example of the present invention using a thin-walled tube coated with the compound;
  • FIG. 11 is a schematic side end view of the example shown in FIG. 10;
  • FIG. 12 is a schematic side end view of the example shown in FIG. 10 showing an inductive heating system generating an alternating magnetic field;
  • FIG. 13 is a schematic side view of an alternate example of that shown in FIG. 10 using a flow restrictor within the thin-walled tube;
  • FIG. 14 is a schematic side view of a fifth example of the present invention using an expandable container for the compound
  • FIG. 15 is a schematic side view of a sixth example of the present invention using a container for the compound in an inert atmosphere;
  • FIG. 16 is a schematic side view of the example shown in FIG. 15 using a recirculation of the inert atmosphere over the compound's surface;
  • FIG. 17 is a schematic side view of a seventh example of the present invention using a tube containing particles coated with the compound
  • FIG. 18 is a schematic side view of the example shown in FIG. 17 using a heating system to heat the gas passing over the coated particles;
  • FIG. 19 is a schematic side view of an eighth example of the present invention referred to herein as the “oven device”;
  • FIG. 20 is a schematic side view of an ninth example of the present invention using gradient heating
  • FIG. 21 is a schematic side view of a tenth example of the present invention using a fine mesh screen coated with the compound
  • FIG. 22 is a top, right end and front perspective view of the example shown in FIG. 21;
  • FIG. 23 is a plot of the rate of aggregation of smaller particles into larger ones
  • FIG. 24 is a plot of the coagulation coefficient (K) versus particle size of the compound
  • FIG. 25 is a plot of vapor pressure of various compounds, e.g., diphenyl ether, hexadecane, geranyl formate and caproic acid, versus temperature;
  • FIG. 26 is a plot of blood levels for both the IV dose and the inhalation dose administered to various dogs during the experiments using the system shown in FIG. 1;
  • FIG. 27 is a plot of calculated and experimental mass median diameter (MMD) versus compound mass in the range of 10 to 310 ⁇ g;
  • FIG. 28 is a plot of calculated and experimental MMD versus compound mass in the range of 10 to 310 ⁇ g.
  • FIG. 29 is a plot of the theoretical size (diameter) of an aerosol as a function of the ratio of the vaporized compound to the volume of the mixing gas.
  • “Aerodynamic diameter” of a given particle refers to the diameter of a spherical droplet with a density of 1 g/mL (the density of water) that has the same settling velocity as the given particle.
  • “Aerosol” refers to a suspension of solid or liquid particles in a gas.
  • Amorphous particle refers to a particle that does not contain more than 50 percent by weight of a crystalline form. Preferably, the particle does not contain more than 25 percent of a crystalline form. More preferably, the particle does not contain more than 10 percent of a crystalline form.
  • composition index refers to a number derived from an assay described in Example 7. The number is determined by substracting the percent purity of the generated aerosol from 1.
  • Drug refers to any chemical compound that is used in the prevention, diagnosis, treatment, or cure of disease, for the relief of pain, or to control or improve any physiological or pathological disorder in humans or animals. Such compounds are oftentimes listed in the Physician's Desk Reference (Medical Economics Company, Inc. at Montvale, N.J., 56 th edition, 2002), which is herein incorporated by reference.
  • Exemplary drugs include the following: cannabanoid extracts from cannabis, THC, ketorolac, fentanyl, morphine, testosterone, ibuprofen, codeine, nicotine, Vitamin A, Vitamin E acetate, Vitamin E, nitroglycerin, pilocarpine, mescaline, testosterone enanthate, menthol, phencaramkde, methsuximide, eptastigmine, promethazine, procaine, retinol, lidocaine, trimeprazine, isosorbide dinitrate, timolol, methyprylon, etamiphyllin, propoxyphene, salmetrol, vitamin E succinate, methadone, oxprenolol, isoproterenol bitartrate, etaqualone, Vitamin D3, ethambutol, ritodrine, omoconazole, cocaine, lomustine, ketamine, ketoprofen
  • the drug of the composition is of one of the following classes: antibiotics, anticonvulsants, antidepressants, antiemetics, antihistamines, antiparkisonian drugs, antipsychotics, anxiolytics, drugs for erectile dysfunction, drugs for migraine headaches, drugs for the treatment of alcoholism, drugs for the treatment of addiction, muscle relaxants, nonsteroidal anti-inflammatories, opioids, other analgesics, cannabanoids, and stimulants.
  • antibiotics antibiotics, anticonvulsants, antidepressants, antiemetics, antihistamines, antiparkisonian drugs, antipsychotics, anxiolytics, drugs for erectile dysfunction, drugs for migraine headaches, drugs for the treatment of alcoholism, drugs for the treatment of addiction, muscle relaxants, nonsteroidal anti-inflammatories, opioids, other analgesics, cannabanoids, and stimulants.
  • the drug is an antibiotic
  • it is selected from one of the following compounds: cefinetazole; cefazolin; cephalexin; cefoxitin; cephacetrile; cephaloglycin; cephaloridine; cephalosporins, such as cephalosporin C; cephalotin; cephamycins, such as cephamycin A, cephamycin B, and cephamycin C; cepharin; cephradine; ampicillin; amoxicillin; hetacillin; carfecillin; carindacillin; carbenicillin; amylpenicillin; azidocillin; benzylpenicillin; clometocillin; cloxacillin; cyclacillin; methicillin; nafcillin; 2-pentenylpenicillin; penicillins, such as penicillin N, penicillin O, penicillin S, penicillin V; chlorobutin penicillin; dicloxacillin; diphenicillin; heptylpenicillin
  • the drug is selected from one of the following compounds: gabapentin, tiagabine, and vigabatrin.
  • the drug is selected from one of the following compounds: amitriptyline, amoxapine, benmoxine, butriptyline, clomipramine, desipramine, dosulepin, doxepin, imipramine, kitanserin, lofepramine, medifoxamine, mianserin, maprotoline, mirtazapine, nortriptyline, protriptyline, trimipramine, viloxazine, citalopram, cotinine, duloxetine, fluoxetine, fluvoxamine, milnacipran, nisoxetine, paroxetine, reboxetine, sertraline, tianeptine, acetaphenazine, binedaline, brofaromine, cericlamine, clovoxamine, iproniazid, isocarboxazid, moclobemide, phenyhydrazine, phen
  • the drug is selected from one of the following compounds: alizapride, azasetron, benzquinamide, bromopride, buclizine, chlorpromazine, cinnarizine, clebopride, cyclizine, diphenhydramine, diphenidol, dolasetron methanesulfonate, dronabinol, droperidol, granisetron, hyoscine, lorazepam, metoclopramide, metopimazine, ondansetron, perphenazine, promethazine, prochlorperazine, scopolamine, triethylperazine, trifluoperazine, triflupromazine, trimethobenzamide, tropisetron, domeridone, and palonosetron.
  • alizapride alizapride, azasetron, benzquinamide, bromopride, buclizine, chlorpromazine, cinnarizine,
  • the drug is an antihistamine
  • it is selected from one of the following compounds: azatadine, brompheniramine, chlorpheniramine, clemastine, cyproheptadine, dexmedetomidine, diphenhydramine, doxylamine, hydroxyzine, cetrizine, fexofenadine, loratidine, and promethazine.
  • the drug is an antiparkisonian drug
  • it is selected one of the following compounds: amantadine, baclofen, biperiden, benztropine, orphenadrine, procyclidine, trihexyphenidyl, levodopa, carbidopa, selegiline, deprenyl, andropinirole, apomorphine, benserazide, bromocriptine, budipine, cabergoline, dihydroergokryptine, eliprodil, eptastigmine, ergoline pramipexole, galanthamine, lazabemide, lisuride, mazindol, memantine, mofegiline, pergolike, pramipexole, propentofylline, rasagiline, remacemide, spheramine, terguride, entacapone, and tolcapone.
  • the drug is selected from one of the following compounds: acetophenazine, alizapride, amperozide, benperidol, benzquinamide, bromperidol, buramate, butaperazine, carphenazine, carpipramine, chlorpromazine, chlorprothixene, clocapramine, clomacran, clopenthixol, clospirazine, clothiapine, cyamemazine, droperidol, flupenthixol, fluphenazine, fluspirilene, haloperidol, mesoridazine, metofenazate, molindrone, penfluridol, pericyazine, perphenazine, pimozide, pipamerone, piperacetazine, pipotiazine, prochlorperazine, promazine, remoxipride, sert
  • the drug is selected from one of the following compounds: mecloqualone, medetomidine, metomidate, adinazolam, chlordiazepoxide, clobenzepam, flurazepam, lorazepam, loprazolam, midazolam, alpidem, alseroxlon, amphenidone, azacyclonol, bromisovalum, buspirone, calcium N-carboamoylaspartate, captodiamine, capuride, carbcloral, carbromal, chloral betaine, enciprazine, flesinoxan, ipsapiraone, lesopitron, loxapine, methaqualone, methprylon, propanolol, tandospirone, trazadone, zopiclone, and zolpidem.
  • the drug is a drug for erectile dysfunction
  • it is selected from one of the following compounds: cialis (IC351), sildenafil, vardenafil, apomorphine, apomorphine diacetate, phentolamine, and yohimbine.
  • the drug is selected from one of the following compounds: almotriptan, alperopride, codeine, dihydroergotamine, ergotamine, eletriptan, frovatriptan, isometheptene, lidocaine, lisuride, metoclopramide, naratriptan, oxycodone, propoxyphene, rizatriptan, sumatriptan, tolfenamic acid, zolmitriptan, amitriptyline, atenolol, clonidine, cyproheptadine, diltiazem, doxepin, fluoxetine, lisinopril, methysergide, metoprolol, nadolol, nortriptyline, paroxetine, pizotifen, pizotyline, propanolol, protriptyline, sertraline,
  • the drug is a drug for the treatment of alcoholism
  • it is selected from one of the following compounds: naloxone, naltrexone, and disulfiram.
  • the drug is a drug for the treatment of addiction it is buprenorphine.
  • the drug is a muscle relaxant
  • it is selected from one of the following compounds: baclofen, cyclobenzaprine, orphenadrine, quinine, and tizanidine.
  • the drug is selected from one of the following compounds: aceclofenac, alminoprofen, amfenac, aminopropylon, amixetrine, benoxaprofen, bromfenac, bufexamac, carprofen, choline, salicylate, cinchophen, cinmetacin, clopriac, clometacin, diclofenac, etodolac, indoprofen, mazipredone, meclofenamate, piroxicam, pirprofen, and tolfenamate.
  • the drug is an opioid
  • it is selected from one of the following compounds: alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, carbiphene, cipramadol, clonitazene, codeine, dextromoramide, dextropropoxyphene, diamorphine, dihydrocodeine, diphenoxylate, dipipanone, fentanyl, hydromorphone, L-alpha acetyl methadol, lofentanil, levorphanol, meperidine, methadone, meptazinol, metopon, morphine, nalbuphine, nalorphine, oxycodone, papaveretum, pethidine, pentazocine, phenazocine, remifentanil, sufentanil, and tramadol.
  • the drug is an other analgesic it is selected from one of the following compounds: apazone, benzpiperylon, benzydramine, caffeine, clonixin, ethoheptazine, flupirtine, nefopam, orphenadrine, propacetamol, and propoxyphene.
  • the drug is a cannabanoid
  • it is tetrahydrocannabinol (e.g., delta-8 or delta-9).
  • the drug is selected from one of the following compounds: amphetamine, brucine, caffeine, dexfenfluramine, dextroamphetamine, ephedrine, fenfluramine, mazindol, methyphenidate, pemoline, phentermine, and sibutramine.
  • Drug degradation product refers to a compound resulting from a chemical modification of a drug.
  • the modification for example, can be the result of a thermally or photochemically induced reaction. Such reactions include, without limitation, oxidation and hydrolysis.
  • Mass median aerodynamic diameter or “MMAD” of an aerosol refers to the aerodynamic diameter for which half the particulate mass of the aerosol is contributed by particles with an aerodynamic diameter larger than the MMAD and half by particles with an aerodynamic diameter smaller than the MMAD.
  • “Stable aerosol” refers to an aerosol where the MMAD of its constituent particles does not vary by more than 50% over a set period of time.
  • an aerosol with an MMAD of 100 nm is stable over 1 s, if at a time 1 second later it has an MMAD between 50 nm and 150 nm.
  • the MMAD does not vary by more than 25% over a set period of time. More preferably, the MMAD does not vary by more than 20%, 15%, 10% or 5% over time.
  • Example 1 is described in terms of an in vivo dog experiment. The example, however, is easily modified to suit human inhalation primarily through increasing airflow through it.
  • FIGS. 1 - 8 a first example (1) of an aerosolization device of the present invention will be described.
  • the device 1 as shown in FIG. 1 is operably connected to flow meter 4 (e.g., a TSI 4100 flow meter).
  • the readings from flow meter 4 are fed to the electronics within chassis 8 shown in FIG. 2.
  • Flow meter 4 is shown in FIG. 1 within a dotted line to indicate housing 10 .
  • Device controller 20 includes Chembook model # N30W laptop computer having actuator switch 22 (FIG. 3) and National Instruments I/O Board (model #SC2345) (not shown) that interfaces with computer 20 to control device 1 and to control the recording of all data collected during the experiments.
  • a software program to carry out these functions was developed using National Instruments' Labview software program.
  • connection between device 1 and the I/O board is accomplished with a cable (e.g., DB25, not shown).
  • a standard power supply e.g., Condor F15-15-A+ not shown
  • Controller 30 is used to control the rate and volume of inhalation through device 1 into an anesthetized dog through an endotracheal tube 34 .
  • Controller 30 has a programmable breath hold delay, at the end of which, exhaust valve 40 in exhaust line 42 opens and the dog is allowed to exhale.
  • Filter 50 in line 42 measures the amount of exhaust and its composition to monitor any exhaled drug.
  • the source air through inlet line 54 , inlet valve 58 , flow meter 4 and inlet orifice 59 is from a compressed air cylinder (not shown).
  • a dose of compound 60 is deposited onto thin, stainless steel foil 64 so that the thickness of compound 60 is less than 10 microns.
  • compound 60 is deposited by making a solution of the compound with an organic solvent. This mixture is then applied to the foil substrate with an automated pump system. As shown, the size of the entire foil 64 (e.g., alloy of 302 or 304 with 0.004 in. thickness) is 0.7 by 2.9 inches and the area in which compound 60 is deposited is 0.35 by 1.6 inches.
  • Other foil materials can be used but stainless steel has an advantage over other materials like aluminum in that it has a much lower thermal conductivity value, while not appreciably increasing the thermal mass.
  • a low thermal conductivity is helpful because the heat generated in foil 64 should stay in the area of interest (i.e., the heating/vaporization zone 70 ).
  • Foil 64 should have a constant cross section, because otherwise the electrical currents induced by the heater will not be uniform.
  • Foil 64 is held in frame 68 , made so that the trailing edge of foil 64 has no lip on movable slide 78 and so compound 60 , once mixed with the air, is free in a downstream direction as indicated by arrow 127 of FIG. 3.
  • Frame 68 is typically made of a non-conductive material to withstand moderate heat (e.g., 200° C.) and to be non-chemically reactive with the compound (e.g., DELRIN AF®, a copolymer of acetal and TEFLON®).
  • moderate heat e.g. 200° C.
  • compound e.g., DELRIN AF®, a copolymer of acetal and TEFLON®
  • Sub-assembly 80 shown in FIG. 7, consists of frame 68 having compound ( 60 ) coated foil 64 mounted therein. Sub-assembly 80 is secured within movable slide 78 by setting each of the downstream, tapered ends of frame 68 to abut against small rods 86 protruding from each downstream end of slide 78 , as shown in FIG. 7. Slide 78 is driven by stepper motor 88 , shown in FIG. 3, that moves sub-assembly 80 containing compound 60 along the longitudinal axis of example 1. This, in turn, moves stainless steel foil 64 through an alternating magnetic field. (It is preferable for the magnetic field to be confined within heating/vaporization zone 70 , shown in FIG.
  • Ferrite toroid 90 is used to direct the magnetic field and is placed below foil 64 (e.g., approximately 0.05 inches below). As shown in FIG. 5, heated area 70 is approximately 0.15 by 0.4 inches, with the smaller dimension along the direction of travel from left to right (i.e., from the upstream to the downstream ends of device 1 ) and the large dimension across the direction of travel (i.e., the width of device 1 ).
  • Foil 64 functions as both a substrate for the drug to be delivered to the subject and the heating element for the vaporization of the drug.
  • Heating element 64 is heated primarily by eddy currents induced by an alternating magnetic field.
  • the alternating magnetic field is produced in ferrite toroid 90 (e.g., from Fair-Rite Company) with slit 94 (e.g., 0.10 in. wide), which was wrapped with coil 98 of copper magnet wire.
  • slit 94 e.g. 0.10 in. wide
  • a magnetic field fills the gap formed by slit 94 and magnetic field fringe lines 100 , shown in FIGS. 5 and 6, extend out from toroid 90 .
  • the magnetic field line fringe lines 100 intersect heating element 64 .
  • the alternating frequency of the field is limited to below 1 MHz. In this device, a frequency between 100 and 300 kHz is typically used.
  • Slide 78 and its contents are housed in airway 102 made up of upper airway section 104 and lower airway section 108 shown in FIG. 3.
  • Upper airway section 104 is removable and allows the insertion of movable slide 78 , sub-assembly 80 and foil 64 .
  • Lower airway section 108 is mounted on top of chassis 8 that houses the electronics (not shown), magnetic field generator 110 , stepper motor 88 and position sensors (not shown).
  • mounted in upper airway section 104 is upstream passage 120 and inlet orifice 59 that couples upper airway section 104 to flow meter 4 . The readings from the flow meter 4 are fed to the electronics housed in chassis 8 .
  • outlet 124 is connected to mouthpiece 126 .
  • a pyrometer at the end of TC2 line 130 is located within airway 102 and is used to measure the temperature of foil 64 . Because of the specific geometry of the example shown in FIGS. 1 - 7 , the temperature reading of foil 64 is taken after heating zone 70 . Calibration of the thermal decay between heating zone 70 and the measurement area is required. Temperature data is collected and used for quality control and verification and not to control any heating parameters.
  • a second temperature sensor is located at the end of TC1 line 132 in outlet 124 and is used to monitor the temperature of the air delivered to the dog.
  • removable block 140 mounted on upper airway section 104 , restricts a cross-sectional area of airway 102 and provides a specific mixing geometry therein.
  • airway 140 lowers the roof of upper airway section 104 (e.g., to within 0.04 inch of) with respect to foil 64 .
  • block 140 contains baffles (e.g., 31 steel rods 0.04 in. in diameter, not shown). The rods are oriented perpendicular to the foil and extend from the top of upper airway section 104 to within a small distance of the foil (e.g., 0.004 in.). The rods are placed in a staggered pattern and have sharp, squared off ends, which cause turbulence as air passes around them. This turbulance assures complete mixing of vaporized compounds with air passing through the device.
  • venturi tube 152 within housing 10 having inlet 154 , outlet 156 includes a throat 158 between inlet 154 and outlet 156 , which is used to restrict the gas flow through venturi tube 152 .
  • a controller 160 is designed to control the flow of air passing through a valve 164 based on readings from the thermocouple 168 of the temperature of the air, which can be controlled by heater 166 .
  • Block 140 is located directly over heating zone 70 and creates a heating/vaporization/mixing zone. Prior to commencing aerosol generation, slide 78 is in the downstream position. Slide 78 , with its contents, is then drawn upstream into this heating/vaporization/mixing zone 70 as energy is applied to foil 64 through the inductive heater system described in detail below.
  • FIG. 6 is a schematic diagram illustrating a third example of a hand held aerosolization device 180 of the present invention. As shown, device 180 includes many of the components of device 150 , discussed above, and additionally includes an annunciating device 170 .
  • a signal from annunciating device 170 would alert the patient to adjust the inhalation rate to the desired range.
  • controller 160 would be connected to annunciating device 170 to send the necessary signal that the flow rate was not within the desired range.
  • the induction drive circuit 190 shown in FIG. 8 is used to drive the induction-heating element of device 1 .
  • the purpose of circuit 190 is to produce an alternating current in drive coil 98 wrapped around ferrite core 90 .
  • Circuit 190 consists of two P-channel transistors 200 and two N-channel MOSFET transistors 202 arranged in a bridge configuration. MOSFET transistors 200 and 202 connected to clock pulse generator 219 are turned on and off in pairs by D-type flip-flop 208 through MOSFET transistor drive circuit 210 .
  • D-type flip-flop 208 is wired to cause the Q output of the flip-flop to alternately change state with the rising edge of the clock generation signal.
  • One pair of MOSFET transistors 200 is connected to the Q output on D-type flip-flop 208 and the other pair, 202 , is connected to the Q-not output of flip-flop 208 .
  • Q is high (5 Volts)
  • a low impedance connection is made between the D.C. power supply (not shown) and the series combination of drive coil 98 and the capacitor through the pair of MOSFET transistors 200 controlled by the Q output.
  • D-type flip-flop 208 changes state and Q-not is high, the low impedance connection from the power supply to the series combination drive coil 98 and capacitor 220 is reversed. Since flip-flop 208 changes state on the rising edge of the clock generation signal, two flip-flop changes are required for one complete drive cycle of the induction-heating element.
  • the clock generation signal is typically set at twice the resonant frequency of the series combination of drive coil 90 and capacitor 220 .
  • the clock signal frequency can be manually or automatically set.
  • venturi tube 152 within housing 10 having inlet 154 , outlet 156 and throat 158 between inlet 154 and outlet 156 is used to restrict the gas flow through venturi tube 152 .
  • Controller 160 is designed to control the flow of air passing through valve 164 based on readings from the thermocouple 168 of the temperature of the air as a result of heater 166 .
  • a fourth example ( 300 ) of an aerosolization device of the present invention will be described in reference to FIGS. 10 and 11.
  • a gas stream is passed into thin walled tube 302 having a coating ( 310 ) of compound 60 on its inside.
  • the flow rate of the gas stream is controlled by valve 314 .
  • the device of example 300 allows for rapid heat-up using a resistive heating system ( 320 ) while controlling the flow direction of vaporized compound.
  • the carrier gas e.g., air, N 2 and the like
  • FIG. 12 shows an alternative heating system to resistive heating system 320 used in connection with the fourth example.
  • inductive heating system 350 consists of a plurality of ferrites 360 for conducting the magnetic flux to vaporize compound 310 .
  • FIG. 13 shows a variation on the fourth example in which flow restrictor 370 is mounted within thin-walled tube 302 by means of support 374 within a housing (not shown) to increase the flow of mixing gas across the surface of compound 310 .
  • a fifth example 400 of an aerosolization device of the present invention will be described in reference to FIG. 14.
  • compound 60 is placed within expandable container 402 (e.g., a foil pouch) and is heated by resistance heater 406 , which is activated by actuator 410 as shown in FIG. 14.
  • the vaporized compound generated is forced into container 420 through outlet passage 440 and mixed with the gas flowing through tube 404 .
  • Additional steps are taken, when necessary, to preclude or retard decomposition of compound 60 .
  • One such step is the removal or reduction of oxygen around 60 during the heat up period. This can be accomplished, for example, by sealing the small container housing in an inert atmosphere.
  • a sixth example 500 of an aerosolization device of the present invention will be described in reference to FIG. 15.
  • Compound 60 is placed in an inert atmosphere or under a vacuum in container 502 within housing 10 and is heated by resistance heater 504 upon being activated by actuator 508 as shown in FIG. 15. Once compound 60 has become vaporized it can then be ejected through outlet passage 510 into the air stream passing through tube 520 .
  • FIG. 16 shows a variation of device 500 in which fan 530 recirculates the inert atmosphere over the surface of compound 60 .
  • the inert gas from a compressed gas cylinder (not shown) enters through inlet 540 and one-way valve 550 and exits through outlet passage 510 into tube 502 .
  • a seventh example ( 600 ) of an aerosolization device of the present invention will be described in reference to FIG. 17.
  • a compound (not shown), such as compound 60 discussed above, is deposited onto a substrate in the form of discrete particles 602 (e.g., aluminum oxide (alumina), silica, coated silica, carbon, graphite, diatomaceous earth, and other packing materials commonly used in gas chromatography).
  • the coated particles are placed within first tube 604 , sandwiched between filters 606 and 608 , and heated by resistance heater 610 , which is activated by actuator 620 .
  • the resulting vapor from tube 604 is combined with the air or other gas passing through second tube 625 .
  • FIG. 18 shows a variation of device 600 in which resistance heater 630 heats the air prior to passing through first tube 604 and over discrete particles 602 .
  • An eighth example 700 of an aerosolization device of the present invention will be described in reference to FIG. 19.
  • Compound 60 is deposited into chamber 710 and is heated by resistance heater 715 , which is activated by actuator 720 .
  • some of compound 60 is vaporized and ejected from chamber 710 by passing an inert gas entering housing 10 through inert gas inlet 725 and valve 728 across the surface of the compound.
  • the mixture of inert gas and vaporized compound passes through passage 730 and is then mixed with a gas passing through tube 735 .
  • a ninth example 800 of an aerosolization device of the present invention will be described in reference to FIG. 20.
  • Thermally conductive substrate 802 is heated by resistance heater 810 at the upstream end of tube 820 , and the thermal energy is allowed to travel along substrate 802 . This produces, when observed in a particular location, a heat up rate that is determined from the characteristics of the thermally conductive substrate. By varying the material and its cross sectional area, it was possible to control the rate of heat up.
  • the resistive heater is embedded in substrate 802 at one end. However, it could be embedded into both ends, or in a variety of positions along the substrate and still allow the temperature gradient to move along the carrier and/or substrate.
  • a tenth example 900 of an aerosolization device of the present invention will be described in reference to FIGS. 21 and 22.
  • Air is channeled through a fine mesh metal screen 902 on which drug is deposited.
  • Screen 902 is positioned across airway passage 910 (e.g., constructed from 18 mm glass tubing).
  • the two sides of the screen are electrically connected to charged capacitor 920 through silicon-controlled rectifier (SCR) 922 to make a circuit.
  • SCR silicon-controlled rectifier
  • the device of the present invention utilizes a flow of gas (e.g., air) across the surface of a compound ( 60 ) to sweep away vaporized molecules.
  • This process drives vaporization as opposed to condensation and therefore enables aerosol formation at relatively moderate temperatures.
  • Nicotine (1 mg, bp 247° C./745 mm), for example, vaporized in less than 2 s at about 130° C. in a device of the present invention.
  • fentanyl (bp>300° C./760 mm) was vaporized around 190° C. in quantities up to 2 mg.
  • Purity of an aerosol produced using a device of the present invention is enhanced by limiting the time during which a compound ( 60 ) is exposed to elevated temperatures. This is accomplished by rapidly heating a thin film of the compound to vaporize it. The vapors are then immediately cooled upon entry into a carrier gas stream.
  • compound 60 is subjected to a temperature rise of at least 1,000° C./second. In certain cases, the compound is subjected to a temperature rise of at least 2,000° C./second, 5,000° C./second, 7,500° C. or 10,000° C./second. A rapid temperature rise within the compound is facilitated when it is coated as a thin film (e.g., between 10 ⁇ and 10 nm in thickness). The compound is oftentimes coated as a film between 5 ⁇ and 10 nm, 4 ⁇ and 10 nm, 3 ⁇ and 10 nm, 2 ⁇ and 10 nm, or even 1 ⁇ to 10 nm in thickness.
  • a thin film e.g., between 10 ⁇ and 10 nm in thickness.
  • the compound is oftentimes coated as a film between 5 ⁇ and 10 nm, 4 ⁇ and 10 nm, 3 ⁇ and 10 nm, 2 ⁇ and 10 nm, or even 1 ⁇ to 10 nm in thickness.
  • Rapid temperature rises and thin coatings ensure that compounds are substantially vaporized in a short time.
  • greater than 0.1 mg, 0.25 mg, 0.5 mg, 0.75 mg or 1 mg of a compound is vaporized in less than 100 milliseconds from the start of heating.
  • the same amount of compound is vaporized in less than 75 milliseconds, 50 milliseconds, 25 milliseconds, or 10 milliseconds from the start of heating.
  • Examples of compounds that have benefited from rapid heating in a device of the present invention include lipophilic substance #87 and fentanyl.
  • Lipophilic substance #87 decomposed by more than 90% when heated at 425° C. for 5 minutes, but only 20% when the temperature was lowered to 350° C. Decomposition of the substance was further lowered to about 12% when the heating time was decreased to 30 seconds and to less than 2% at 10-50 milliseconds.
  • a fentanyl sample decomposed entirely when heated to 200° C. for 30 seconds, and only 15-30% decomposed when heated for 10 milliseconds. Vaporizing fentanyl in device 1 led to less than 0.1% decomposition.
  • An aerosol of the present invention contains particles having an MMAD between 10 nm and 1 ⁇ , preferably 10 nm to 900 nm, 10 nm to 800 nm, 10 nm to 700 nm, 10 nm to 600 nm, 10 nm to 500 nm, 10 nm to 400 nm, 10 nm to 300 nm, 10 nm to 200 nm, or 10 nm to 100 nm. Particles are produced such that their size is stable for several seconds (e.g., 1 to 3 s). The aerosol particle size and subsequent stability is controlled by the rate of compound vaporization, the rate of carrier gas introduction, and the mixing of resultant vapors and the carrier gas.
  • Such control is accomplished using a number of methods, including the following: (a) measuring the quantity and regulating the flow rate of the mixing air; and/or, (b) regulating the vaporization rate of the compound (e.g., by changing the energy transferred to the compound during the heating process or changing the amount of compound introduced into a heating region).
  • a desired particle size is achieved by mixing a compound in its vapor state into a volume of a carrier gas in a ratio such that, when the number concentration of the mixture reaches approximately 10 9 particles/mL, a particle that exists in a size range from 10 nm to 1 ⁇ for 1 to 3 seconds results.
  • FIG. 23 is a plot of theoretical data calculated from a mathematical model. See “Aerosol Technology” W. C. Hinds, second edition 1999, Wiley, New York. It shows the time in seconds it takes for the number concentration of an aerosol to aggregate to half of its original value as a function of the particle concentration. For example, a 1.0 mg vaporized dose of a compound with a molecular weight of 200 that is mixed into 1 liter of aire will have approximately 3 ⁇ 10 18 molecules (particles) in the liter. This results in a number concentration of 3 ⁇ 10 15 /cc. Extrapolating from FIG. 23, one can see that it takes less than 10 milliseconds for the number of particles to halve in this example.
  • FIG. 23 also shows that when the number concentration of the mixture reaches approximately 10 9 particles/cc, the particle size is “stable” for the purpose of drug delivery by inhalation.
  • FIG. 23 is for an aerosol having a Coagulation Coefficient (K) of 5 ⁇ 10 ⁇ 16 meters 3 /second.
  • K Coagulation Coefficient
  • This K value corresponds to a particle size of 200 nm.
  • Table 1 below gives the K values for various particle sizes.
  • K increases, the time required for the aerosol to aggregate from a particular particle size to a larger particle size is reduced.
  • Table 1 and FIG. 24 when the particle is in the 10 nm to 100 nm range, the effect of a changing K value tends to accelerate the coagulation process towards 100 nm in size.
  • Coagulation Coefficient (x e ⁇ 15 Particle size (diameter in nm) meters 3 /second) 1 3.11 5 6.93 10 9.48 20 11.50 50 9.92 100 7.17 200 5.09 500 3.76 1000 3.35 2000 3.15 5000 3.04 10000 3.00
  • the ratio of mass of vaporized compound to the volume of the mixing gas is the controlling condition. By changing this ratio, the particle size can be manipulated (see FIG. 29). However, not all compounds and not all gases, with the same ratio will result in the same particle size distribution (PSD). Other factors must be known to be able to accurately predict the resultant particle size. A compound's density, polarity, and temperature are examples of some of these factors. Additionally, whether the compound is hydrophilic or hydrophobic will affect the eventual particle size, because this factor affects an aerosol's tendency to grow by taking on water from the surrounding environment.
  • the compound is non polar (or has a weak polarity).
  • the compound is hydrophobic or hydrophilic with a mixing gas that is dry.
  • the resultant aerosol is at or close to standard temperature and pressure.
  • N Number concentration in particles/cc
  • MMD mass median diameter (in cm)
  • M the mass per unit volume of the aerosol in gms/cc
  • MMD 1 /MMD 2 exp[ ⁇ 3/2(ln ⁇ g2 ) 2 ]
  • MMD 1 To calculate MMD 1 , divide the compound's mass into the number of particles and then, calculate its diameter using the density of the compound.
  • MMD 1 (6 C/ ⁇ NV ) 1/3 for an aerosol with a GSD of 1
  • N Number concentration in particles/cc (as before)
  • V volume of the mixing gas in cc
  • MMD 2 (6 C/ ⁇ NV ⁇ ) 1/3 /[exp[ ⁇ 3/2(ln ⁇ g2 ) 2 ], measured in centimeters.
  • a resultant MMD can be calculated from the number concentration, the mass of the compound, the compound density, the volume of the mixing gas, and the GSD of the aerosol.
  • the required vaporization rate depends on the particle size one wishes to create. If the particle size is in the 10 nm to 100 nm range, then the compound, once vaporized, must be mixed, in most cases, into the largest possible volume of air. This volume of air is determined from lung physiology and can be assumed to have a reasonable upper limit of 2 liters. If the volume of air is limited to below 2 liters (e.g., 500 cc), too large a particle will result unless the dose is exceedingly small (e.g., less than 50 ⁇ g).
  • FIG. 1 The first example of the present invention is shown in FIG. 1 and is the basic device through which the principles cited above have been demonstrated in the laboratory. This device is described in detail in the EXAMPLES.
  • the use of a reduced airway cross section increases the speed of the air across the compound's surface to about 10 meters/second. If complete mixing is to happen within 1 millisecond, then the distance the gas and vaporized mixture must travel to achieve complete mixing must be no longer than 10 millimeters. However, it is more desirable for complete mixing to happen before the compound has aggregated to a larger size, so a desirable mixing distance is typically about 1 millimeter or less.
  • an aerosol having particles with an MMAD in the 10 nm to 100 nm range is generated by allowing air to sweep over a thin film of the compound during the heating process. This allows the compound to become vaporized at a lower temperature due to the lowering of the partial pressure of the compound near the surface of the film.
  • the fifth example shown in FIG. 14, the sixth example shown in FIGS. 15 and 16, and the eighth example shown in FIG. 19 overcome a problem with certain compounds that react rapidly with oxygen at elevated temperatures.
  • the compound is heated in an expandable container (fourth example), a small container housing under a vacuum or containing a small amount, e.g., about 1 to about 10 ml, of an inert gas (fifth example).
  • an inert gas e.g., about 1 to about 10 ml
  • the volume of inert gas can also be re-circulated over the surface of the heated compound to aid in its vaporization as shown in FIG. 16.
  • the compound is introduced into the gas as a pure vapor. This involves vaporizing the compound in an oven or other container and then injecting the vapor into an air or other gas stream through one or more mixing nozzles.
  • gas is passed through a first tube and over discrete substrate particles, having a large surface area to mass ratio, and coated with the compound.
  • the particles are heated as shown in FIG. 17 to vaporize the compound, or the gas is heated and the heated gas vaporizes the compound as shown in FIG. 18.
  • the gaseous mixture from the first tube is combined with the gas passing through second tube to rapidly cool the mixture before administering it to a patient.
  • the eighth example shown in FIG. 20 is a thermal gradient device that is similar to device 1 used in the laboratory experiments. This example also has a moving heating zone without any moving parts, accomplished by establishing a heat gradient that transverses from one end of the device to the other over time. As the heating zone moves, exposed portions of the compound are sequentially heated and vaporized. In this manner the vaporized compound can be introduced into a gas stream over time.
  • the ninth example shown in FIGS. 21 - 22 is the screen device and is preferred for generating a aerosols containing particles with an MMAD greater than 100 nm.
  • air is channeled through a fine mesh screen upon which the drug to be administered to the patient has been deposited.
  • the examples above can create aerosols without significant drug decomposition. This is accomplished while maintaining a required vaporization rate for particle size control by employing a short duration heating cycle. An airflow over the surface of the compound is established such that when the compound is heated and reaches the temperature where vaporization is first possible, the resulting compound vapors will immediately cool in the air. In the preferred examples, this is accomplished by extending the increased velocity and mixing region over an area that is larger than the heating zone region. As a result, precise control of temperature is not necessary since the compound vaporizes the instant its vaporization temperature is reached. Additionally because mixing is also present at the point of vaporization, cooling is accomplished quickly upon vaporization.
  • a patient is directed to breathe in a way that maximizes deposition of the drug in the lung.
  • This kind of breathing usually involves a full exhalation, followed by a deep inhalation sometimes at a prescribed inhalation flow rate range, e.g., about 10 to about 150 liters/minute, followed by a breath hold of several seconds.
  • the aerosol is not uniformly distributed in the air being inhaled, but is loaded into the early part of the breath as a bolus of aerosol, followed by a volume of clean air so that the aerosol is drawn into the alveoli and flushed out of the conductive airways, bronchi and trachea by the volume of clean air that follows.
  • a typical deep adult human breath has a volume of about 2 to 5 liters.
  • delivery of the drug bolus should be completed in the first 1-12 liters or so of inhaled air.
  • a compound should be vaporized in a minimum amount of time, preferably no greater than 1 to 2 seconds. As discussed earlier, it is also advantageous, to keep the temperature of vaporization at a minimum. In order for a compound to be vaporized in 2 seconds or less and for the temperature to be kept at a minimum, rapid air movement, in the range of about 10 to about 120 liters/minute, should flow across the surface of the compound.
  • the compound should to be vaporized over approximately 1 to 2 seconds for creation of particles in the ultra fine range.
  • the compound should be mixed into the air or other gas at a consistent rate to have a consistent and repeatable particle size.
  • the parameters of the design for one of the examples shown in FIGS. 2 - 5 , 7 and 8 are the result of meeting and balancing the competing requirements listed above.
  • One especially important requirement for an aerosol containing particles with an MMAD between 10 nm and 100 nm is that a compound, while needing to be vaporized within at least a 1-second period, also needs to have each portion of the compound exposed to a heat-up period that is as brief as possible.
  • the compound is deposited onto a foil substrate and an alternating magnetic field is swept along a foil substrate heating the substrate such that the compound is vaporized sequentially over no more than about a one second period of time. Because of the sweeping action of the magnetic field, each segment of the compound has a heat-up time that is much less than one second.
  • the compound is laid down on a thin metallic foil.
  • stainless steel alloy of 302, 304, or 316
  • Other foil materials can be used, but it is important that the surface and texture of the material is such that it is “wetted” by the compound when the compound is in its liquid phase, otherwise it is possible for the liquid compound to “ball” up which would defeat the design of the device and significantly change the volatilizing parameters. If the liquid compound “balls” up, the compound can be blown into and picked up by the airflow without ever vaporizing. This leads to delivery of a particle size that is uncontrolled and undesirable.
  • Stainless steel has advantages over materials like aluminum because it has a lower thermal conductivity value, without an appreciable increase in thermal mass. Low thermal conductivity is helpful because heat generated by the process needs to remain in the immediate area of interest.
  • example 1 was designed to deliver an experimental dose of fentanyl between 20 ⁇ g and 500 ⁇ g, in a range of ultra fine particle sizes, in about 800 cc of air to a 10 kg dog.
  • the lung volume of each dog under experimentation was approximately 600-700 cc and the device was designed to deliver the compound to the lung in the first half of the inhalation.
  • device 1 in this experiment can be considered a 1 ⁇ 4 scale device for administering a dose to a human. It is believed that scaling the device to work for human subjects involves mainly increasing the airflow through the device.
  • the time frame of the introduction of the compound into the heating/vaporization/mixing zone was set such that the compound vaporized into a volume of air that was suitable for both the volume required by dog lung anatomy (600-700 cc) and the volume needed to control the ratio of the compound to the air.
  • Controller 30 signaled controller 20 to start example 1 and to begin collecting data from the two temperature sensors and flow meter 4 .
  • example 1 After a pre-programmed delay, example 1 initiated the generation of the aerosol. (Note: there was a delay of about 0.4 seconds between the start of the controller 30 and the start of aerosol generation.)
  • controller 30 opened input valve 58 to start forced inhalation to a dog under experimentation.
  • Example 1 completed the aerosol generation during the inhalation.
  • Controller 30 monitored flow meter 4 and pressure transducer 240 throughout the inhalation and closed off flow at input valve 58 when a pre-specified volume or pressure was met. (Note: the pre-specified pressure is a safety feature to prevent injury to the subject animal. Termination of the breath at the pre-specified volume is the desirable occurrence of the experiment.)
  • Controller 30 recorded values for the following: volume dispensed, terminal pressure, duration of air pulse, and average flow rate. Controller 20 continuously recorded at millisecond resolution, input flow rate, exhaust flow rate, foil temperature, mouthpiece temperature, slide position, heater on/off time, and other internal diagnostic electrical parameters.
  • Three weight-matched female beagle dogs received fentanyl at a 100 ⁇ g intravenous bolus dose.
  • the same dogs received fentanyl UF for Inhalation (100 ⁇ g aerosolized and administered as two successive activations of device 1 , containing approximately 50 ⁇ g fentanyl base) at a particle size of 80 nm (MMAD).
  • the aerosol was administered to anesthetized dogs via the system schematically represented in FIG. 1, with a target delivered volume of 600-700 ml air, followed by a 5 second breath hold. After dosing, plasma samples for pharmacokinetic analysis were obtained at various time points from 2 min to 24 hr. Fentanyl remaining in device 1 was recovered and measured. Fentanyl concentrations were measured by using a validated GC method, with a limit of detection of 0.2 ng/ml.
  • Plasma pharmacokinetics from this example were compared to intravenous (IV) fentanyl (100 ⁇ g) in the same dogs. Inhalation of fentanyl resulted in rapid absorption (C max , maximum concentration in plasma, 11.6 ng/ml and T max , maximum time, 2 min.) and high bioavailability (84%). The time course of inhaled fentanyl was nearly identical to that of IV fentanyl. Thus, fentanyl UF for inhalation had an exposure profile that was similar to that of an IV injection.
  • FIG. 26 plots the data obtained on the blood levels, by dog, for both the IV doses and the inhalation doses using device 1 as described above under Example 1.
  • Table 2 summarizes the data collected from use of example 1 for in vitro testing of fentanyl. Particle size was measured with a Moudi cascade impactor. TABLE 2 Compound Mass Mixing air volume (ug) (cc) MMAD (nm) GSD 20 400 71 1.9 25 400 72-78 1.7-1.8 50 400 77-88 1.7-185 100 400 100-105 1.4-1.8 200 400 103-123 1.6-1.9 300 400 140-160 1.8-2.1
  • example 1 was slightly modified and the flow rate changed, as discussed below, to make a fine aerosol in the 1 to 3 micron particle size range.
  • Airway section 140 was removed and the air channel heating/vaporization zone 70 was changed.
  • An airway insert (not shown) had a “roof” that was 0.25 inches above the foil. There were no mixing rods as rapid mixing was not desirable in this example. Because of these two device changes, there was much less mixing with the air, thus the vapor/aerosol cloud was mixed with less air and produced a larger particle size aerosol. The airflow rate was reduced 1 liter/minute in this example. Again, this allowed the vapor to be mixed with much less air, resulting in the larger particle size aerosol.
  • a fine particle size can be made with device 1 merely by changing the ratio of the compound to the mixing air.
  • a tank was partially filled with DOP and placed inside an oven (not shown) having an inlet and an outlet. DOP was used as the test compound.
  • the tank was purged with helium prior to heating the tank and its contents to a temperature of 350° C. Helium was pumped through the tank and used to carry the DOP vapor out of the outlet.
  • the gaseous mixture of helium and vaporized compound 60 was introduced into different size mixing tubes through a nozzle. Each of the tubes had air moving through them at 14 liters/minute. The nozzle was perpendicular to the flow direction. After this gaseous mixture was mixed with the air, the resulting aerosol was introduced into a parallel flow diffusion battery for particle size analysis. Results are set forth in Table 4 below. TABLE 4 Mixing tube size (ID) MMAD GSD 4.8 mm 65 nm 1.3 14 mm 516 nm 3.3
  • a 4-inch long piece of aluminum was fitted with a 150-watt cartridge heater at one end.
  • the heater was powered with a variac AC power transformer.
  • the thickness of the aluminum was designed to ensure that heat would transverse from one end of the aluminum to the other in approximately 30 seconds.
  • an indentation was machined to hold the compound and to hold one of two top covers.
  • the indentation for the compound was approximately 3.5 inches long and 0.4 inches wide.
  • the indentation was 0.025 inches deep, and was filled with 1 mg of DOP.
  • the first top consisted of a sheet of flat glass placed 0.04 inches above the heated surface, creating an airway. At the exit end an outlet was fitted allowing the air to be drawn into an analytical measurement device. Air was made to flow through the airway at a rate of 15 liters/minute.
  • airway passage 910 was constructed from 18 mm diameter glass tubing.
  • the passage can be made in any shape with a comparable cross-sectional area and out of any suitable material.
  • the screen size, mesh, and the amount of compound were chosen in this example so that a gas could pass through the screen without interference once the compound had been deposited on it.
  • the discharge rate (the RC time constant) of the capacitor was rapid, and on the order of a few milliseconds, i.e. less than 20 milliseconds, preferably in the range of about 2 to about 10 milliseconds.
  • the deposited compound was rapidly vaporized. Because air moved through screen 902 , the vaporized compound rapidly mixed with air and cooled.
  • the compound was deposited onto the fine stainless steel screen, e.g., 200 mesh, made from 316 stainless steel, having measurements of 2.54 cm. ⁇ 2.54 cm.
  • the current from the capacitor was passed between one edge and another. It was not necessary to heat the screen to temperatures comparable to the thin foil in Example 1, because the compound vaporized at a lower temperature due to the rapid air movement. Rapid air movement allowed the compound to vaporize at a lower vapor pressure, since airflow constantly removed compound vapors from the surface as soon as they were formed. Thus, the compound vaporized at a lower temperature without decomposition.
  • Deposition of the compound onto the screen was accomplished by mixing the compound with an organic solvent until the compound dissolved. The resulting solution was then applied to the fine stainless steel screen 902 and the solvent was allowed to evaporate. The screen was then inserted into holder 940 that electrically connected two sides of screen 902 to the power circuit described above.
  • a 10,000 mF capacitor was discharged while the gas was passing through screen 902 .
  • the rapid heat up of the screen resulted in a rapid vaporization of the compound into the gas.
  • the resulting vaporized compound was mixed into a small volume of the gas. Because the ratio of the mass of the compound to the volume of the mixing gas was large, a fine (1-3 micron diameter) particle aerosol was made.
  • Drug (1 mg) is dissolved or suspended in a minimal amount of solvent (e.g., dichloromethane or methanol).
  • solvent e.g., dichloromethane or methanol.
  • the solution or suspension is pipeted onto the middle portion of a 3 cm by 3 cm piece of aluminum foil.
  • the coated foil is wrapped around the end of a 11 ⁇ 2 cm diameter vial and secured with parafilm.
  • a hot plate is preheated to approximately 300° C., and the vial is placed on it foil side down.
  • the vial is left on the hotplate for 10 s after volatilization or decomposition has begun. After removal from the hotplate, the vial is allowed to cool to room temperature.
  • the foil is removed, and the vial is extracted with dichloromethane followed by saturated aqueous NaHCO 3 .
  • the organic and aqueous extracts are shaken together, separated, and the organic extract is dried over Na 2 SO 4 .
  • An aliquot of the organic solution is removed and injected into a reverse-phase HPLC with detection by absorption of 225 nm light.
  • a drug is preferred for aerosolization where the purity of the drug isolated by this method is greater than 85%.
  • Such a drug has a decomposition index less than 0.15. The decomposition index is arrived at by substracting the percent purity (i.e., 0.85) from 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nozzles (AREA)
  • Organic Insulating Materials (AREA)
  • Dental Preparations (AREA)

Abstract

The present invention relates to the inhalation delivery of aerosols containing small particles. Specifically, it relates to the delivery of drug containing aerosols having particles with a mass median aerodynamic diameter less than 1μ for inhalation therapy. In an aspect of the present invention the drug containing aerosol comprises particles having a mass median aerodynamic diameter between 10 nm and 1μ. Preferably, the particles have a mass median aerodynamic diameter between 10 nm and 900 nm. More preferably, the particles have a mass median aerodynamic diameter between 10 nm and 800 nm, 10 nm and 700 nm, 10 nm and 600 nm, 10 nm and 500 nm, 10 nm and 400 nm, 10 nm and 300 nm, 10 nm and 200 nm, or 10 nm and 100 nm.

Description

  • This application is a continuation of U.S. patent application Ser. No. 10/146,515 entitled “Delivery of Aerosols Containing Small Particles Through an Inhalation Route,” filed May 13, 2002, which is a continuation-in-part of U.S. patent application Ser. No. 10/057,198 entitled “Method and Device for Delivering a Physiologically Active Compound,” filed Oct. 26, 2001, Lloyd et al. and of U.S. patent application Ser. No. 10/057,197 entitled “Aerosol Generating Device and Method,” filed Oct. 26, 2001, Wensley et al., both of which are hereby incorporated by reference for all purposes. This application further claims priority to U.S. provisional application Ser. No. 60/296,225 entitled “Aerosol Generating Device and Method,” filed Jun. 5, 2001, Wensley et al., the entire disclosure of which is hereby incorporated by reference.[0001]
  • FIELD OF THE INVENTION
  • The present invention relates to the inhalation delivery of aerosols containing small particles. Specifically, it relates to the delivery of drug containing aerosols having particles with a mass median aerodynamic diameter less than 1μ for inhalation therapy. [0002]
  • BACKGROUND OF THE INVENTION
  • Currently, there are a number of approved devices for the inhalation delivery of drugs, including dry powder inhalers, nebulizers, and pressurized metered dose inhalers. A typical goal of these devices is to produce an aerosol containing drug particles with a mass median aerodynamic diameter between 1 μl and 10 μl. [0003]
  • It is desirable to provide aerosols having particles with a mass median aerodynamic diameter less than 1μ. The provision of such aerosols is an object of the present invention. [0004]
  • SUMMARY OF THE INVENTION
  • The present invention relates to the inhalation delivery of aerosols containing small particles. Specifically, it relates to the delivery of drug containing aerosols having particles with a mass median aerodynamic diameter less than 1μ for inhalation therapy. [0005]
  • In a composition aspect of the present invention the drug containing aerosol contains particles having a mass median aerodynamic diameter between 10 nm and 1μ. Preferably the particles have a mass median aerodynamic diameter between 10 nm and 900 nm. More preferably, the particles have a mass median aerodynamic diameter between 10 nm and 800 nm, 10 nm and 700 nm, 10 nm and 600 nm, 10 nm and 500 nm, 10 nm and 400 nm, 10 nm and 300 nm, 10 nm and 200 nm, or 10 nm and 100 nm. [0006]
  • Typically, the particles comprise at least 5 percent by weight of drug. Preferably, the particles comprise at least 10 percent by weight of drug. More preferably, the particles comprise at least 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, 90 percent, 95 percent, 97 percent, 99 percent, 99.5 percent, or 99.97 percent by weight of drug. [0007]
  • Typically, at least 50 percent by weight of the aerosol is amorphous in form, wherein crystalline forms make up less than 50 percent by weight of the total aerosol weight, regardless of the nature of individual particles. Preferably, at least 75 percent by weight of the aerosol is amorphous in form. More preferably, at least 90 percent by weight of the aerosol is amorphous in form. [0008]
  • Typically, the aerosol comprises less than 10 percent by weight of drug degradation products. Preferably, the particles contain less than 5 percent of drug degradation products. More preferably, the particles contain less than 2.5, 1, 0.5, 0.1 or 0.03 percent by weight of drug degradation products. [0009]
  • Typically, the mass of the aerosol is at least 0.05 mg. Preferably, the mass of the aerosol is at least 0.10 mg. More preferably, the mass of the aerosol is at least 0.15 mg, 0.20 mg, or 0.25 mg. [0010]
  • Typically, the geometric standard deviation around the mass median aerodynamic diameter of the aerosol particles is less than 2. Preferably, the geometric standard deviation is less than 1.9. More preferably, the geometric standard deviation is less than 1.8, 1.7, 1.6 or 1.5. [0011]
  • Typically, the drug has a decomposition index less than 0.15. Preferably, the drug has a decomposition index less than 0.10. More preferably, the drug has a decomposition index less than 0.05. [0012]
  • Typically, the drug of the aerosol is of one of the following classes: antibiotics, anticonvulsants, antidepressants, antiemetics, antihistamines, antiparkisonian drugs, antipsychotics, anxiolytics, drugs for erectile dysfunction, drugs for migraine headaches, drugs for the treatment of alcoholism, drugs for the treatment of addiction, muscle relaxants, nonsteroidal anti-inflammatories, opioids, other analgesics and stimulants. [0013]
  • Typically, where the drug is an antibiotic, it is selected from one of the following compounds: cefinetazole; cefazolin; cephalexin; cefoxitin; cephacetrile; cephaloglycin; cephaloridine; cephalosporins, such as cephalosporin C; cephalotin; cephamycins, such as cephamycin A, cephamycin B, and cephamycin C; cepharin; cephradine; ampicillin; amoxicillin; hetacillin; carfecillin; carindacillin; carbenicillin; amylpenicillin; azidocillin; benzylpenicillin; clometocillin; cloxacillin; cyclacillin; methicillin; nafcillin; 2-pentenylpenicillin; penicillins, such as penicillin N, penicillin O, penicillin S, penicillin V; chlorobutin penicillin; dicloxacillin; diphenicillin; heptylpenicillin; and metampicillin. [0014]
  • Typically, where the drug is an anticonvulsant, it is selected from one of the following compounds: gabapentin, tiagabine, and vigabatrin. [0015]
  • Typically, where the drug is an antidepressant, it is selected from one of the following compounds: amitriptyline, amoxapine, benmoxine, butriptyline, clomipramine, desipramine, dosulepin, doxepin, imipramine, kitanserin, lofepramine, medifoxamine, mianserin, maprotoline, mirtazapine, nortriptyline, protriptyline, trimipramine, viloxazine, citalopram, cotinine, duloxetine, fluoxetine, fluvoxamine, milnacipran, nisoxetine, paroxetine, reboxetine, sertraline, tianeptine, acetaphenazine, binedaline, brofaromine, cericlamine, clovoxamine, iproniazid, isocarboxazid, moclobemide, phenyhydrazine, phenelzine, selegiline, sibutramine, tranylcypromine, ademetionine, adrafinil, amesergide, amisulpride, amperozide, benactyzine, bupropion, caroxazone, gepirone, idazoxan, metralindole, milnacipran, minaprine, nefazodone, nomifensine, ritanserin, roxindole, S-adenosylmethionine, tofenacin, trazodone, tryptophan, venlafaxine, and zalospirone. [0016]
  • Typically, where the drug is an antiemetic, it is selected from one of the following compounds: alizapride, azasetron, benzquinamide, bromopride, buclizine, chlorpromazine, cinnarizine, clebopride, cyclizine, diphenhydramine, diphenidol, dolasetron methanesulfonate, droperidol, granisetron, hyoscine, lorazepam, metoclopramide, metopimazine, ondansetron, perphenazine, promethazine, prochlorperazine, scopolamine, triethylperazine, trifluoperazine, triflupromazine, trimethobenzamide, tropisetron, domeridone, and palonosetron. [0017]
  • Typically, where the drug is an antihistamine, it is selected from one of the following compounds: azatadine, brompheniramine, chlorpheniramine, clemastine, cyproheptadine, dexmedetomidine, diphenhydramine, doxylamine, hydroxyzine, cetrizine, fexofenadine, loratidine, and promethazine. [0018]
  • Typically, where the drug is an antiparkisonian drug, it is selected one of the following compounds: amantadine, baclofen, biperiden, benztropine, orphenadrine, procyclidine, trihexyphenidyl, levodopa, carbidopa, selegiline, deprenyl, andropinirole, apomorphine, benserazide, bromocriptine, budipine, cabergoline, dihydroergokryptine, eliprodil, eptastigmine, ergoline pramipexole, galanthamine, lazabemide, lisuride, mazindol, memantine, mofegiline, pergolike, pramipexole, propentofylline, rasagiline, remacemide, spheramine, terguride, entacapone, and tolcapone. [0019]
  • Typically, where the drug is an antipsychotic, it is selected from one of the following compounds: acetophenazine, alizapride, amperozide, benperidol, benzquinamide, bromperidol, buramate, butaperazine, carphenazine, carpipramine, chlorpromazine, chlorprothixene, clocapramine, clomacran, clopenthixol, clospirazine, clothiapine, cyamemazine, droperidol, flupenthixol, fluphenazine, fluspirilene, haloperidol, mesoridazine, metofenazate, molindrone, penfluridol, pericyazine, perphenazine, pimozide, pipamerone, piperacetazine, pipotiazine, prochlorperazine, promazine, remoxipride, sertindole, spiperone, sulpiride, thioridazine, thiothixene, trifluperidol, triflupromazine, trifluoperazine, ziprasidone, zotepine, zuclopenthixol, amisulpride, butaclamol, clozapine, melperone, olanzapine, quetiapine, and risperidone. [0020]
  • Typically, where the drug is an anxiolytic, it is selected from one of the following compounds: mecloqualone, medetomidine, metomidate, adinazolam, chlordiazepoxide, clobenzepam, flurazepam, lorazepam, loprazolam, midazolam, alpidem, alseroxlon, amphenidone, azacyclonol, bromisovalum, buspirone, calcium N-carboamoylaspartate, captodiamine, capuride, carbcloral, carbromal, chloral betaine, enciprazine, flesinoxan, ipsapiraone, lesopitron, loxapine, methaqualone, methprylon, propanolol, tandospirone, trazadone, zopiclone, and zolpidem. [0021]
  • Typically, where the drug is a drug for erectile dysfunction, it is selected from one of the following compounds: cialis (IC351), sildenafil, vardenafil, apomorphine, apomorphine diacetate, phentolamine, and yohimbine. [0022]
  • Typically, where the drug is a drug for migraine headache, it is selected from one of the following compounds: almotriptan, alperopride, codeine, dihydroergotamine, ergotamine, eletriptan, frovatriptan, isometheptene, lidocaine, lisuride, metoclopramide, naratriptan, oxycodone, propoxyphene, rizatriptan, sumatriptan, tolfenamic acid, zolmitriptan, amitriptyline, atenolol, clonidine, cyproheptadine, diltiazem, doxepin, fluoxetine, lisinopril, methysergide, metoprolol, nadolol, nortriptyline, paroxetine, pizotifen, pizotyline, propanolol, protriptyline, sertraline, timolol, and verapamil. [0023]
  • Typically, where the drug is a drug for the treatment of alcoholism, it is selected from one of the following compounds: naloxone, naltrexone, and disulfiram. [0024]
  • Typically, where the drug is a drug for the treatment of addiction it is buprenorphine. [0025]
  • Typically, where the drug is a muscle relaxant, it is selected from one of the following compounds: baclofen, cyclobenzaprine, orphenadrine, quinine, and tizanidine. [0026]
  • Typically, where the drug is a nonsteroidal anti-inflammatory, it is selected from one of the following compounds: aceclofenac, alminoprofen, amfenac, aminopropylon, amixetrine, benoxaprofen, bromfenac, bufexamac, carprofen, choline, salicylate, cinchophen, cinmetacin, clopriac, clometacin, diclofenac, etodolac, indoprofen, mazipredone, meclofenamate, piroxicam, pirprofen, and tolfenamate. [0027]
  • Typically, where the drug is an opioid, it is selected from one of the following compounds: alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, carbiphene, cipramadol, clonitazene, codeine, dextromoramide, dextropropoxyphene, diamorphine, dihydrocodeine, diphenoxylate, dipipanone, fentanyl, hydromorphone, L-alpha acetyl methadol, lofentanil, levorphanol, meperidine, methadone, meptazinol, metopon, morphine, nalbuphine, nalorphine, oxycodone, papaveretum, pethidine, pentazocine, phenazocine, remifentanil, sufentanil, and tramadol. [0028]
  • Typically, where the drug is an other analgesic it is selected from one of the following compounds: apazone, benzpiperylon, benzydramine, caffeine, clonixin, ethoheptazine, flupirtine, nefopam, orphenadrine, propacetamol, and propoxyphene. [0029]
  • Typically, where the drug is a stimulant, it is selected from one of the following compounds: amphetamine, brucine, caffeine, dexfenfluramine, dextroamphetamine, ephedrine, fenfluramine, mazindol, methyphenidate, pemoline, phentermine, and sibutramine.[0030]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • Further features and advantages will become apparent from the following description of various examples of the invention, as illustrated in the accompanying drawings in which: [0031]
  • FIG. 1 is a schematic diagram of the overall system for conducting experiments using a laboratory example of a device of the present invention; [0032]
  • FIG. 2 is a top, right end and front perspective view of the example depicted in FIG. 1; [0033]
  • FIG. 3 is a partial cross-sectional and partial schematic side view of the example shown in FIG. 2; [0034]
  • FIG. 4 is a partial cross-sectional and partial schematic end view of the example shown in FIG. 2; [0035]
  • FIG. 5 is a partial cross-sectional and partial schematic top view of the example shown in FIG. 2; [0036]
  • FIG. 6 is a schematic cross-sectional side view of an alternate example of the device of the present invention using an annunciating device; [0037]
  • FIG. 7 is a top, left end and front perspective views of the removable sub-assembly containing the compound and a movable slide of the example shown in FIG. 2 showing the sub-assembly being mounted within the slide; [0038]
  • FIG. 8 is a schematic view of the heating element of the example shown in FIG. 2 showing the electric drive circuit; [0039]
  • FIG. 9 is a schematic side view of a second example of the present invention using a venturi tube; [0040]
  • FIG. 10 is a schematic side view of a fourth example of the present invention using a thin-walled tube coated with the compound; [0041]
  • FIG. 11 is a schematic side end view of the example shown in FIG. 10; [0042]
  • FIG. 12 is a schematic side end view of the example shown in FIG. 10 showing an inductive heating system generating an alternating magnetic field; [0043]
  • FIG. 13 is a schematic side view of an alternate example of that shown in FIG. 10 using a flow restrictor within the thin-walled tube; [0044]
  • FIG. 14 is a schematic side view of a fifth example of the present invention using an expandable container for the compound; [0045]
  • FIG. 15 is a schematic side view of a sixth example of the present invention using a container for the compound in an inert atmosphere; [0046]
  • FIG. 16 is a schematic side view of the example shown in FIG. 15 using a recirculation of the inert atmosphere over the compound's surface; [0047]
  • FIG. 17 is a schematic side view of a seventh example of the present invention using a tube containing particles coated with the compound; [0048]
  • FIG. 18 is a schematic side view of the example shown in FIG. 17 using a heating system to heat the gas passing over the coated particles; [0049]
  • FIG. 19 is a schematic side view of an eighth example of the present invention referred to herein as the “oven device”; [0050]
  • FIG. 20 is a schematic side view of an ninth example of the present invention using gradient heating; [0051]
  • FIG. 21 is a schematic side view of a tenth example of the present invention using a fine mesh screen coated with the compound; [0052]
  • FIG. 22 is a top, right end and front perspective view of the example shown in FIG. 21; [0053]
  • FIG. 23 is a plot of the rate of aggregation of smaller particles into larger ones; [0054]
  • FIG. 24 is a plot of the coagulation coefficient (K) versus particle size of the compound; [0055]
  • FIG. 25 is a plot of vapor pressure of various compounds, e.g., diphenyl ether, hexadecane, geranyl formate and caproic acid, versus temperature; [0056]
  • FIG. 26 is a plot of blood levels for both the IV dose and the inhalation dose administered to various dogs during the experiments using the system shown in FIG. 1; [0057]
  • FIG. 27 is a plot of calculated and experimental mass median diameter (MMD) versus compound mass in the range of 10 to 310 μg; [0058]
  • FIG. 28 is a plot of calculated and experimental MMD versus compound mass in the range of 10 to 310 μg; and [0059]
  • FIG. 29 is a plot of the theoretical size (diameter) of an aerosol as a function of the ratio of the vaporized compound to the volume of the mixing gas.[0060]
  • DETAILED DESCRIPTION
  • Definitions [0061]
  • “Aerodynamic diameter” of a given particle refers to the diameter of a spherical droplet with a density of 1 g/mL (the density of water) that has the same settling velocity as the given particle. [0062]
  • “Aerosol” refers to a suspension of solid or liquid particles in a gas. [0063]
  • “Amorphous particle” refers to a particle that does not contain more than 50 percent by weight of a crystalline form. Preferably, the particle does not contain more than 25 percent of a crystalline form. More preferably, the particle does not contain more than 10 percent of a crystalline form. [0064]
  • “Decomposition index” refers to a number derived from an assay described in Example 7. The number is determined by substracting the percent purity of the generated aerosol from 1. [0065]
  • “Drug” refers to any chemical compound that is used in the prevention, diagnosis, treatment, or cure of disease, for the relief of pain, or to control or improve any physiological or pathological disorder in humans or animals. Such compounds are oftentimes listed in the Physician's Desk Reference (Medical Economics Company, Inc. at Montvale, N.J., 56[0066] th edition, 2002), which is herein incorporated by reference.
  • Exemplary drugs include the following: cannabanoid extracts from cannabis, THC, ketorolac, fentanyl, morphine, testosterone, ibuprofen, codeine, nicotine, Vitamin A, Vitamin E acetate, Vitamin E, nitroglycerin, pilocarpine, mescaline, testosterone enanthate, menthol, phencaramkde, methsuximide, eptastigmine, promethazine, procaine, retinol, lidocaine, trimeprazine, isosorbide dinitrate, timolol, methyprylon, etamiphyllin, propoxyphene, salmetrol, vitamin E succinate, methadone, oxprenolol, isoproterenol bitartrate, etaqualone, Vitamin D3, ethambutol, ritodrine, omoconazole, cocaine, lomustine, ketamine, ketoprofen, cilazaprol, propranolol, sufentanil, metaproterenol, prentoxapylline, testosterone proprionate, valproic acid, acebutolol, terbutaline, diazepam, topiramate, pentobarbital, alfentanil HCl, papaverine, nicergoline, fluconazole, zafirlukast, testosterone acetate, droperidol, atenolol, metoclopramide, enalapril, albuterol, ketotifen, isoproterenol, amiodarone HCl, zileuton, midazolam, oxycodone, cilostazol, propofol, nabilone, gabapentin, famotidine, lorezepam, naltrexone, acetaminophen, sumatriptan, bitolterol, nifedipine, Phenobarbital, phentolamine, 13-cis retinoic acid, droprenilamin HCl, amlodipine, caffeine, zopiclone, tramadol HCl, pirbuterol naloxone, meperidine HCl, trimethobenzamide, nalmefene, scopolamine, sildenafil, carbamazepine, procaterol HCl, methysergide, glutathione, olanzapine, zolpidem, levorphanol, buspirone and mixtures thereof. [0067]
  • Typically, the drug of the composition is of one of the following classes: antibiotics, anticonvulsants, antidepressants, antiemetics, antihistamines, antiparkisonian drugs, antipsychotics, anxiolytics, drugs for erectile dysfunction, drugs for migraine headaches, drugs for the treatment of alcoholism, drugs for the treatment of addiction, muscle relaxants, nonsteroidal anti-inflammatories, opioids, other analgesics, cannabanoids, and stimulants. [0068]
  • Typically, where the drug is an antibiotic, it is selected from one of the following compounds: cefinetazole; cefazolin; cephalexin; cefoxitin; cephacetrile; cephaloglycin; cephaloridine; cephalosporins, such as cephalosporin C; cephalotin; cephamycins, such as cephamycin A, cephamycin B, and cephamycin C; cepharin; cephradine; ampicillin; amoxicillin; hetacillin; carfecillin; carindacillin; carbenicillin; amylpenicillin; azidocillin; benzylpenicillin; clometocillin; cloxacillin; cyclacillin; methicillin; nafcillin; 2-pentenylpenicillin; penicillins, such as penicillin N, penicillin O, penicillin S, penicillin V; chlorobutin penicillin; dicloxacillin; diphenicillin; heptylpenicillin; and metampicillin. [0069]
  • Typically, where the drug is an anticonvulsant, it is selected from one of the following compounds: gabapentin, tiagabine, and vigabatrin. [0070]
  • Typically, where the drug is an antidepressant, it is selected from one of the following compounds: amitriptyline, amoxapine, benmoxine, butriptyline, clomipramine, desipramine, dosulepin, doxepin, imipramine, kitanserin, lofepramine, medifoxamine, mianserin, maprotoline, mirtazapine, nortriptyline, protriptyline, trimipramine, viloxazine, citalopram, cotinine, duloxetine, fluoxetine, fluvoxamine, milnacipran, nisoxetine, paroxetine, reboxetine, sertraline, tianeptine, acetaphenazine, binedaline, brofaromine, cericlamine, clovoxamine, iproniazid, isocarboxazid, moclobemide, phenyhydrazine, phenelzine, selegiline, sibutramine, tranylcypromine, ademetionine, adrafinil, amesergide, amisulpride, amperozide, benactyzine, bupropion, caroxazone, gepirone, idazoxan, metralindole, milnacipran, minaprine, nefazodone, nomifensine, ritanserin, roxindole, S-adenosylmethionine, tofenacin, trazodone, tryptophan, venlafaxine, and zalospirone. [0071]
  • Typically, where the drug is an antiemetic, it is selected from one of the following compounds: alizapride, azasetron, benzquinamide, bromopride, buclizine, chlorpromazine, cinnarizine, clebopride, cyclizine, diphenhydramine, diphenidol, dolasetron methanesulfonate, dronabinol, droperidol, granisetron, hyoscine, lorazepam, metoclopramide, metopimazine, ondansetron, perphenazine, promethazine, prochlorperazine, scopolamine, triethylperazine, trifluoperazine, triflupromazine, trimethobenzamide, tropisetron, domeridone, and palonosetron. [0072]
  • Typically, where the drug is an antihistamine, it is selected from one of the following compounds: azatadine, brompheniramine, chlorpheniramine, clemastine, cyproheptadine, dexmedetomidine, diphenhydramine, doxylamine, hydroxyzine, cetrizine, fexofenadine, loratidine, and promethazine. [0073]
  • Typically, where the drug is an antiparkisonian drug, it is selected one of the following compounds: amantadine, baclofen, biperiden, benztropine, orphenadrine, procyclidine, trihexyphenidyl, levodopa, carbidopa, selegiline, deprenyl, andropinirole, apomorphine, benserazide, bromocriptine, budipine, cabergoline, dihydroergokryptine, eliprodil, eptastigmine, ergoline pramipexole, galanthamine, lazabemide, lisuride, mazindol, memantine, mofegiline, pergolike, pramipexole, propentofylline, rasagiline, remacemide, spheramine, terguride, entacapone, and tolcapone. [0074]
  • Typically, where the drug is an antipsychotic, it is selected from one of the following compounds: acetophenazine, alizapride, amperozide, benperidol, benzquinamide, bromperidol, buramate, butaperazine, carphenazine, carpipramine, chlorpromazine, chlorprothixene, clocapramine, clomacran, clopenthixol, clospirazine, clothiapine, cyamemazine, droperidol, flupenthixol, fluphenazine, fluspirilene, haloperidol, mesoridazine, metofenazate, molindrone, penfluridol, pericyazine, perphenazine, pimozide, pipamerone, piperacetazine, pipotiazine, prochlorperazine, promazine, remoxipride, sertindole, spiperone, sulpiride, thioridazine, thiothixene, trifluperidol, triflupromazine, trifluoperazine, ziprasidone, zotepine, zuclopenthixol, amisulpride, butaclamol, clozapine, melperone, olanzapine, quetiapine, and risperidone. [0075]
  • Typically, where the drug is an anxiolytic, it is selected from one of the following compounds: mecloqualone, medetomidine, metomidate, adinazolam, chlordiazepoxide, clobenzepam, flurazepam, lorazepam, loprazolam, midazolam, alpidem, alseroxlon, amphenidone, azacyclonol, bromisovalum, buspirone, calcium N-carboamoylaspartate, captodiamine, capuride, carbcloral, carbromal, chloral betaine, enciprazine, flesinoxan, ipsapiraone, lesopitron, loxapine, methaqualone, methprylon, propanolol, tandospirone, trazadone, zopiclone, and zolpidem. [0076]
  • Typically, where the drug is a drug for erectile dysfunction, it is selected from one of the following compounds: cialis (IC351), sildenafil, vardenafil, apomorphine, apomorphine diacetate, phentolamine, and yohimbine. [0077]
  • Typically, where the drug is a drug for migraine headache, it is selected from one of the following compounds: almotriptan, alperopride, codeine, dihydroergotamine, ergotamine, eletriptan, frovatriptan, isometheptene, lidocaine, lisuride, metoclopramide, naratriptan, oxycodone, propoxyphene, rizatriptan, sumatriptan, tolfenamic acid, zolmitriptan, amitriptyline, atenolol, clonidine, cyproheptadine, diltiazem, doxepin, fluoxetine, lisinopril, methysergide, metoprolol, nadolol, nortriptyline, paroxetine, pizotifen, pizotyline, propanolol, protriptyline, sertraline, timolol, and verapamil. [0078]
  • Typically, where the drug is a drug for the treatment of alcoholism, it is selected from one of the following compounds: naloxone, naltrexone, and disulfiram. [0079]
  • Typically, where the drug is a drug for the treatment of addiction it is buprenorphine. [0080]
  • Typically, where the drug is a muscle relaxant, it is selected from one of the following compounds: baclofen, cyclobenzaprine, orphenadrine, quinine, and tizanidine. [0081]
  • Typically, where the drug is a nonsteroidal anti-inflammatory, it is selected from one of the following compounds: aceclofenac, alminoprofen, amfenac, aminopropylon, amixetrine, benoxaprofen, bromfenac, bufexamac, carprofen, choline, salicylate, cinchophen, cinmetacin, clopriac, clometacin, diclofenac, etodolac, indoprofen, mazipredone, meclofenamate, piroxicam, pirprofen, and tolfenamate. [0082]
  • Typically, where the drug is an opioid, it is selected from one of the following compounds: alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, carbiphene, cipramadol, clonitazene, codeine, dextromoramide, dextropropoxyphene, diamorphine, dihydrocodeine, diphenoxylate, dipipanone, fentanyl, hydromorphone, L-alpha acetyl methadol, lofentanil, levorphanol, meperidine, methadone, meptazinol, metopon, morphine, nalbuphine, nalorphine, oxycodone, papaveretum, pethidine, pentazocine, phenazocine, remifentanil, sufentanil, and tramadol. [0083]
  • Typically, where the drug is an other analgesic it is selected from one of the following compounds: apazone, benzpiperylon, benzydramine, caffeine, clonixin, ethoheptazine, flupirtine, nefopam, orphenadrine, propacetamol, and propoxyphene. [0084]
  • Typically, where the drug is a cannabanoid, it is tetrahydrocannabinol (e.g., delta-8 or delta-9). [0085]
  • Typically, where the drug is a stimulant, it is selected from one of the following compounds: amphetamine, brucine, caffeine, dexfenfluramine, dextroamphetamine, ephedrine, fenfluramine, mazindol, methyphenidate, pemoline, phentermine, and sibutramine. [0086]
  • “Drug degradation product” refers to a compound resulting from a chemical modification of a drug. The modification, for example, can be the result of a thermally or photochemically induced reaction. Such reactions include, without limitation, oxidation and hydrolysis. [0087]
  • “Mass median aerodynamic diameter” or “MMAD” of an aerosol refers to the aerodynamic diameter for which half the particulate mass of the aerosol is contributed by particles with an aerodynamic diameter larger than the MMAD and half by particles with an aerodynamic diameter smaller than the MMAD. [0088]
  • “Stable aerosol” refers to an aerosol where the MMAD of its constituent particles does not vary by more than 50% over a set period of time. For example, an aerosol with an MMAD of 100 nm is stable over 1 s, if at a [0089] time 1 second later it has an MMAD between 50 nm and 150 nm. Preferably, the MMAD does not vary by more than 25% over a set period of time. More preferably, the MMAD does not vary by more than 20%, 15%, 10% or 5% over time.
  • Aerosolization Device [0090]
  • Example 1 is described in terms of an in vivo dog experiment. The example, however, is easily modified to suit human inhalation primarily through increasing airflow through it. [0091]
  • Referring to FIGS. [0092] 1-8, a first example (1) of an aerosolization device of the present invention will be described. The device 1 as shown in FIG. 1 is operably connected to flow meter 4 (e.g., a TSI 4100 flow meter). The readings from flow meter 4 are fed to the electronics within chassis 8 shown in FIG. 2. Flow meter 4 is shown in FIG. 1 within a dotted line to indicate housing 10. Device controller 20 includes Chembook model # N30W laptop computer having actuator switch 22 (FIG. 3) and National Instruments I/O Board (model #SC2345) (not shown) that interfaces with computer 20 to control device 1 and to control the recording of all data collected during the experiments. A software program to carry out these functions was developed using National Instruments' Labview software program.
  • Connection between [0093] device 1 and the I/O board is accomplished with a cable (e.g., DB25, not shown). A standard power supply (e.g., Condor F15-15-A+ not shown) delivers power to device 1. Inhalation controller 30 is used to control the rate and volume of inhalation through device 1 into an anesthetized dog through an endotracheal tube 34. Controller 30 has a programmable breath hold delay, at the end of which, exhaust valve 40 in exhaust line 42 opens and the dog is allowed to exhale. Filter 50 in line 42 measures the amount of exhaust and its composition to monitor any exhaled drug. The source air through inlet line 54, inlet valve 58, flow meter 4 and inlet orifice 59 is from a compressed air cylinder (not shown).
  • Now referring to FIGS. [0094] 3-5 and 7, a dose of compound 60 is deposited onto thin, stainless steel foil 64 so that the thickness of compound 60 is less than 10 microns. In most cases, compound 60 is deposited by making a solution of the compound with an organic solvent. This mixture is then applied to the foil substrate with an automated pump system. As shown, the size of the entire foil 64 (e.g., alloy of 302 or 304 with 0.004 in. thickness) is 0.7 by 2.9 inches and the area in which compound 60 is deposited is 0.35 by 1.6 inches. Other foil materials can be used but stainless steel has an advantage over other materials like aluminum in that it has a much lower thermal conductivity value, while not appreciably increasing the thermal mass. A low thermal conductivity is helpful because the heat generated in foil 64 should stay in the area of interest (i.e., the heating/vaporization zone 70). Foil 64 should have a constant cross section, because otherwise the electrical currents induced by the heater will not be uniform. Foil 64 is held in frame 68, made so that the trailing edge of foil 64 has no lip on movable slide 78 and so compound 60, once mixed with the air, is free in a downstream direction as indicated by arrow 127 of FIG. 3. Frame 68 is typically made of a non-conductive material to withstand moderate heat (e.g., 200° C.) and to be non-chemically reactive with the compound (e.g., DELRIN AF®, a copolymer of acetal and TEFLON®).
  • Sub-assembly [0095] 80, shown in FIG. 7, consists of frame 68 having compound (60) coated foil 64 mounted therein. Sub-assembly 80 is secured within movable slide 78 by setting each of the downstream, tapered ends of frame 68 to abut against small rods 86 protruding from each downstream end of slide 78, as shown in FIG. 7. Slide 78 is driven by stepper motor 88, shown in FIG. 3, that moves sub-assembly 80 containing compound 60 along the longitudinal axis of example 1. This, in turn, moves stainless steel foil 64 through an alternating magnetic field. (It is preferable for the magnetic field to be confined within heating/vaporization zone 70, shown in FIG. 5, as in this laboratory example.) Ferrite toroid 90 is used to direct the magnetic field and is placed below foil 64 (e.g., approximately 0.05 inches below). As shown in FIG. 5, heated area 70 is approximately 0.15 by 0.4 inches, with the smaller dimension along the direction of travel from left to right (i.e., from the upstream to the downstream ends of device 1) and the large dimension across the direction of travel (i.e., the width of device 1).
  • [0096] Foil 64 functions as both a substrate for the drug to be delivered to the subject and the heating element for the vaporization of the drug. Heating element 64 is heated primarily by eddy currents induced by an alternating magnetic field. The alternating magnetic field is produced in ferrite toroid 90 (e.g., from Fair-Rite Company) with slit 94 (e.g., 0.10 in. wide), which was wrapped with coil 98 of copper magnet wire. When an alternating current is passed through coil 98, an alternating magnetic field is produced in ferrite toroid 90. A magnetic field fills the gap formed by slit 94 and magnetic field fringe lines 100, shown in FIGS. 5 and 6, extend out from toroid 90. The magnetic field line fringe lines 100 intersect heating element 64. When using a ferrite core, the alternating frequency of the field is limited to below 1 MHz. In this device, a frequency between 100 and 300 kHz is typically used.
  • The location and geometry of the eddy currents determine where [0097] foil 64 will be heated. Since magnetic field fringe lines 100 pass through foil 64 twice, once leaving ferrite toroid 90 and once returning, two rings of current are produced, and in opposite directions. One of the rings is formed around magnetic field lines 100 that leave toroid 90 and the other ring forms around magnetic field lines 100 that return toroid 90. The rings of current overlap directly over the center of slit 94. Since they were in opposite directions, they sum together. The greatest heating effect is therefore produced over the center of slit 94.
  • [0098] Slide 78 and its contents are housed in airway 102 made up of upper airway section 104 and lower airway section 108 shown in FIG. 3. Upper airway section 104 is removable and allows the insertion of movable slide 78, sub-assembly 80 and foil 64. Lower airway section 108 is mounted on top of chassis 8 that houses the electronics (not shown), magnetic field generator 110, stepper motor 88 and position sensors (not shown). Referring again to FIG. 1, mounted in upper airway section 104 is upstream passage 120 and inlet orifice 59 that couples upper airway section 104 to flow meter 4. The readings from the flow meter 4 are fed to the electronics housed in chassis 8. Additionally, at the downstream end of airway passage 102, outlet 124 is connected to mouthpiece 126. During administration of compound 60 to the dog, when joined to the system, air is forced through inlet line 54, flow meter 4, airway 102, and outlet 124 into the dog.
  • Additionally, a pyrometer at the end of [0099] TC2 line 130 is located within airway 102 and is used to measure the temperature of foil 64. Because of the specific geometry of the example shown in FIGS. 1-7, the temperature reading of foil 64 is taken after heating zone 70. Calibration of the thermal decay between heating zone 70 and the measurement area is required. Temperature data is collected and used for quality control and verification and not to control any heating parameters. A second temperature sensor is located at the end of TC1 line 132 in outlet 124 and is used to monitor the temperature of the air delivered to the dog.
  • In a preferred example of the experimental device, [0100] removable block 140, mounted on upper airway section 104, restricts a cross-sectional area of airway 102 and provides a specific mixing geometry therein. In this preferred example, airway 140 lowers the roof of upper airway section 104 (e.g., to within 0.04 inch of) with respect to foil 64. Additionally, block 140 contains baffles (e.g., 31 steel rods 0.04 in. in diameter, not shown). The rods are oriented perpendicular to the foil and extend from the top of upper airway section 104 to within a small distance of the foil (e.g., 0.004 in.). The rods are placed in a staggered pattern and have sharp, squared off ends, which cause turbulence as air passes around them. This turbulance assures complete mixing of vaporized compounds with air passing through the device.
  • A second example ([0101] 150) of an aerosolization device of the present invention, in which the cross-sectional area is also restricted along the gas/vapor mixing area, will be described in reference to FIG. 9. In this example, venturi tube 152 within housing 10 having inlet 154, outlet 156 includes a throat 158 between inlet 154 and outlet 156, which is used to restrict the gas flow through venturi tube 152. Additionally, a controller 160 is designed to control the flow of air passing through a valve 164 based on readings from the thermocouple 168 of the temperature of the air, which can be controlled by heater 166.
  • [0102] Block 140 is located directly over heating zone 70 and creates a heating/vaporization/mixing zone. Prior to commencing aerosol generation, slide 78 is in the downstream position. Slide 78, with its contents, is then drawn upstream into this heating/vaporization/mixing zone 70 as energy is applied to foil 64 through the inductive heater system described in detail below.
  • The device of the present invention is optionally equipped with an annunciating device. One of the many functions for the annunciating device is to alert the operator of the device that a compound is not being vaporized or is being improperly vaporized. The annunciating device can also be used to alert the operator that the gas flow rate is outside a desired range. FIG. 6 is a schematic diagram illustrating a third example of a hand held [0103] aerosolization device 180 of the present invention. As shown, device 180 includes many of the components of device 150, discussed above, and additionally includes an annunciating device 170. During the use of device 180 in which the patient's inhalation rate controls the airflow rate, a signal from annunciating device 170 would alert the patient to adjust the inhalation rate to the desired range. In this case, controller 160 would be connected to annunciating device 170 to send the necessary signal that the flow rate was not within the desired range.
  • The [0104] induction drive circuit 190 shown in FIG. 8 is used to drive the induction-heating element of device 1. The purpose of circuit 190 is to produce an alternating current in drive coil 98 wrapped around ferrite core 90. Circuit 190 consists of two P-channel transistors 200 and two N-channel MOSFET transistors 202 arranged in a bridge configuration. MOSFET transistors 200 and 202 connected to clock pulse generator 219 are turned on and off in pairs by D-type flip-flop 208 through MOSFET transistor drive circuit 210. D-type flip-flop 208 is wired to cause the Q output of the flip-flop to alternately change state with the rising edge of the clock generation signal. One pair of MOSFET transistors 200 is connected to the Q output on D-type flip-flop 208 and the other pair, 202, is connected to the Q-not output of flip-flop 208. When Q is high (5 Volts), a low impedance connection is made between the D.C. power supply (not shown) and the series combination of drive coil 98 and the capacitor through the pair of MOSFET transistors 200 controlled by the Q output. When D-type flip-flop 208 changes state and Q-not is high, the low impedance connection from the power supply to the series combination drive coil 98 and capacitor 220 is reversed. Since flip-flop 208 changes state on the rising edge of the clock generation signal, two flip-flop changes are required for one complete drive cycle of the induction-heating element. The clock generation signal is typically set at twice the resonant frequency of the series combination of drive coil 90 and capacitor 220. The clock signal frequency can be manually or automatically set.
  • A second example ([0105] 150) of an aerosolization device of the present invention, in which the cross-sectional area is also restricted along the gas/vapor mixing area, will be described in reference to FIG. 9. In this example, venturi tube 152 within housing 10 having inlet 154, outlet 156 and throat 158 between inlet 154 and outlet 156 is used to restrict the gas flow through venturi tube 152. Controller 160 is designed to control the flow of air passing through valve 164 based on readings from the thermocouple 168 of the temperature of the air as a result of heater 166.
  • A fourth example ([0106] 300) of an aerosolization device of the present invention will be described in reference to FIGS. 10 and 11. A gas stream is passed into thin walled tube 302 having a coating (310) of compound 60 on its inside. The flow rate of the gas stream is controlled by valve 314. The device of example 300, as with others, allows for rapid heat-up using a resistive heating system (320) while controlling the flow direction of vaporized compound. After activating heating system 320 with actuator 330, current is passed along tube 302 in the heating/vaporization zone 340 as the carrier gas (e.g., air, N2 and the like) is passed through tube 302 and mixes with the resulting vapor.
  • FIG. 12 shows an alternative heating system to [0107] resistive heating system 320 used in connection with the fourth example. In this case, inductive heating system 350 consists of a plurality of ferrites 360 for conducting the magnetic flux to vaporize compound 310.
  • FIG. 13 shows a variation on the fourth example in which flow [0108] restrictor 370 is mounted within thin-walled tube 302 by means of support 374 within a housing (not shown) to increase the flow of mixing gas across the surface of compound 310.
  • A fifth example [0109] 400 of an aerosolization device of the present invention will be described in reference to FIG. 14. For this example, compound 60 is placed within expandable container 402 (e.g., a foil pouch) and is heated by resistance heater 406, which is activated by actuator 410 as shown in FIG. 14. The vaporized compound generated is forced into container 420 through outlet passage 440 and mixed with the gas flowing through tube 404. Additional steps are taken, when necessary, to preclude or retard decomposition of compound 60. One such step is the removal or reduction of oxygen around 60 during the heat up period. This can be accomplished, for example, by sealing the small container housing in an inert atmosphere.
  • A sixth example [0110] 500 of an aerosolization device of the present invention will be described in reference to FIG. 15. Compound 60 is placed in an inert atmosphere or under a vacuum in container 502 within housing 10 and is heated by resistance heater 504 upon being activated by actuator 508 as shown in FIG. 15. Once compound 60 has become vaporized it can then be ejected through outlet passage 510 into the air stream passing through tube 520.
  • FIG. 16 shows a variation of [0111] device 500 in which fan 530 recirculates the inert atmosphere over the surface of compound 60. The inert gas from a compressed gas cylinder (not shown) enters through inlet 540 and one-way valve 550 and exits through outlet passage 510 into tube 502.
  • A seventh example ([0112] 600) of an aerosolization device of the present invention will be described in reference to FIG. 17. A compound (not shown), such as compound 60 discussed above, is deposited onto a substrate in the form of discrete particles 602 (e.g., aluminum oxide (alumina), silica, coated silica, carbon, graphite, diatomaceous earth, and other packing materials commonly used in gas chromatography). The coated particles are placed within first tube 604, sandwiched between filters 606 and 608, and heated by resistance heater 610, which is activated by actuator 620. The resulting vapor from tube 604 is combined with the air or other gas passing through second tube 625.
  • FIG. 18 shows a variation of [0113] device 600 in which resistance heater 630 heats the air prior to passing through first tube 604 and over discrete particles 602.
  • An eighth example [0114] 700 of an aerosolization device of the present invention will be described in reference to FIG. 19. Compound 60 is deposited into chamber 710 and is heated by resistance heater 715, which is activated by actuator 720. Upon heating, some of compound 60 is vaporized and ejected from chamber 710 by passing an inert gas entering housing 10 through inert gas inlet 725 and valve 728 across the surface of the compound. The mixture of inert gas and vaporized compound passes through passage 730 and is then mixed with a gas passing through tube 735.
  • A ninth example [0115] 800 of an aerosolization device of the present invention will be described in reference to FIG. 20. Thermally conductive substrate 802 is heated by resistance heater 810 at the upstream end of tube 820, and the thermal energy is allowed to travel along substrate 802. This produces, when observed in a particular location, a heat up rate that is determined from the characteristics of the thermally conductive substrate. By varying the material and its cross sectional area, it was possible to control the rate of heat up. The resistive heater is embedded in substrate 802 at one end. However, it could be embedded into both ends, or in a variety of positions along the substrate and still allow the temperature gradient to move along the carrier and/or substrate.
  • A tenth example [0116] 900 of an aerosolization device of the present invention will be described in reference to FIGS. 21 and 22. Air is channeled through a fine mesh metal screen 902 on which drug is deposited. Screen 902 is positioned across airway passage 910 (e.g., constructed from 18 mm glass tubing). The two sides of the screen are electrically connected to charged capacitor 920 through silicon-controlled rectifier (SCR) 922 to make a circuit. The charge of the capacitor is calculated and set at a value such that, when actuator 930 closes SCR 922, the energy from capacitor 920 is converted to a desired temperature rise in screen 902.
  • General Considerations [0117]
  • The device of the present invention utilizes a flow of gas (e.g., air) across the surface of a compound ([0118] 60) to sweep away vaporized molecules. This process drives vaporization as opposed to condensation and therefore enables aerosol formation at relatively moderate temperatures. Nicotine (1 mg, bp 247° C./745 mm), for example, vaporized in less than 2 s at about 130° C. in a device of the present invention. Similarly, fentanyl (bp>300° C./760 mm) was vaporized around 190° C. in quantities up to 2 mg.
  • Purity of an aerosol produced using a device of the present invention is enhanced by limiting the time during which a compound ([0119] 60) is exposed to elevated temperatures. This is accomplished by rapidly heating a thin film of the compound to vaporize it. The vapors are then immediately cooled upon entry into a carrier gas stream.
  • Typically, [0120] compound 60 is subjected to a temperature rise of at least 1,000° C./second. In certain cases, the compound is subjected to a temperature rise of at least 2,000° C./second, 5,000° C./second, 7,500° C. or 10,000° C./second. A rapid temperature rise within the compound is facilitated when it is coated as a thin film (e.g., between 10μ and 10 nm in thickness). The compound is oftentimes coated as a film between 5μ and 10 nm, 4μ and 10 nm, 3μ and 10 nm, 2μ and 10 nm, or even 1μ to 10 nm in thickness.
  • Rapid temperature rises and thin coatings ensure that compounds are substantially vaporized in a short time. Typically, greater than 0.1 mg, 0.25 mg, 0.5 mg, 0.75 mg or 1 mg of a compound is vaporized in less than 100 milliseconds from the start of heating. Oftentimes, the same amount of compound is vaporized in less than 75 milliseconds, 50 milliseconds, 25 milliseconds, or 10 milliseconds from the start of heating. [0121]
  • Examples of compounds that have benefited from rapid heating in a device of the present invention include lipophilic substance #87 and fentanyl. Lipophilic substance #87 decomposed by more than 90% when heated at 425° C. for 5 minutes, but only 20% when the temperature was lowered to 350° C. Decomposition of the substance was further lowered to about 12% when the heating time was decreased to 30 seconds and to less than 2% at 10-50 milliseconds. A fentanyl sample decomposed entirely when heated to 200° C. for 30 seconds, and only 15-30% decomposed when heated for 10 milliseconds. Vaporizing fentanyl in [0122] device 1 led to less than 0.1% decomposition.
  • An aerosol of the present invention contains particles having an MMAD between 10 nm and 1μ, preferably 10 nm to 900 nm, 10 nm to 800 nm, 10 nm to 700 nm, 10 nm to 600 nm, 10 nm to 500 nm, 10 nm to 400 nm, 10 nm to 300 nm, 10 nm to 200 nm, or 10 nm to 100 nm. Particles are produced such that their size is stable for several seconds (e.g., 1 to 3 s). The aerosol particle size and subsequent stability is controlled by the rate of compound vaporization, the rate of carrier gas introduction, and the mixing of resultant vapors and the carrier gas. Such control is accomplished using a number of methods, including the following: (a) measuring the quantity and regulating the flow rate of the mixing air; and/or, (b) regulating the vaporization rate of the compound (e.g., by changing the energy transferred to the compound during the heating process or changing the amount of compound introduced into a heating region). [0123]
  • A desired particle size is achieved by mixing a compound in its vapor state into a volume of a carrier gas in a ratio such that, when the number concentration of the mixture reaches approximately 10[0124] 9 particles/mL, a particle that exists in a size range from 10 nm to 1μ for 1 to 3 seconds results.
  • FIG. 23 is a plot of theoretical data calculated from a mathematical model. See “Aerosol Technology” W. C. Hinds, second edition 1999, Wiley, New York. It shows the time in seconds it takes for the number concentration of an aerosol to aggregate to half of its original value as a function of the particle concentration. For example, a 1.0 mg vaporized dose of a compound with a molecular weight of 200 that is mixed into 1 liter of aire will have approximately 3×10[0125] 18 molecules (particles) in the liter. This results in a number concentration of 3×1015/cc. Extrapolating from FIG. 23, one can see that it takes less than 10 milliseconds for the number of particles to halve in this example. Therefore, to insure uniform mixing of a vaporized compound, the mixing must occur in a very short time. FIG. 23 also shows that when the number concentration of the mixture reaches approximately 109 particles/cc, the particle size is “stable” for the purpose of drug delivery by inhalation.
  • FIG. 23 is for an aerosol having a Coagulation Coefficient (K) of 5×10[0126] −16 meters3/second. This K value corresponds to a particle size of 200 nm. As the particle size changes, so can its K value. Table 1 below gives the K values for various particle sizes. As K increases, the time required for the aerosol to aggregate from a particular particle size to a larger particle size is reduced. As can be seen from Table 1 and FIG. 24, when the particle is in the 10 nm to 100 nm range, the effect of a changing K value tends to accelerate the coagulation process towards 100 nm in size.
    TABLE 1
    Coagulation Coefficient (x e−15
    Particle size (diameter in nm) meters3/second)
    1 3.11
    5 6.93
    10 9.48
    20 11.50
    50 9.92
    100 7.17
    200 5.09
    500 3.76
    1000 3.35
    2000 3.15
    5000 3.04
    10000 3.00
  • In creating an aerosol of a particular particle size, the ratio of mass of vaporized compound to the volume of the mixing gas is the controlling condition. By changing this ratio, the particle size can be manipulated (see FIG. 29). However, not all compounds and not all gases, with the same ratio will result in the same particle size distribution (PSD). Other factors must be known to be able to accurately predict the resultant particle size. A compound's density, polarity, and temperature are examples of some of these factors. Additionally, whether the compound is hydrophilic or hydrophobic will affect the eventual particle size, because this factor affects an aerosol's tendency to grow by taking on water from the surrounding environment. [0127]
  • In order to simplify the approach used to predict the resulting particle size, the following assumptions were made: [0128]
  • 1. The compound is non polar (or has a weak polarity). [0129]
  • 2. The compound is hydrophobic or hydrophilic with a mixing gas that is dry. [0130]
  • 3. The resultant aerosol is at or close to standard temperature and pressure. [0131]
  • 4. The coagulation coefficient is constant over the particle size range and therefore the number concentration that predicts the stability of the particle size is constant. [0132]
  • Consequently, the following variables are taken into consideration in predicting the resulting particle size: [0133]
  • 1. The amount (in grams) of compound vaporized. [0134]
  • 2. The volume of gas (in cc's) that the vaporized compound is mixed into. [0135]
  • 3. The “stable” number concentration in number of particles/cc. [0136]
  • 4. The geometric standard deviation (GSD) of the aerosol. [0137]
  • Where the GSD is 1, all of the particle sizes are the same size and therefore the calculation of particle size becomes a matter of dividing a compound's mass into the number of particles given by the number concentration and from there calculating the particle size diameter using the density of the compound. The problem becomes different, though, if the GSD is other than 1. As an aerosol changes from a GSD of 1 to a GSD of 1.35, the mass median diameter (MMD) will increase. MMD is the point of equilibrium where an equal mass of material exists in smaller diameter particles as exists in larger diameter particles. Since total mass is not changing as the GSD changes, and since there are large and small particles, the MMD must become larger as the GSD increases because the mass of a particle goes up as the cube of its diameter. Therefore larger particles, in effect, carry more weight and the MMD becomes larger to “balance” out the masses. [0138]
  • To determine the effect of a changing GSD, one can start with the formula for the mass per unit volume of an aerosol given a known MMD, GSD, density, and number concentration. The formula is from Finlay's “[0139] The Mechanics of Inhaled Pharmaceutical Aerosols” (2001, Academic press). Formula 2.39 states that the mass per unit volume of an aerosol is:
  • M=(ρNπ/6)(MMD)3 exp[−9/2(ln σg)2]
  • Where: ρ=density in gm/cc [0140]
  • N=Number concentration in particles/cc [0141]
  • MMD=mass median diameter (in cm) [0142]
  • σ[0143] g=the GSD
  • M=the mass per unit volume of the aerosol in gms/cc [0144]
  • If the change in the MMD is considered as an aerosol changes from one GSD to another, while the density, number concentration, and the mass remain unchanged the following equality can be set up: [0145]
  • ρNπ/6(MMD 1)3 exp[−9/2(ln σg1)2 ]=ρNπ/6(MMD 2)3 exp[−9/2(ln σg2)2]
  • simplifying: [0146]
  • (MMD 1)3 exp[−9/2(ln σg1)2]=(MMD 2)3 exp[−9/2(ln σg2)2]
  • Or [0147]
  • (MMD 1)3/(MMD 2)3 =exp[−9/2(ln σg2)2 ]/exp[−9/2(ln σg1)2]
  • If one sets the GSD of [0148] case 1 to 1.0 then:
  • exp[−9/2(ln σg1)2=1
  • And therefore: [0149]
  • (MMD 1 /MMD 2)3 =exp[−9/2(ln σg2)2]
  • Or: [0150]
  • MMD 1 /MMD 2 =exp[−3/2(ln σg2)2]
  • It is advantageous to calculate the change in the MMD as the GSD changes. Solving for MMD[0151] 2 as a function of MMD1 and the new GSD2 yields:
  • MMD 2 =MMD 1 /exp[−3/2(ln σg2)2] for a σg1=1
  • To calculate MMD[0152] 1, divide the compound's mass into the number of particles and then, calculate its diameter using the density of the compound.
  • MMD 1=(6C/ρNV)1/3 for an aerosol with a GSD of 1
  • Where: C=the mass of the compound in gm's [0153]
  • ρ=Density in gm/cc (as before) [0154]
  • N=Number concentration in particles/cc (as before) [0155]
  • V=volume of the mixing gas in cc [0156]
  • Insertion of MMD[0157] 1 into the above equation leads to:
  • MMD 2=(6C/ρNVπ)1/3 /[exp[−3/2(ln σg2)2], measured in centimeters.
  • A resultant MMD can be calculated from the number concentration, the mass of the compound, the compound density, the volume of the mixing gas, and the GSD of the aerosol. [0158]
  • The required vaporization rate depends on the particle size one wishes to create. If the particle size is in the 10 nm to 100 nm range, then the compound, once vaporized, must be mixed, in most cases, into the largest possible volume of air. This volume of air is determined from lung physiology and can be assumed to have a reasonable upper limit of 2 liters. If the volume of air is limited to below 2 liters (e.g., 500 cc), too large a particle will result unless the dose is exceedingly small (e.g., less than 50 μg). [0159]
  • In the 10 nm to 100 m range, doses of 1-2 mg are possible. If this dose is mixed into 2 liters of air, which will be inhaled in 1-2 seconds, the required, desired vaporization rate is in the range of about 0.5 to about 2 mg/second. [0160]
  • The first example of the present invention is shown in FIG. 1 and is the basic device through which the principles cited above have been demonstrated in the laboratory. This device is described in detail in the EXAMPLES. [0161]
  • In the second example of the present invention shown in FIG. 9, the use of a reduced airway cross section increases the speed of the air across the compound's surface to about 10 meters/second. If complete mixing is to happen within 1 millisecond, then the distance the gas and vaporized mixture must travel to achieve complete mixing must be no longer than 10 millimeters. However, it is more desirable for complete mixing to happen before the compound has aggregated to a larger size, so a desirable mixing distance is typically about 1 millimeter or less. [0162]
  • In the fourth example of the present invention shown in FIGS. [0163] 10-13, an aerosol having particles with an MMAD in the 10 nm to 100 nm range is generated by allowing air to sweep over a thin film of the compound during the heating process. This allows the compound to become vaporized at a lower temperature due to the lowering of the partial pressure of the compound near the surface of the film.
  • The fifth example shown in FIG. 14, the sixth example shown in FIGS. 15 and 16, and the eighth example shown in FIG. 19 overcome a problem with certain compounds that react rapidly with oxygen at elevated temperatures. To solve this problem, the compound is heated in an expandable container (fourth example), a small container housing under a vacuum or containing a small amount, e.g., about 1 to about 10 ml, of an inert gas (fifth example). Once a compound is vaporized and mixed with an inert gas while the gaseous mixture is maintained at a temperature sufficient to keep the compound in its vaporized state, the gaseous mixture is then injected into an air stream. The volume of inert gas can also be re-circulated over the surface of the heated compound to aid in its vaporization as shown in FIG. 16. In the seventh example, the compound is introduced into the gas as a pure vapor. This involves vaporizing the compound in an oven or other container and then injecting the vapor into an air or other gas stream through one or more mixing nozzles. [0164]
  • In the sixth example shown in FIGS. [0165] 17-18, gas is passed through a first tube and over discrete substrate particles, having a large surface area to mass ratio, and coated with the compound. The particles are heated as shown in FIG. 17 to vaporize the compound, or the gas is heated and the heated gas vaporizes the compound as shown in FIG. 18. The gaseous mixture from the first tube is combined with the gas passing through second tube to rapidly cool the mixture before administering it to a patient.
  • The eighth example shown in FIG. 20 is a thermal gradient device that is similar to [0166] device 1 used in the laboratory experiments. This example also has a moving heating zone without any moving parts, accomplished by establishing a heat gradient that transverses from one end of the device to the other over time. As the heating zone moves, exposed portions of the compound are sequentially heated and vaporized. In this manner the vaporized compound can be introduced into a gas stream over time.
  • The ninth example shown in FIGS. [0167] 21-22 is the screen device and is preferred for generating a aerosols containing particles with an MMAD greater than 100 nm. In this example, air is channeled through a fine mesh screen upon which the drug to be administered to the patient has been deposited.
  • The examples above can create aerosols without significant drug decomposition. This is accomplished while maintaining a required vaporization rate for particle size control by employing a short duration heating cycle. An airflow over the surface of the compound is established such that when the compound is heated and reaches the temperature where vaporization is first possible, the resulting compound vapors will immediately cool in the air. In the preferred examples, this is accomplished by extending the increased velocity and mixing region over an area that is larger than the heating zone region. As a result, precise control of temperature is not necessary since the compound vaporizes the instant its vaporization temperature is reached. Additionally because mixing is also present at the point of vaporization, cooling is accomplished quickly upon vaporization. [0168]
  • Application of the present invention to human inhalation drug delivery must accommodate constraints of the human body and breathing physiology. Many studies of particle deposition in the lung have been conducted in the fields of public health, environmental toxicology and radiation safety. Most of the models and the in vivo data collected from those studies, relate to the exposure of people to aerosols homogeneously distributed in the air that they breathe, where the subject does nothing actively to minimize or maximize particle deposition in the lung. The International Commission On Radiological Protection (ICRP) models are examples of this. (See James A C, Stahlhofen W, Rudolph G, Egan M J, Nixon W, Gehr P, Briant J K, [0169] The respiratory tract deposition model proposed by the ICRP Task Group, Radiation Protection Dosimetry, 1991; vol. 38: pgs.157-168).
  • However, in the field of aerosol drug delivery, a patient is directed to breathe in a way that maximizes deposition of the drug in the lung. This kind of breathing usually involves a full exhalation, followed by a deep inhalation sometimes at a prescribed inhalation flow rate range, e.g., about 10 to about 150 liters/minute, followed by a breath hold of several seconds. In addition, ideally, the aerosol is not uniformly distributed in the air being inhaled, but is loaded into the early part of the breath as a bolus of aerosol, followed by a volume of clean air so that the aerosol is drawn into the alveoli and flushed out of the conductive airways, bronchi and trachea by the volume of clean air that follows. A typical deep adult human breath has a volume of about 2 to 5 liters. In order to ensure consistent delivery in the whole population of adult patients, delivery of the drug bolus should be completed in the first 1-12 liters or so of inhaled air. [0170]
  • As a result of the constraints of human inhalation drug delivery, a compound should be vaporized in a minimum amount of time, preferably no greater than 1 to 2 seconds. As discussed earlier, it is also advantageous, to keep the temperature of vaporization at a minimum. In order for a compound to be vaporized in 2 seconds or less and for the temperature to be kept at a minimum, rapid air movement, in the range of about 10 to about 120 liters/minute, should flow across the surface of the compound. [0171]
  • The following parameters are optimal in using a device of the present invention, due to human lung physiology, the physics of particle growth, and the physical chemistry of the desirable compounds: [0172]
  • (1) The compound should to be vaporized over approximately 1 to 2 seconds for creation of particles in the ultra fine range. [0173]
  • (2) The compound should to be raised to the vaporization temperature as rapidly as possible. [0174]
  • (3) The compound, once vaporized, should be cooled as quickly as possible. [0175]
  • (4) The compound should be raised to the maximum temperature for a minimum duration of time to minimize decomposition. [0176]
  • (5) The air or other gas should be moved rapidly across the surface of the compound to achieve the maximum rate of vaporization. [0177]
  • (6) The heating of the air or other gas should be kept to a minimum, i.e., an increase of temperature of no greater than about 15° C. above ambient. [0178]
  • (7) The compound should be mixed into the air or other gas at a consistent rate to have a consistent and repeatable particle size. [0179]
  • (8) As the gas speed increases across the compound being vaporized, the cross sectional area through the device should decrease. Furthermore, as the surface area of the compound increases the heating of the gas increases. [0180]
  • The parameters of the design for one of the examples shown in FIGS. [0181] 2-5, 7 and 8 are the result of meeting and balancing the competing requirements listed above. One especially important requirement for an aerosol containing particles with an MMAD between 10 nm and 100 nm is that a compound, while needing to be vaporized within at least a 1-second period, also needs to have each portion of the compound exposed to a heat-up period that is as brief as possible. In this example, the compound is deposited onto a foil substrate and an alternating magnetic field is swept along a foil substrate heating the substrate such that the compound is vaporized sequentially over no more than about a one second period of time. Because of the sweeping action of the magnetic field, each segment of the compound has a heat-up time that is much less than one second.
  • In the example noted directly above, the compound is laid down on a thin metallic foil. In one of the examples set forth below, stainless steel (alloy of 302, 304, or 316) was used in which the surface was treated to produce a rough texture. Other foil materials can be used, but it is important that the surface and texture of the material is such that it is “wetted” by the compound when the compound is in its liquid phase, otherwise it is possible for the liquid compound to “ball” up which would defeat the design of the device and significantly change the volatilizing parameters. If the liquid compound “balls” up, the compound can be blown into and picked up by the airflow without ever vaporizing. This leads to delivery of a particle size that is uncontrolled and undesirable. [0182]
  • Stainless steel has advantages over materials like aluminum because it has a lower thermal conductivity value, without an appreciable increase in thermal mass. Low thermal conductivity is helpful because heat generated by the process needs to remain in the immediate area of interest. [0183]
  • EXAMPLES
  • The following examples further illustrate the method and various examples of the present invention. These examples are for illustrative purposes and are not meant to limit the scope of the claims in any way. [0184]
  • Example 1 In Vivo Results Using Example 1
  • In this example, example 1, was designed to deliver an experimental dose of fentanyl between 20 μg and 500 μg, in a range of ultra fine particle sizes, in about 800 cc of air to a 10 kg dog. The lung volume of each dog under experimentation was approximately 600-700 cc and the device was designed to deliver the compound to the lung in the first half of the inhalation. Because of the value of these parameters, [0185] device 1 in this experiment can be considered a ¼ scale device for administering a dose to a human. It is believed that scaling the device to work for human subjects involves mainly increasing the airflow through the device. The time frame of the introduction of the compound into the heating/vaporization/mixing zone was set such that the compound vaporized into a volume of air that was suitable for both the volume required by dog lung anatomy (600-700 cc) and the volume needed to control the ratio of the compound to the air.
  • The following was the sequence of events that took place during each operation: [0186]
  • 1. At the beginning of the run, the operator triggered [0187] inhalation controller 30 to start monitoring data from pressure transducer 240 and input flow meter 4.
  • 2. [0188] Controller 30 signaled controller 20 to start example 1 and to begin collecting data from the two temperature sensors and flow meter 4.
  • 3. After a pre-programmed delay, example 1 initiated the generation of the aerosol. (Note: there was a delay of about 0.4 seconds between the start of the [0189] controller 30 and the start of aerosol generation.)
  • 4. After an independent preprogrammed delay (from original trigger signal), [0190] controller 30 opened input valve 58 to start forced inhalation to a dog under experimentation.
  • 5. Example 1 completed the aerosol generation during the inhalation. [0191]
  • 6. [0192] Controller 30 monitored flow meter 4 and pressure transducer 240 throughout the inhalation and closed off flow at input valve 58 when a pre-specified volume or pressure was met. (Note: the pre-specified pressure is a safety feature to prevent injury to the subject animal. Termination of the breath at the pre-specified volume is the desirable occurrence of the experiment.)
  • 7. After a breath hold delay (5 seconds), [0193] exhaust valve 40 was opened and the dog was allowed to exhale.
  • 8. Exhaled aerosol was trapped on [0194] exhaust filter 40 for later analysis. Controller 30 recorded values for the following: volume dispensed, terminal pressure, duration of air pulse, and average flow rate. Controller 20 continuously recorded at millisecond resolution, input flow rate, exhaust flow rate, foil temperature, mouthpiece temperature, slide position, heater on/off time, and other internal diagnostic electrical parameters.
  • Three weight-matched female beagle dogs received fentanyl at a 100 μg intravenous bolus dose. The same dogs received fentanyl UF for Inhalation (100 μg aerosolized and administered as two successive activations of [0195] device 1, containing approximately 50 μg fentanyl base) at a particle size of 80 nm (MMAD). The aerosol was administered to anesthetized dogs via the system schematically represented in FIG. 1, with a target delivered volume of 600-700 ml air, followed by a 5 second breath hold. After dosing, plasma samples for pharmacokinetic analysis were obtained at various time points from 2 min to 24 hr. Fentanyl remaining in device 1 was recovered and measured. Fentanyl concentrations were measured by using a validated GC method, with a limit of detection of 0.2 ng/ml.
  • Plasma pharmacokinetics from this example were compared to intravenous (IV) fentanyl (100 μg) in the same dogs. Inhalation of fentanyl resulted in rapid absorption (C[0196] max, maximum concentration in plasma, 11.6 ng/ml and Tmax, maximum time, 2 min.) and high bioavailability (84%). The time course of inhaled fentanyl was nearly identical to that of IV fentanyl. Thus, fentanyl UF for inhalation had an exposure profile that was similar to that of an IV injection.
  • Standard non-compartmental pharmacokinetic methods were used to calculate pharmacokinetic parameters for each animal. The maximum concentration in plasma (C[0197] max) and the maximum time it occurred (Tmax) were determined by examination of the data. The area under the plasma concentration vs. time curve (AUC) was determined. The bioavailability (F) of inhaled fentanyl was determined as:
  • F=(DIV/DINHAL)*(AUCINHAL/AUCIV)
  • where D was the dose and AUC was the AUC determined to the last measurable time point. [0198]
  • FIG. 26 plots the data obtained on the blood levels, by dog, for both the IV doses and the inhalation [0199] doses using device 1 as described above under Example 1.
  • The fentanyl aerosol was rapidly absorbed, with the same T[0200] max (2 min, the earliest time point) observed for both routes of administration. The maximum plasma concentration of fentanyl aerosol (11.6±1.9 ng/ml) was nearly two-thirds that of IV fentanyl (17.6±3.6 ng/ml). Plasma concentrations fell below the assay limit of quantitation by 6-8 hr after IV administration and by 3-4 hr after aerosol inhalation. Bioavailability calculations were based on the AUC's observed to the last measurable time point for the inhalation administration. Bioavailability for the inhalation study was 84% based on the nominal (uncorrected) fentanyl dose.
  • The mean plasma elimination half-life was similar after IV (75.4 min) and inhalation dose. Distribution phase half-lives (3-4 min) were also similar after both routes of administration. The inter-animal variability of pharmacokinetic parameters after the inhalation dose was low, with relative standard deviations (RSD<25%) lower than those observed for IV administration. [0201]
  • Example 2 In Vitro Results Using Example 1
  • Table 2 below summarizes the data collected from use of example 1 for in vitro testing of fentanyl. Particle size was measured with a Moudi cascade impactor. [0202]
    TABLE 2
    Compound Mass Mixing air volume
    (ug) (cc) MMAD (nm) GSD
    20 400 71 1.9
    25 400 72-78 1.7-1.8
    50 400 77-88  1.7-185
    100 400 100-105 1.4-1.8
    200 400 103-123 1.6-1.9
    300 400 140-160 1.8-2.1
  • Example 3 Use of Example 1 to Make Fine Aerosol Particles
  • In this example, example 1 was slightly modified and the flow rate changed, as discussed below, to make a fine aerosol in the 1 to 3 micron particle size range. [0203]
  • [0204] Airway section 140 was removed and the air channel heating/vaporization zone 70 was changed. An airway insert (not shown) had a “roof” that was 0.25 inches above the foil. There were no mixing rods as rapid mixing was not desirable in this example. Because of these two device changes, there was much less mixing with the air, thus the vapor/aerosol cloud was mixed with less air and produced a larger particle size aerosol. The airflow rate was reduced 1 liter/minute in this example. Again, this allowed the vapor to be mixed with much less air, resulting in the larger particle size aerosol.
  • Some operational problems with high compound loading on [0205] foil 64 in example 1 were encountered. The compound tested, dioctyl phthalate (DOP), was an oil and during the aerosolization process, a substantial quantity was blown downwind and not aerosolized. Three additional design alternatives were made to address this issue, involving changes to the substrate surface that the compound was deposited on. In the three alternatives, the substrate was made to “hold” the compound through the use of texture. They were: a) texturing the foil; b) adding a stainless steel screen on top of the foil; and, c) replacing the foil with a fine stainless steel screen.
  • The results from this example are set forth below in Table 3 below: [0206]
    TABLE 3
    Substrate Type MMAD, microns GSD Emitted Dose, ug
    Textured foil 1.49 microns 1.9 97
    Textured foil 2.70 microns 1.95 824
    Fine screen alone 1.59 microns 1.8 441
    Fine screen alone 1.66 microns 1.8 530
    Screen on Foil 2.42 microns 2.2 482
  • As shown above, a fine particle size can be made with [0207] device 1 merely by changing the ratio of the compound to the mixing air.
  • Example 4 In Vitro Results Using Example 700
  • A tank was partially filled with DOP and placed inside an oven (not shown) having an inlet and an outlet. DOP was used as the test compound. The tank was purged with helium prior to heating the tank and its contents to a temperature of 350° C. Helium was pumped through the tank and used to carry the DOP vapor out of the outlet. The gaseous mixture of helium and vaporized [0208] compound 60 was introduced into different size mixing tubes through a nozzle. Each of the tubes had air moving through them at 14 liters/minute. The nozzle was perpendicular to the flow direction. After this gaseous mixture was mixed with the air, the resulting aerosol was introduced into a parallel flow diffusion battery for particle size analysis. Results are set forth in Table 4 below.
    TABLE 4
    Mixing tube size (ID) MMAD GSD
    4.8 mm 65 nm 1.3
    14 mm 516 nm 3.3
  • As can be seen above, as the tube diameter became larger so did the particle size. Additionally, as the diameter became larger, the GSD also became larger. As the tube becomes larger, it is believed that the vaporized gas is introduced into a smaller segment of the mixing gas because the gas is being introduced as a point source leading to uneven mixing, which results in a large GSD. [0209]
  • Example 5 In Vitro Results Using Example 800
  • To demonstrate effectiveness of example [0210] 800, a 4-inch long piece of aluminum was fitted with a 150-watt cartridge heater at one end. The heater was powered with a variac AC power transformer. The thickness of the aluminum was designed to ensure that heat would transverse from one end of the aluminum to the other in approximately 30 seconds.
  • On the topside of the aluminum, an indentation was machined to hold the compound and to hold one of two top covers. The indentation for the compound was approximately 3.5 inches long and 0.4 inches wide. The indentation was 0.025 inches deep, and was filled with 1 mg of DOP. [0211]
  • The first top consisted of a sheet of flat glass placed 0.04 inches above the heated surface, creating an airway. At the exit end an outlet was fitted allowing the air to be drawn into an analytical measurement device. Air was made to flow through the airway at a rate of 15 liters/minute. [0212]
  • In the second configuration, the top was replaced with a half cylinder made of glass. This increased the cross sectional area of the airway by an order of magnitude. [0213]
  • Particle size was measured with both configurations and shown to be affected by the cross sectional area of the airway. [0214]
  • Results from the thermal gradient test are set forth in Table 5 below: [0215]
    TABLE 5
    Cover size and
    cross-section MMAD GSD
    Small 92 nm 1.4
    Big 650 nm unknown
  • As shown above, the results confirm that as the cross section becomes larger, so does the particle size. [0216]
  • Example 6 In Vitro Results Using Example 900
  • In this example for producing aerosols, [0217] airway passage 910 was constructed from 18 mm diameter glass tubing. However, the passage can be made in any shape with a comparable cross-sectional area and out of any suitable material. The screen size, mesh, and the amount of compound were chosen in this example so that a gas could pass through the screen without interference once the compound had been deposited on it.
  • Because the internal resistance of the screen was low, i.e., between 0.01 and 0.2 ohms, the discharge rate (the RC time constant) of the capacitor was rapid, and on the order of a few milliseconds, i.e. less than 20 milliseconds, preferably in the range of about 2 to about 10 milliseconds. Upon discharge of [0218] capacitor 902 and the subsequent heating of screen 902, the deposited compound was rapidly vaporized. Because air moved through screen 902, the vaporized compound rapidly mixed with air and cooled.
  • The compound was deposited onto the fine stainless steel screen, e.g., 200 mesh, made from 316 stainless steel, having measurements of 2.54 cm.×2.54 cm. The current from the capacitor was passed between one edge and another. It was not necessary to heat the screen to temperatures comparable to the thin foil in Example 1, because the compound vaporized at a lower temperature due to the rapid air movement. Rapid air movement allowed the compound to vaporize at a lower vapor pressure, since airflow constantly removed compound vapors from the surface as soon as they were formed. Thus, the compound vaporized at a lower temperature without decomposition. [0219]
  • Deposition of the compound onto the screen was accomplished by mixing the compound with an organic solvent until the compound dissolved. The resulting solution was then applied to the fine [0220] stainless steel screen 902 and the solvent was allowed to evaporate. The screen was then inserted into holder 940 that electrically connected two sides of screen 902 to the power circuit described above.
  • A 10,000 mF capacitor was discharged while the gas was passing through [0221] screen 902. The rapid heat up of the screen resulted in a rapid vaporization of the compound into the gas. Thus the resulting vaporized compound was mixed into a small volume of the gas. Because the ratio of the mass of the compound to the volume of the mixing gas was large, a fine (1-3 micron diameter) particle aerosol was made.
  • Example 7 General Procedure for Screening Drugs to Determine Aerosolization Preferability
  • Drug (1 mg) is dissolved or suspended in a minimal amount of solvent (e.g., dichloromethane or methanol). The solution or suspension is pipeted onto the middle portion of a 3 cm by 3 cm piece of aluminum foil. The coated foil is wrapped around the end of a 1½ cm diameter vial and secured with parafilm. A hot plate is preheated to approximately 300° C., and the vial is placed on it foil side down. The vial is left on the hotplate for 10 s after volatilization or decomposition has begun. After removal from the hotplate, the vial is allowed to cool to room temperature. The foil is removed, and the vial is extracted with dichloromethane followed by saturated aqueous NaHCO[0222] 3. The organic and aqueous extracts are shaken together, separated, and the organic extract is dried over Na2SO4. An aliquot of the organic solution is removed and injected into a reverse-phase HPLC with detection by absorption of 225 nm light. A drug is preferred for aerosolization where the purity of the drug isolated by this method is greater than 85%. Such a drug has a decomposition index less than 0.15. The decomposition index is arrived at by substracting the percent purity (i.e., 0.85) from 1.
  • One of ordinary skill in the art can combine the foregoing embodiments or make various other embodiments and aspects of the method and device of the present invention to adapt them to specific usages and conditions. As such, these changes and modifications are properly, equitably, and intended to be, within the full range of equivalents of the following claims. [0223]

Claims (17)

1. A method for preparing an aerosol of particles having a mass median aerodynamic diameter of less than 1 μm comprising the steps of
a) depositing a compound composition on a substrate
b) heating said substrate to form a vapor of at least a portion of the composition
c) mixing the resulting vapor with a gas, in a ratio to form an aerosol with a mass median aerodynamic diameter of less than 1 μm when a stable number concentration of particles in the gas is reached.
2. The method of claim 1, wherein said mixing involves passing a gas across the surface of said composition during heating.
3. The method of claim 1, wherein said mixing involves passing a gas with turbulence across the surface of said composition during heating.
4. The method of claim 3, wherein said gas is air.
5. The method of claim 1, wherein the composition is deposited as a thin film.
6. Method of claim 5, wherein the thin film is of a thickness of less than 10 microns.
7. The method of claim 6, wherein the thin film is vaporized at a rate of 0.5 to 2 mg/sec.
8. The method of claim 1, wherein said mass median aerodynamic diameter is between 10 nm and 900 nm.
9. The method of claim 1, wherein said mass median aerodynamic diameter is between 10 nm and 500 nm.
10. The method of claim 1, wherein said mass median aerodynamic diameter is between 10 nm and 100 nm
11. The method of claim 1, wherein said vaporization is complete in less than 2 seconds.
12. The method of claim 1, wherein said heating is at a rate of at least 1000° C./second.
13. The method of claim 1, wherein the substrate is metallic.
14. The method of claim 13, wherein the metallic substrate is stainless steel.
15. The method of claim 1, wherein said heating is resistive or inductive.
16. The method of claim 1, wherein the mass median aerodynamic diameter has a geometric standard deviation of less than 2.
17. The method of claim 1, wherein the stable number concentration of particles in the gas is about 109 particles/mL.
US10/696,959 2001-06-05 2003-10-30 Delivery of aerosols containing small particles through an inhalation route Abandoned US20040096402A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/696,959 US20040096402A1 (en) 2001-06-05 2003-10-30 Delivery of aerosols containing small particles through an inhalation route

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29622501P 2001-06-05 2001-06-05
US10/057,197 US7766013B2 (en) 2001-06-05 2001-10-26 Aerosol generating method and device
US10/057,198 US20030051728A1 (en) 2001-06-05 2001-10-26 Method and device for delivering a physiologically active compound
US10/146,515 US6682716B2 (en) 2001-06-05 2002-05-13 Delivery of aerosols containing small particles through an inhalation route
US10/696,959 US20040096402A1 (en) 2001-06-05 2003-10-30 Delivery of aerosols containing small particles through an inhalation route

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/146,515 Continuation US6682716B2 (en) 2001-05-24 2002-05-13 Delivery of aerosols containing small particles through an inhalation route

Publications (1)

Publication Number Publication Date
US20040096402A1 true US20040096402A1 (en) 2004-05-20

Family

ID=27369190

Family Applications (15)

Application Number Title Priority Date Filing Date
US10/057,198 Abandoned US20030051728A1 (en) 2001-05-24 2001-10-26 Method and device for delivering a physiologically active compound
US10/057,197 Expired - Fee Related US7766013B2 (en) 2001-05-24 2001-10-26 Aerosol generating method and device
US10/146,088 Active 2024-10-28 US7537009B2 (en) 2001-05-24 2002-05-13 Method of forming an aerosol for inhalation delivery
US10/146,080 Expired - Fee Related US7942147B2 (en) 2001-05-24 2002-05-13 Aerosol forming device for use in inhalation therapy
US10/146,515 Expired - Fee Related US6682716B2 (en) 2001-05-24 2002-05-13 Delivery of aerosols containing small particles through an inhalation route
US10/696,959 Abandoned US20040096402A1 (en) 2001-06-05 2003-10-30 Delivery of aerosols containing small particles through an inhalation route
US12/471,070 Expired - Fee Related US8074644B2 (en) 2001-06-05 2009-05-22 Method of forming an aerosol for inhalation delivery
US12/847,584 Expired - Fee Related US9308208B2 (en) 2001-06-05 2010-07-30 Aerosol generating method and device
US13/078,606 Abandoned US20110240013A1 (en) 2001-06-05 2011-04-01 Method of forming an aerosol for inhalation delivery
US13/078,600 Abandoned US20110240022A1 (en) 2001-06-05 2011-04-01 Aerosol forming device for use in inhalation therapy
US13/851,577 Expired - Fee Related US8955512B2 (en) 2001-06-05 2013-03-27 Method of forming an aerosol for inhalation delivery
US14/077,015 Expired - Fee Related US9439907B2 (en) 2001-06-05 2013-11-11 Method of forming an aerosol for inhalation delivery
US14/078,577 Expired - Lifetime US9687487B2 (en) 2001-06-05 2013-11-13 Aerosol forming device for use in inhalation therapy
US14/624,311 Abandoned US20150157635A1 (en) 2001-06-05 2015-02-17 Method Of Forming An Aerosol For Inhalation Delivery
US15/633,508 Expired - Lifetime US11065400B2 (en) 2001-06-05 2017-06-26 Aerosol forming device for use in inhalation therapy

Family Applications Before (5)

Application Number Title Priority Date Filing Date
US10/057,198 Abandoned US20030051728A1 (en) 2001-05-24 2001-10-26 Method and device for delivering a physiologically active compound
US10/057,197 Expired - Fee Related US7766013B2 (en) 2001-05-24 2001-10-26 Aerosol generating method and device
US10/146,088 Active 2024-10-28 US7537009B2 (en) 2001-05-24 2002-05-13 Method of forming an aerosol for inhalation delivery
US10/146,080 Expired - Fee Related US7942147B2 (en) 2001-05-24 2002-05-13 Aerosol forming device for use in inhalation therapy
US10/146,515 Expired - Fee Related US6682716B2 (en) 2001-05-24 2002-05-13 Delivery of aerosols containing small particles through an inhalation route

Family Applications After (9)

Application Number Title Priority Date Filing Date
US12/471,070 Expired - Fee Related US8074644B2 (en) 2001-06-05 2009-05-22 Method of forming an aerosol for inhalation delivery
US12/847,584 Expired - Fee Related US9308208B2 (en) 2001-06-05 2010-07-30 Aerosol generating method and device
US13/078,606 Abandoned US20110240013A1 (en) 2001-06-05 2011-04-01 Method of forming an aerosol for inhalation delivery
US13/078,600 Abandoned US20110240022A1 (en) 2001-06-05 2011-04-01 Aerosol forming device for use in inhalation therapy
US13/851,577 Expired - Fee Related US8955512B2 (en) 2001-06-05 2013-03-27 Method of forming an aerosol for inhalation delivery
US14/077,015 Expired - Fee Related US9439907B2 (en) 2001-06-05 2013-11-11 Method of forming an aerosol for inhalation delivery
US14/078,577 Expired - Lifetime US9687487B2 (en) 2001-06-05 2013-11-13 Aerosol forming device for use in inhalation therapy
US14/624,311 Abandoned US20150157635A1 (en) 2001-06-05 2015-02-17 Method Of Forming An Aerosol For Inhalation Delivery
US15/633,508 Expired - Lifetime US11065400B2 (en) 2001-06-05 2017-06-26 Aerosol forming device for use in inhalation therapy

Country Status (17)

Country Link
US (15) US20030051728A1 (en)
EP (3) EP1392263A2 (en)
JP (4) JP4510438B2 (en)
CN (2) CN100496458C (en)
AT (2) ATE503516T1 (en)
AU (4) AU2002311923B2 (en)
CA (4) CA2646756C (en)
CZ (2) CZ20033249A3 (en)
DE (2) DE60239604D1 (en)
ES (1) ES2343678T3 (en)
HK (2) HK1068293A1 (en)
HU (2) HUP0401008A2 (en)
IL (2) IL158955A0 (en)
MX (2) MXPA03011269A (en)
NZ (2) NZ529296A (en)
PL (2) PL373836A1 (en)
WO (3) WO2002098390A2 (en)

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009128A1 (en) * 2002-05-13 2004-01-15 Rabinowitz Joshua D Delivery of drug amines through an inhalation route
US20040102434A1 (en) * 2002-11-26 2004-05-27 Alexza Molecular Delivery Corporation Method for treating pain with loxapine and amoxapine
US20040156791A1 (en) * 2001-05-24 2004-08-12 Alexza Molecular Delivery Corporation Delivery of antipsychotics through an inhalation route
US20050034723A1 (en) * 2003-08-04 2005-02-17 Bryson Bennett Substrates for drug delivery device and methods of preparing and use
US20050079166A1 (en) * 2003-05-21 2005-04-14 Alexza Molecular Delivery Corporation Self-contained heating unit and drug-supply unit employing same
US20050258159A1 (en) * 2004-05-20 2005-11-24 Alexza Molecular Delivery Corporation Stable initiator compositions and igniters
US20060160888A1 (en) * 2004-12-09 2006-07-20 Insys Therapeutics, Inc. Room-temperature stable dronabinol formulations
US20060233718A1 (en) * 2001-05-24 2006-10-19 Alexza Pharmaceuticals, Inc. Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US20060257328A1 (en) * 2001-11-21 2006-11-16 Alexza Pharmaceuticals, Inc. Delivery of caffeine through an inhalation route
WO2007030162A2 (en) 2005-05-18 2007-03-15 Nektar Therapeutics Valves, devices, and methods for endobronchial therapy
US20070207207A1 (en) * 2006-01-06 2007-09-06 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US20070286818A1 (en) * 2006-06-07 2007-12-13 Wyeth Treating cystic fibrosis with antibiotics via an aerosol drug
WO2007145868A1 (en) * 2006-06-07 2007-12-21 Wyeth Treating cystic fibrosis with antibiotics via an aerosol drug
US20070299687A1 (en) * 2006-06-23 2007-12-27 Pamela Palmer Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed
US20080112895A1 (en) * 2006-08-04 2008-05-15 Insys Therapeutics Inc. Aqueous dronabinol formulations
US20080268023A1 (en) * 2006-01-06 2008-10-30 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US20080299048A1 (en) * 2006-12-22 2008-12-04 Alexza Pharmaceuticals, Inc. Mixed drug aerosol compositions
US20090062254A1 (en) * 2002-11-26 2009-03-05 Alexza Pharmaceuticals, Inc. Acute Treatment of Headache with Phenothiazine Antipsychotics
US20090131479A1 (en) * 2006-01-06 2009-05-21 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage
US20090181080A1 (en) * 2007-08-06 2009-07-16 Insys Therapeutics Inc. Oral cannabinnoid liquid formulations and methods of treatment
US20090258075A1 (en) * 2002-11-26 2009-10-15 Alexza Pharmaceuticals, Inc. Respiratory Drug Condensation Aerosols and Methods of Making and Using Them
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US20100055048A1 (en) * 2002-05-20 2010-03-04 Alexza Pharmaceuticals, Inc. Acute treatment of headache with phenothiazine antipsychotics
US20100065052A1 (en) * 2008-09-16 2010-03-18 Alexza Pharmaceuticals, Inc. Heating Units
US20100126502A1 (en) * 2005-08-23 2010-05-27 Aerogen, Inc. Self-sealing t-piece and valved t-piece
US20100196286A1 (en) * 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
US20100192945A1 (en) * 2008-12-23 2010-08-05 Robert Owen Cook Inhalation devices and related methods for administration of sedative hypnotic compounds
US7834295B2 (en) 2008-09-16 2010-11-16 Alexza Pharmaceuticals, Inc. Printable igniters
US20100300433A1 (en) * 2009-05-28 2010-12-02 Alexza Pharmaceuticals, Inc. Substrates for Enhancing Purity or Yield of Compounds Forming a Condensation Aerosol
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
US7942147B2 (en) 2001-06-05 2011-05-17 Alexza Pharmaceuticals, Inc. Aerosol forming device for use in inhalation therapy
US20110166063A1 (en) * 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of therapeutic peptides
US20110171312A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Modified therapeutic peptides, methods of their preparation and use
US7981401B2 (en) 2002-11-26 2011-07-19 Alexza Pharmaceuticals, Inc. Diuretic aerosols and methods of making and using them
US7987846B2 (en) 2002-05-13 2011-08-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US8235037B2 (en) 2001-05-24 2012-08-07 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8333197B2 (en) 2004-06-03 2012-12-18 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
US20150223523A1 (en) * 2014-02-11 2015-08-13 Timothy McCullough Drug delivery system and method
US9220294B2 (en) 2014-02-11 2015-12-29 Timothy McCullough Methods and devices using cannabis vapors
US9289583B2 (en) 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US20160354561A1 (en) * 2014-02-11 2016-12-08 Timothy McCullough Methods and drug delivery devices using cannabis
US9642980B2 (en) 2013-03-15 2017-05-09 Trudell Medical International Ventilator circuit, adapter for use in ventilator circuit and methods for the use thereof
US9724341B2 (en) 2013-07-11 2017-08-08 Alexza Pharmaceuticals, Inc. Nicotine salt with meta-salicylic acid
US10625033B2 (en) 2007-03-09 2020-04-21 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US10786635B2 (en) 2010-08-26 2020-09-29 Alexza Pharmaceuticals, Inc. Heat units using a solid fuel capable of undergoing an exothermic metal oxidation-reduction reaction propagated without an igniter
US11241383B2 (en) 2016-12-09 2022-02-08 Alexza Pharmaceuticals, Inc. Method of treating epilepsy
US11497249B2 (en) 2019-09-16 2022-11-15 Vapor Cartridge Technology Llc Drug delivery system with stackable substrates
US11511054B2 (en) 2015-03-11 2022-11-29 Alexza Pharmaceuticals, Inc. Use of antistatic materials in the airway for thermal aerosol condensation process

Families Citing this family (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962904B1 (en) * 1998-03-13 2005-11-08 Connective Tissue Imagineering Elastin peptide analogs and uses thereof
US6759029B2 (en) 2001-05-24 2004-07-06 Alexza Molecular Delivery Corporation Delivery of rizatriptan and zolmitriptan through an inhalation route
US6805853B2 (en) 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
US7090830B2 (en) * 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
GB2381450B (en) * 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
MXPA04004726A (en) * 2001-11-19 2004-07-30 Becton Dickinson Co Pharmaceutical compositions in particulate form.
GB2384184B (en) * 2002-01-10 2005-01-12 Aea Technology Plc Cannabis aerosol
AU2003297087B2 (en) * 2003-02-04 2009-06-11 Philip Morris Products S.A. Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem
US7648981B2 (en) * 2003-02-28 2010-01-19 Ym Biosciences Inc. Opioid delivery system
US7648982B2 (en) * 2003-02-28 2010-01-19 Ym Biosciences Inc. Opioid delivery system
EP1732555A4 (en) * 2003-02-28 2008-07-16 Ym Biosciences Inc Opioid delivery system
PT1603533E (en) * 2003-02-28 2009-07-23 Ym Biosciences Inc Opioid delivery system
CN100381083C (en) 2003-04-29 2008-04-16 韩力 Electronic nonflammable spraying cigarette
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Composition for treating insomnia
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
US20050037506A1 (en) * 2003-08-04 2005-02-17 Alexza Molecular Delivery Corporation Methods of determining film thicknesses for an aerosol delivery article
US7252050B2 (en) * 2003-09-04 2007-08-07 Maury Dean Cole Substance inhalation system
WO2005037949A2 (en) * 2003-10-07 2005-04-28 Chrysalis Technologies Incorporated Aerosol formulations of butalbital, lorazepam, ipratropium, baclofen, morphine and scopolamine
DE10356925B4 (en) * 2003-12-05 2006-05-11 Lts Lohmann Therapie-Systeme Ag Inhaler for basic active pharmaceutical ingredients and process for its preparation
CN2719043Y (en) 2004-04-14 2005-08-24 韩力 Atomized electronic cigarette
CA2854037C (en) 2004-06-03 2020-06-23 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and uses thereof
US20100006092A1 (en) * 2004-08-12 2010-01-14 Alexza Pharmaceuticals, Inc. Aerosol Drug Delivery Device Incorporating Percussively Activated Heat Packages
FR2880279A1 (en) * 2005-01-05 2006-07-07 Cvb Sarl Sarl MULTI-ODOR DIFFUSION DEVICE
JP5738509B2 (en) * 2005-02-23 2015-06-24 テバ ファーマシューティカル インダストリーズ リミティド Rasagiline formulation with improved content uniformity
US7213347B2 (en) * 2005-05-03 2007-05-08 Eastman Kodak Company Metering material to promote rapid vaporization
EP1733753A1 (en) * 2005-06-14 2006-12-20 RIZK, Nelly Kamel An apparatus containing a composition
EP1896002A4 (en) 2005-06-27 2009-11-25 Biovail Lab Int Srl Modified-release formulations of a bupropion salt
US20090107495A1 (en) * 2005-07-21 2009-04-30 National Institute For Materials Science Device for inhalation of medicine
US7900625B2 (en) * 2005-08-26 2011-03-08 North Carolina State University Inhaler system for targeted maximum drug-aerosol delivery
JP2009507925A (en) * 2005-09-13 2009-02-26 エラン ファーマ インターナショナル リミテッド Nanoparticle tadalafil formulation
FR2891435B1 (en) * 2005-09-23 2007-11-09 Bull Sa Sa HOLDING SYSTEM IN POSITION OF A THREE-PART ASSEMBLY PROVIDING A PREDETERMINAL COMPRESSION EFFORT ON THE INTERMEDIATE PART
WO2007079118A1 (en) * 2005-12-29 2007-07-12 Molex Incorporated Heating element connector assembly with press-fit terminals
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US20070260491A1 (en) * 2006-05-08 2007-11-08 Pamela Palmer System for delivery and monitoring of administration of controlled substances
WO2007141668A2 (en) 2006-06-09 2007-12-13 Philip Morris Products S.A. Indirectly heated capillary aerosol generator
US20090054333A1 (en) * 2006-10-17 2009-02-26 Antonio Giordano Peptide inhibitors of cyclin-dependent kinase activity and uses thereof
WO2008073757A1 (en) * 2006-12-07 2008-06-19 Helsinn Healthcare Sa Crystalline and amorphous forms of palonosetron hydrochloride
US7513781B2 (en) 2006-12-27 2009-04-07 Molex Incorporated Heating element connector assembly with insert molded strips
EP1964564A1 (en) * 2007-04-19 2008-09-03 LAB International SRL Breakthrough Pain Management
KR101606944B1 (en) * 2007-08-07 2016-03-28 아셀알엑스 파마슈티컬스 인코퍼레이티드 Compositions and methods for procedural sedation and analgesia using oral transmucosal dosage forms
US8551534B2 (en) 2007-10-10 2013-10-08 Parion Sciences, Inc. Inhaled hypertonic saline delivered by a heated nasal cannula
EP2534957B1 (en) 2007-12-14 2015-05-27 AeroDesigns, Inc Delivering aerosolizable products
KR101672511B1 (en) 2008-03-06 2016-11-03 아나코르 파마슈티칼스 인코포레이티드 Boron-containing small molecules as anti-inflammatory agents
AU2009253739B2 (en) * 2008-05-27 2014-02-06 Otolanum Ag Methods of treating mammals with eustachian tube dysfunctions
WO2010107761A1 (en) 2009-03-18 2010-09-23 Acelrx Pharmaceuticals, Inc. Improved storage and dispensing devices for administration of oral transmucosal dosage forms
CN201445686U (en) * 2009-06-19 2010-05-05 李文博 High-frequency induction atomizing device
US8488952B2 (en) * 2009-06-22 2013-07-16 Magic-Flight General Manufacturing, Inc. Aromatic vaporizer
US9180263B2 (en) * 2009-07-01 2015-11-10 Microdose Therapeutx, Inc. Laboratory animal pulmonary dosing device
ES2614917T3 (en) * 2009-07-17 2017-06-02 Nektar Therapeutics Systems and methods for propulsion in sealed nebulizers
US9149605B2 (en) 2009-07-28 2015-10-06 Clement Kleinstreuer Methods and devices for targeted injection of microspheres
CN106267289B (en) 2009-10-13 2020-07-31 菲利普莫里斯生产公司 Aerosol generator
US20110091544A1 (en) * 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
WO2011094450A1 (en) 2010-01-27 2011-08-04 Anacor Pharmaceuticals, Inc Boron-containing small molecules
WO2011112531A2 (en) * 2010-03-08 2011-09-15 Stc. Unm Dry powder nebulizer
CN102009012B (en) * 2010-03-31 2012-10-24 范维林 Liquid atomized aerosol generating device with temperature control
US11247003B2 (en) 2010-08-23 2022-02-15 Darren Rubin Systems and methods of aerosol delivery with airflow regulation
DK2613788T3 (en) 2010-09-07 2017-08-07 Anacor Pharmaceuticals Inc BENZOXABOROLD DERIVATIVES FOR TREATMENT OF BACTERIA INFECTIONS
US9775379B2 (en) 2010-12-22 2017-10-03 Syqe Medical Ltd. Method and system for drug delivery
JP6219271B2 (en) 2011-06-07 2017-10-25 パリオン・サイエンシィズ・インコーポレーテッド Method of treatment
US8945605B2 (en) * 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
JP5717218B2 (en) * 2011-08-19 2015-05-13 日本たばこ産業株式会社 Aerosol inhaler
RU2595971C2 (en) 2011-09-06 2016-08-27 Бритиш Америкэн Тобэкко (Инвестментс) Лимитед Heating smoking material
US9854839B2 (en) 2012-01-31 2018-01-02 Altria Client Services Llc Electronic vaping device and method
SI2846859T1 (en) * 2012-03-09 2017-07-31 Vectura Gmbh Mixing channel for an inhalation device and inhalation device
WO2013138910A1 (en) * 2012-03-19 2013-09-26 Michael Klein Virtual respiratory gas delivery systems and circuits
GB201217067D0 (en) 2012-09-25 2012-11-07 British American Tobacco Co Heating smokable material
PL2925395T3 (en) * 2012-11-28 2019-08-30 Fontem Holdings 1 B.V. Device for generating a condensation aerosol from a liquid formulation
US10034988B2 (en) 2012-11-28 2018-07-31 Fontem Holdings I B.V. Methods and devices for compound delivery
CN105722817A (en) * 2013-01-18 2016-06-29 通尼克斯制药有限公司 Isometheptene isomer
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
GB2515992A (en) 2013-03-22 2015-01-14 British American Tobacco Co Heating smokeable material
CA3208137A1 (en) 2013-05-06 2014-11-13 Juul Labs, Inc. Nicotine salt formulations for aerosol devices and methods thereof
US11202470B2 (en) 2013-05-22 2021-12-21 Njoy, Inc. Compositions, devices, and methods for nicotine aerosol delivery
CN104274426A (en) 2013-07-03 2015-01-14 陆克塞纳医药公司 Novel aerosol formulations of ondansetron and uses thereof
WO2016004409A1 (en) * 2014-07-03 2016-01-07 Luxena Pharmaceuticals, Inc. Novel aerosol formulations of ondansetron and uses thereof
US10010692B2 (en) * 2013-07-08 2018-07-03 Virginia Commonwealth University Systems, devices, and methods for changing therapeutic aerosol size and improving efficiency of ventilation and aerosol drug delivery
US11278682B2 (en) 2014-11-09 2022-03-22 Sipnose Ltd. Device and method for aerosolized delivery of substance to a natural orifice of the body
US11992604B2 (en) 2014-11-09 2024-05-28 Sipnose Ltd. Devices and methods for delivering a substance to a body cavity
US11471618B2 (en) 2014-11-09 2022-10-18 Sipnose Ltd. Adjustable dosing delivery and multi sectioned drug compartment
US11116914B2 (en) 2014-11-09 2021-09-14 Sipnose Ltd. Device and method for aerosolized delivering of substance to a natural orifice of the body
DE202013105715U1 (en) 2013-08-22 2014-02-19 Sipnose Ltd. Device for delivering a predetermined amount of a substance to a natural opening of the body
US10194693B2 (en) 2013-09-20 2019-02-05 Fontem Holdings 1 B.V. Aerosol generating device
US10039321B2 (en) 2013-11-12 2018-08-07 Vmr Products Llc Vaporizer
WO2015073975A1 (en) 2013-11-15 2015-05-21 VMR Products, LLC Vaporizer with cover sleeve
KR102665932B1 (en) 2013-12-05 2024-05-13 쥴 랩스, 인크. Nicotine liquid formulations for aerosol devices and methods thereof
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
CN104740737A (en) * 2013-12-26 2015-07-01 北京谊安医疗系统股份有限公司 Anesthesia machine and heating device of absorption loop of anesthesia machine
EP3104721B1 (en) 2014-02-10 2020-10-14 Philip Morris Products S.a.s. An aerosol-generating system having a fluid-permeable heater assembly
USD763502S1 (en) 2014-03-04 2016-08-09 Vmr Products Llc Cartomizer for a vaporizer
USD788697S1 (en) 2014-03-04 2017-06-06 VMR Products, LLC Battery portion for a vaporizer
USD752278S1 (en) 2014-03-07 2016-03-22 VMR Products, LLC Battery portion of a vaporizer
USD752280S1 (en) 2014-03-07 2016-03-22 VMR Products, LLC Cartomizer for a vaporizer
USD749505S1 (en) 2014-03-07 2016-02-16 VMR Products, LLC Charger for a vaporizer
TWI589308B (en) * 2014-03-25 2017-07-01 林信湧 Inhalation-type pharmaceutical composition for parkinson's disease and preparation method thereof
USD804090S1 (en) 2014-04-08 2017-11-28 VMR Products, LLC Vaporizer with indicators
USD750320S1 (en) 2014-08-05 2016-02-23 VMR Products, LLC Vaporizer
TWI661782B (en) 2014-05-21 2019-06-11 瑞士商菲利浦莫里斯製品股份有限公司 Electrically heated aerosol-generating system,electrically heated aerosol-generating deviceand method of generating an aerosol
TWI669072B (en) 2014-05-21 2019-08-21 瑞士商菲利浦莫里斯製品股份有限公司 Electrically heated aerosol-generating system and cartridge for use in such a system
HUE031205T2 (en) 2014-05-21 2017-07-28 Philip Morris Products Sa Aerosol-generating article with multi-material susceptor
GB201410562D0 (en) 2014-06-13 2014-07-30 Nicoventures Holdings Ltd Aerosol provision system
CA2952934A1 (en) 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
PT3160552T (en) 2014-06-30 2019-08-26 Syqe Medical Ltd Drug dose cartridge for an inhaler device
CA2953082C (en) 2014-06-30 2023-07-11 Syqe Medical Ltd. Flow regulating inhaler device
JP6716475B2 (en) 2014-06-30 2020-07-01 サイケ メディカル リミテッドSyqe Medical Ltd. Method and device for vaporizing and inhaling an isolated substance
US11298477B2 (en) 2014-06-30 2022-04-12 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
AU2015283590B2 (en) 2014-06-30 2020-04-16 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
CN113616883B (en) 2014-06-30 2023-06-06 Syqe医药有限公司 System for pulmonary delivery of at least one pharmacologically active agent in plant material to a subject
CN104122179B (en) * 2014-08-05 2017-03-22 云南中烟工业有限责任公司 Method for evaluating smoke volume of electronic cigarettes
WO2016061166A1 (en) 2014-10-15 2016-04-21 Altria Client Services Llc Electronic vaping device and components thereof
MX2017008428A (en) 2014-12-23 2018-03-23 Acelrx Pharmaceuticals Inc Systems, devices and methods for dispensing oral transmucosal dosage forms.
GB201423317D0 (en) 2014-12-29 2015-02-11 British American Tobacco Co Apparatus for heating smokable material
GB201423318D0 (en) 2014-12-29 2015-02-11 British American Tobacco Co Cartridge for use with apparatus for heating smokable material
GB201423312D0 (en) 2014-12-29 2015-02-11 British American Tobacco Co Heating device for apparatus for heating smokable material and method of manufacture
WO2016126698A1 (en) * 2015-02-02 2016-08-11 Intrepid Brands, LLC Personal electronic vaporizer
CA2977802A1 (en) * 2015-02-27 2016-09-01 Ebbu, LLC Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
WO2017100369A1 (en) * 2015-12-07 2017-06-15 Ebbu, LLC Printable cannabinoid and terpene compositions
GB201511358D0 (en) 2015-06-29 2015-08-12 Nicoventures Holdings Ltd Electronic aerosol provision systems
GB201511349D0 (en) 2015-06-29 2015-08-12 Nicoventures Holdings Ltd Electronic aerosol provision systems
GB201511361D0 (en) 2015-06-29 2015-08-12 Nicoventures Holdings Ltd Electronic vapour provision system
US9943388B2 (en) 2015-06-30 2018-04-17 Maury D. Cole Substance inhalation system and method
US10994084B2 (en) 2015-06-30 2021-05-04 Maury D. Cole Substance inhalation system and method
US10034857B2 (en) 2015-07-02 2018-07-31 Civitas Therapeutics, Inc. Triptan powders for pulmonary delivery
US20170038184A1 (en) * 2015-08-06 2017-02-09 Charles E. Ankner Formulation delivery system
US20170055575A1 (en) 2015-08-31 2017-03-02 British American Tobacco (Investments) Limited Material for use with apparatus for heating smokable material
US20170055574A1 (en) 2015-08-31 2017-03-02 British American Tobacco (Investments) Limited Cartridge for use with apparatus for heating smokable material
US20170055584A1 (en) 2015-08-31 2017-03-02 British American Tobacco (Investments) Limited Article for use with apparatus for heating smokable material
US11924930B2 (en) 2015-08-31 2024-03-05 Nicoventures Trading Limited Article for use with apparatus for heating smokable material
US20170119050A1 (en) 2015-10-30 2017-05-04 British American Tobacco (Investments) Limited Article for Use with Apparatus for Heating Smokable Material
US20180317554A1 (en) 2015-10-30 2018-11-08 British American Tobacco (Investments) Limited Article for use with apparatus for heating smokable material
US20170119046A1 (en) 2015-10-30 2017-05-04 British American Tobacco (Investments) Limited Apparatus for Heating Smokable Material
US20170119047A1 (en) 2015-10-30 2017-05-04 British American Tobacco (Investments) Limited Article for Use with Apparatus for Heating Smokable Material
US20170119051A1 (en) 2015-10-30 2017-05-04 British American Tobacco (Investments) Limited Article for Use with Apparatus for Heating Smokable Material
WO2017118980A1 (en) * 2016-01-06 2017-07-13 Syqe Medical Ltd. Low dose therapeutic treatment
KR20240055129A (en) 2016-01-11 2024-04-26 사이키 메디컬 엘티디. Personal vaporizing device
US11027086B2 (en) * 2016-02-07 2021-06-08 The Government Of The United States As Represented By The Secretary Of The Army Oro-nasal inhalation plethysmography mask exposure system
WO2017153827A1 (en) 2016-03-07 2017-09-14 Wallbrooke Investments Ltd. Inductive heating apparatus and related method
US10244795B2 (en) * 2016-03-31 2019-04-02 Altria Client Services Llc Vaporizing assembly comprising sheet heating element and liquid delivery device for an aerosol generating system
JP7025344B2 (en) * 2016-03-31 2022-02-24 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム Vaporization assembly with sheet heating element and liquid delivery device for aerosol generation system
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
WO2017192767A1 (en) * 2016-05-03 2017-11-09 Pneuma Respiratory, Inc. Droplet delivery device for delivery of fluids to the pulmonary system and methods of use
JP2019519487A (en) 2016-05-05 2019-07-11 アクエスティブ セラピューティクス インコーポレイテッド Delivery enhancing epinephrine composition
CA3028019C (en) 2016-06-29 2021-05-25 British American Tobacco (Investments) Limited Apparatus for heating smokable material
WO2018044953A1 (en) 2016-08-29 2018-03-08 Ebbu, LLC Water soluble compositions comprising purified cannabinoids
US10736359B2 (en) 2016-12-02 2020-08-11 VMR Products, LLC Cartridge-based vaporizers
US10413505B1 (en) 2017-02-07 2019-09-17 Genus Lifesciences Inc. Pharmaceutical compositions and methods of using the same
US10149843B1 (en) 2017-02-07 2018-12-11 Gneus Lifescineces Inc. Pharmaceutical compositions and methods of using the same
US10231961B1 (en) 2017-02-07 2019-03-19 Genus Lifesciences Inc. Pharmaceutical compositions and methods of using the same
CA3056077A1 (en) 2017-03-13 2018-09-20 Beyondspring Pharmaceuticals, Inc. Compositions of plinabulin and use thereof
EP3634552A4 (en) 2017-05-19 2021-03-03 Pneuma Respiratory, Inc. Dry powder delivery device and methods of use
TWI760513B (en) * 2017-06-30 2022-04-11 瑞士商菲利浦莫里斯製品股份有限公司 Aerosol-generating device and aerosol-generating system with inductive heating system with efficient power control
US10292436B2 (en) 2017-07-10 2019-05-21 Arc Innovations, Inc. Electronic smoking systems, devices, and methods
PL3681321T3 (en) 2017-09-15 2023-05-29 Nicoventures Trading Limited Apparatus for heating smokable material
US10506830B2 (en) 2017-09-22 2019-12-17 Altria Client Services Llc Air flow design for an e-vaping cartridge, method of making the e-vaping cartridge, and e-vaping device including the cartridge
US20190099237A1 (en) 2017-10-02 2019-04-04 Lightlab Imaging, Inc. Intravascular Data Collection Probes and Related Assemblies
EP3691728B1 (en) 2017-10-04 2024-05-22 Pneuma Respiratory, Inc. Electronic breath actuated in-line droplet delivery device
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CA3082192A1 (en) 2017-11-08 2019-05-16 Pneuma Respiratory, Inc. Electronic breath actuated in-line droplet delivery device with small volume ampoule and methods of use
EP3746138A4 (en) * 2018-02-02 2021-11-03 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device
CN112912124A (en) * 2018-05-17 2021-06-04 赛诺丝有限公司 Device and method for aerosol delivery of substances to the natural orifice of the body
US11260195B2 (en) * 2018-09-20 2022-03-01 General Electric Company Systems and methods for an inductively heated anesthetic vaporizer
CA3118875A1 (en) 2018-11-05 2020-05-14 Juul Labs, Inc. Cartridges for vaporizer devices
JP7411654B2 (en) 2018-11-05 2024-01-11 ジュール・ラブズ・インコーポレイテッド Cartridges for vaporizer devices
MX2021006867A (en) 2018-12-17 2021-07-02 Philip Morris Products Sa 3-(1,2,3,6-tetrahydropyridin-2-yl)pyridine glutarate or a pharmaceutically acceptable solvate thereof.
LT3927337T (en) 2019-02-22 2024-07-10 GH Research Ireland Limited 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating major depression
CN109876252A (en) * 2019-04-04 2019-06-14 林晓霞 A kind of fixed atomizing inhalation device for paediatric internal medicine
EP3955936A1 (en) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Treatment of depression and other various disorders with psilocybin
EP3868364A1 (en) 2020-02-24 2021-08-25 GH Research Limited Aerosol comprising 5-methoxy-n,n-dimethyltryptamine
US11666553B2 (en) 2020-02-25 2023-06-06 North Cell Pharmceticals Inc. Method of reducing anxiety in non-human mammals by increasing brain serotonin levels
JP2024505429A (en) * 2021-01-15 2024-02-06 アクエスティブ セラピューティクス インコーポレイテッド Prodrug compositions and methods of treatment
KR20240037245A (en) 2021-06-22 2024-03-21 뉴마 레스퍼러토리 인코포레이티드 Droplet delivery device by push ejection
RU209490U1 (en) * 2021-07-05 2022-03-16 Общество с ограниченной ответственностью "ИнертГаз Медикал" Universal inhalation device for inert gas therapy with the function of heating the gas mixture
EP4159192A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders
CN114028595B (en) * 2021-10-28 2023-09-19 武汉生物制品研究所有限责任公司 Novel disinfection and evaluation method for coronavirus aerosol exposure system
CN113876748A (en) * 2021-11-22 2022-01-04 兆科药业(广州)有限公司 Atomization method of treprostinil aerosol inhalant for treating pulmonary hypertension
WO2023186835A1 (en) 2022-03-27 2023-10-05 GH Research Ireland Limited Treatment of mental disorders
WO2024160390A1 (en) 2023-01-30 2024-08-08 GH Research Ireland Limited 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression

Citations (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560607A (en) * 1962-11-30 1971-02-02 Fisons Pharmaceuticals Ltd Aerosol formulations of finely divided solid medicaments with anionic surface-active agents
US3949743A (en) * 1973-03-19 1976-04-13 Schick Incorporated Medicated vapor production method and apparatus
US4141369A (en) * 1977-01-24 1979-02-27 Burruss Robert P Noncombustion system for the utilization of tobacco and other smoking materials
US4566451A (en) * 1982-07-02 1986-01-28 Plantorgan Werk Heinrich G. E. Christensen Kg Vapor inhalation device
US4734560A (en) * 1987-01-20 1988-03-29 Medical Enterprises, Ltd. Vaporizing unit
US4735217A (en) * 1986-08-21 1988-04-05 The Procter & Gamble Company Dosing device to provide vaporized medicament to the lungs as a fine aerosol
US4753758A (en) * 1983-05-19 1988-06-28 Intertech Resources Inc. Respiratory humidifier
US4756318A (en) * 1985-10-28 1988-07-12 R. J. Reynolds Tobacco Company Smoking article with tobacco jacket
US4819665A (en) * 1987-01-23 1989-04-11 R. J. Reynolds Tobacco Company Aerosol delivery article
US4848374A (en) * 1987-06-11 1989-07-18 Chard Brian C Smoking device
US4853517A (en) * 1988-03-28 1989-08-01 John G. Bowen Vaporizing unit
US4854331A (en) * 1984-09-14 1989-08-08 R. J. Reynolds Tobacco Company Smoking article
US4858630A (en) * 1986-12-08 1989-08-22 R. J. Reynolds Tobacco Company Smoking article with improved aerosol forming substrate
US4895719A (en) * 1985-05-22 1990-01-23 Liposome Technology, Inc. Method and apparatus for administering dehydrated liposomes by inhalation
US4906417A (en) * 1988-02-08 1990-03-06 Associated Mills Inc. Humidifier
US4917119A (en) * 1988-11-30 1990-04-17 R. J. Reynolds Tobacco Company Drug delivery article
US4922901A (en) * 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US4924883A (en) * 1987-03-06 1990-05-15 R. J. Reynolds Tobacco Company Smoking article
US4928714A (en) * 1985-04-15 1990-05-29 R. J. Reynolds Tobacco Company Smoking article with embedded substrate
US4941483A (en) * 1989-09-18 1990-07-17 R. J. Reynolds Tobacco Company Aerosol delivery article
US4947874A (en) * 1988-09-08 1990-08-14 R. J. Reynolds Tobacco Company Smoking articles utilizing electrical energy
US4947875A (en) * 1988-09-08 1990-08-14 R. J. Reynolds Tobacco Company Flavor delivery articles utilizing electrical energy
US4989619A (en) * 1985-08-26 1991-02-05 R. J. Reynolds Tobacco Company Smoking article with improved fuel element
US5019122A (en) * 1987-08-21 1991-05-28 R. J. Reynolds Tobacco Company Smoking article with an enclosed heat conductive capsule containing an aerosol forming substance
US5020548A (en) * 1985-08-26 1991-06-04 R. J. Reynolds Tobacco Company Smoking article with improved fuel element
US5027836A (en) * 1984-12-21 1991-07-02 R. J. Reynolds Tobacco Company Insulated smoking article
US5033483A (en) * 1985-10-28 1991-07-23 R. J. Reynolds Tobacco Company Smoking article with tobacco jacket
US5099861A (en) * 1990-02-27 1992-03-31 R. J. Reynolds Tobacco Company Aerosol delivery article
US5105831A (en) * 1985-10-23 1992-04-21 R. J. Reynolds Tobacco Company Smoking article with conductive aerosol chamber
US5119834A (en) * 1985-04-15 1992-06-09 R. J. Reynolds Tobacco Company Smoking article with improved substrate
US5133368A (en) * 1986-12-12 1992-07-28 R. J. Reynolds Tobacco Company Impact modifying agent for use with smoking articles
US5224498A (en) * 1989-12-01 1993-07-06 Philip Morris Incorporated Electrically-powered heating element
US5388574A (en) * 1993-07-29 1995-02-14 Ingebrethsen; Bradley J. Aerosol delivery article
US5511726A (en) * 1988-09-23 1996-04-30 Battelle Memorial Institute Nebulizer device
US5605146A (en) * 1993-11-29 1997-02-25 Instrumentarium Oy Method and an arrangement in connection with vaporizing an anaesthetic
US5649554A (en) * 1995-10-16 1997-07-22 Philip Morris Incorporated Electrical lighter with a rotatable tobacco supply
US5735263A (en) * 1993-01-29 1998-04-07 Aradigm Corporation Lockout device for controlled release of drug from patient-activated dispenser
US5738865A (en) * 1995-04-07 1998-04-14 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5743251A (en) * 1996-05-15 1998-04-28 Philip Morris Incorporated Aerosol and a method and apparatus for generating an aerosol
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5758637A (en) * 1995-08-31 1998-06-02 Aerogen, Inc. Liquid dispensing apparatus and methods
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US5894841A (en) * 1993-06-29 1999-04-20 Ponwell Enterprises Limited Dispenser
US5915378A (en) * 1993-01-29 1999-06-29 Aradigm Corporation Creating an aerosolized formulation of insulin
US5918595A (en) * 1995-12-21 1999-07-06 Siemens-Elema Ab Method for vaporizing an anesthetic liquid and vaporizer operating according to the method
US6041777A (en) * 1995-12-01 2000-03-28 Alliance Pharmaceutical Corp. Methods and apparatus for closed-circuit ventilation therapy
US6051566A (en) * 1991-02-09 2000-04-18 B.S.D. Bio Science Development Snc Di Omini C. & Zuccari G. Anti-reactive anti-asthmatic activity of non-steroidal anti-inflammatory drugs by inhalation
US6060212A (en) * 1998-06-11 2000-05-09 Clariant Finance (Bvi) Limited 193 nm positive-working photoresist composition
US6234167B1 (en) * 1998-10-14 2001-05-22 Chrysalis Technologies, Incorporated Aerosol generator and methods of making and using an aerosol generator
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6255334B1 (en) * 1998-10-30 2001-07-03 Pfizer Inc 5HT 1 receptor agonists and metoclopramide for the treatment of migraine
US6264922B1 (en) * 1995-02-24 2001-07-24 Elan Pharma International Ltd. Nebulized aerosols containing nanoparticle dispersions
US20020037828A1 (en) * 1997-10-28 2002-03-28 Wilson Leland F. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US20020058009A1 (en) * 2000-09-19 2002-05-16 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US20020086852A1 (en) * 1998-05-14 2002-07-04 Cantor Jerome O. Method for treating respiratory disorders associated with pulmonary elastic fiber injury
US20030000518A1 (en) * 2001-05-24 2003-01-02 Rabinowitz Joshua D. Delivery of nonsteroidal antiinflammatory drugs through an inhalation route
US20030004142A1 (en) * 2001-04-18 2003-01-02 Prior Christopher P. Use of NSAIDs for prevention and treatment of cellular abnormalities of the lung or bronchial pathway
US20030005925A1 (en) * 2001-05-24 2003-01-09 Hale Ron L. Delivery of rizatriptan or zolmitriptan through an inhalation route
US6506762B1 (en) * 1999-09-30 2003-01-14 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
US20030012738A1 (en) * 2001-05-24 2003-01-16 Rabinowitz Joshua D. Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US20030015196A1 (en) * 2001-06-05 2003-01-23 Hodges Craig C. Aerosol forming device for use in inhalation therapy
US6514482B1 (en) * 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US20030032638A1 (en) * 2001-05-24 2003-02-13 Kim John J. Delivery of benzodiazepines through an inhalation route
US20030091511A1 (en) * 2001-11-09 2003-05-15 Rabinowitz Joshua D. Delivery of diazepam through an inhalation route
US6591839B2 (en) * 1999-02-17 2003-07-15 Dieter Meyer Filter material for reducing harmful substances in tobacco smoke
US20030138382A1 (en) * 2001-11-21 2003-07-24 Rabinowitz Joshua D. Delivery of caffeine through an inhalation route
US20040010148A1 (en) * 2002-06-06 2004-01-15 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US20040009128A1 (en) * 2002-05-13 2004-01-15 Rabinowitz Joshua D Delivery of drug amines through an inhalation route
US20040016427A1 (en) * 2000-04-27 2004-01-29 Byron Peter R. Method and apparatus for generating an aerosol
US6701922B2 (en) * 2001-12-20 2004-03-09 Chrysalis Technologies Incorporated Mouthpiece entrainment airflow control for aerosol generators
US20040099269A1 (en) * 2001-05-24 2004-05-27 Alexza Molecular Delivery Corporation Drug condensation aerosols and kits
US20040105819A1 (en) * 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Respiratory drug condensation aerosols and methods of making and using them
US20040105818A1 (en) * 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them

Family Cites Families (481)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1803334A (en) * 1931-05-05 Ootthujp lehmann
US1864980A (en) * 1932-06-28 Vapobizeb
US3080624A (en) 1963-03-12 weber iii
US2243669A (en) 1941-05-27 Electrical vaporizer
US1239634A (en) 1916-07-25 1917-09-11 Frank J Stuart Medical appliance.
US1535486A (en) * 1922-08-28 1925-04-28 James W Lundy Electric-lamp bulb
US2086140A (en) 1933-09-08 1937-07-06 Silten Ernst Automatic temperature regulated narcosis apparatus
US2084299A (en) 1934-12-15 1937-06-15 Arthur G Borden Medicament holder for nasal inhalers
US2230753A (en) 1937-02-15 1941-02-04 Bilhuber Corp E Unsaturated ethylamine derivatives
US2230754A (en) 1937-02-15 1941-02-04 Bilhuber Corp E Unsaturated ethylamine derivatives
GB502761A (en) 1938-01-29 1939-03-24 Christopher Engelbreth Improvements in and relating to hand inhalation apparatus
US2309846A (en) * 1941-03-06 1943-02-02 Holm Einar Marius Inhaler
FR921852A (en) 1945-12-06 1947-05-21 Diffuser of volatile products
US2469656A (en) 1946-04-19 1949-05-10 Peter H Lienert Vaporizer
US2714649A (en) 1952-11-25 1955-08-02 Lyle H Critzer Vaporizer
US2761055A (en) 1953-06-10 1956-08-28 Malcome Van Ike Lamp-heated vaporizer
US2741812A (en) 1954-02-15 1956-04-17 Tellier Andre Perfume dispenser
US2902484A (en) 1954-04-27 1959-09-01 Rhone Poulenc Sa Phenthiazine derivatives and processes for their preparation
US2887106A (en) * 1956-09-27 1959-05-19 Robinson Joseph Combined vaporizer and cover for medicament jar
US2898649A (en) 1956-11-19 1959-08-11 Elaine T Cassidy Perfume diffuser
US3371085A (en) 1959-12-10 1968-02-27 Hoffmann La Roche 5-aryl-3h-1,4-benzodiazepin-2(1h)-ones
US3043977A (en) 1960-03-30 1962-07-10 Puritron Corp Device and method for producing negative ions
US3474101A (en) * 1960-09-05 1969-10-21 Reckitt & Sons Ltd Thebaine and oripavine derivatives
GB903866A (en) 1961-05-09 1962-08-22 Dausse Lab Therapeutic preparations containing 7-substituted theophylline derivatives
BE623427A (en) * 1961-10-10
US3299185A (en) 1962-09-27 1967-01-17 Ube Nitto Kasei Co Dyeable polyolefin fibers containing a binary copolymer of styrene and acrylonitrile
US3169095A (en) * 1962-10-30 1965-02-09 Rexall Drug Chemical Self-propelling powder-dispensing compositions
BE629985A (en) 1962-11-29
US3282729A (en) 1963-02-27 1966-11-01 Union Carbide Corp Barrier coated thermoplastic olefin polymer substrates
US3200819A (en) 1963-04-17 1965-08-17 Herbert A Gilbert Smokeless non-tobacco cigarette
NL298071A (en) 1963-06-04
IL26896A (en) 1966-01-19 1970-11-30 Endo Lab 14-hydroxynormorphines and 14-hydroxynormorphinones
US3909463A (en) 1968-11-29 1975-09-30 Allied Chem Grafted block copolymers of synthetic rubbers and polyolefins
US3987052A (en) 1969-03-17 1976-10-19 The Upjohn Company 6-Phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines
US4008723A (en) 1970-03-23 1977-02-22 Imperial Chemical Industries Limited Smoking mixture
US3863347A (en) * 1970-04-13 1975-02-04 Philip Michael Banner Navigation device
US3773955A (en) 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US3831606A (en) 1971-02-19 1974-08-27 Alza Corp Auto inhaler
US3847650A (en) 1971-09-09 1974-11-12 Airco Inc Flashlamp with improved combustion foil and method of making same
US3749547A (en) 1971-09-09 1973-07-31 Airco Inc Flashlamp with improved combustible foil
US4166087A (en) 1971-11-22 1979-08-28 Cline-Buckner, Inc. Automatic intermittent vapor dispenser
US3701782A (en) 1972-02-10 1972-10-31 Upjohn Co 1-carbolower alkoxy - 6 - phenyl-4h-s-triazolo(1,4)benzodiazepine compounds
US3763347A (en) 1972-04-13 1973-10-02 Ncr Co Vaporous lamp
IE37524B1 (en) 1972-04-20 1977-08-17 Gallaher Ltd Synthetic smoking product
US3864326A (en) 1972-05-22 1975-02-04 Robert S Babington Spraying devices, in particular nebulizing devices
USRE30285E (en) 1972-05-22 1980-05-27 Spraying devices, in particular nebulizing devices
GB1366041A (en) 1972-07-21 1974-09-11 Kodama Bros Co Ltd Device for volatilizing insecticides and the like
US3773995A (en) 1972-10-27 1973-11-20 Westinghouse Electric Corp Motor advanced spring charging pawl and ratchet mechanism with spring assist
US3930796A (en) * 1973-09-13 1976-01-06 Universal Oil Products Company Catalytic fume control device
US3982095A (en) 1973-10-04 1976-09-21 Searle Cardio-Pulmonary Systems Inc. Respiratory humidifier
US3971377A (en) 1974-06-10 1976-07-27 Alza Corporation Medicament dispensing process for inhalation therapy
US3894040A (en) 1974-09-16 1975-07-08 American Home Prod 2,5,6,7-Tetrahydro-3H-imidazo(1,2-D)(1,4)benzodiazepine-5,6-dicarboxylic acid esters
US4045156A (en) 1974-12-23 1977-08-30 Gte Sylvania Incorporated Photoflash lamp
US4020379A (en) 1975-10-02 1977-04-26 Eg&G, Inc. Bulb-shaped flashtube with metal envelope
US4104210A (en) 1975-12-17 1978-08-01 Monsanto Company Thermoplastic compositions of high unsaturation diene rubber and polyolefin resin
US4121583A (en) 1976-07-13 1978-10-24 Wen Yuan Chen Method and apparatus for alleviating asthma attacks
US4286604A (en) 1976-10-05 1981-09-01 Gallaher Limited Smoking materials
US4079742A (en) 1976-10-20 1978-03-21 Philip Morris Incorporated Process for the manufacture of synthetic smoking materials
US4160765A (en) 1976-11-17 1979-07-10 Smithkline Corporation Method for 6-bromination of 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds
US4184099A (en) 1977-04-27 1980-01-15 International Flavors & Fragrances Inc. Composition for slow release of volatile ingredients at _high temperature; and article comprising same
DE2752384A1 (en) 1977-08-29 1979-03-15 Simes PHARMACEUTICAL PREPARATION BASED ON ANTY-RELEASE AGENTS AND INHIBITANTS OF BETA ADRENERGIC RECEPTORS
SE7812207L (en) 1977-12-01 1979-06-02 Welsh Nat School Med APPARATUS, PROCEDURE AND MANUFACTURED PRODUCTS FOR USE IN THE ADMINISTRATION OF ANTIHISTAMINES
US4183912A (en) 1978-01-16 1980-01-15 American Home Products Corporation Inhalation therapy for relieving bronchial spasm using quaternary salts of promethazine
JPS54120065A (en) 1978-02-24 1979-09-18 Osaka Takeshi Stick for blind person
US4198200A (en) 1978-05-18 1980-04-15 Lord Corporation Damage-preventive coatings
US4284089A (en) 1978-10-02 1981-08-18 Ray Jon P Simulated smoking device
US4276243A (en) * 1978-12-08 1981-06-30 Western Electric Company, Inc. Vapor delivery control system and method
US4280629A (en) 1979-01-08 1981-07-28 Anchor Brush Company, Inc. Container for nail polish or the like
US4229931A (en) 1979-03-05 1980-10-28 Deere & Company Hydraulic height sensing system with cylinder by-pass
US4219031A (en) 1979-03-05 1980-08-26 Philip Morris Incorporated Smoking product having core of fibrillar carbonized matter
IL59407A (en) 1979-03-06 1983-12-30 Sanofi Sa Di-n-propylacetic acid diesters of glycerol,their preparation and pharmaceutical compositions containing them
US4654370A (en) 1979-03-12 1987-03-31 Abbott Laboratories Glyceryl valproates
US4251525A (en) 1979-05-25 1981-02-17 Smithkline Corporation 3-Allyl-7,8-dihydroxy-6-halo-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine derivatives
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4340072A (en) 1979-11-16 1982-07-20 Imperial Group Limited Smokeable device
EP0039369B1 (en) 1980-05-02 1983-06-15 Schering Corporation Beclomethasone ester solvates, process for their preparation, and preparation of a formulation
US4391285A (en) 1980-05-09 1983-07-05 Philip Morris, Incorporated Smoking article
US4347855A (en) 1980-07-23 1982-09-07 Philip Morris Incorporated Method of making smoking articles
US4303083A (en) 1980-10-10 1981-12-01 Burruss Jr Robert P Device for evaporation and inhalation of volatile compounds and medications
US4376767A (en) 1981-01-02 1983-03-15 Merck & Co., Inc. Pyridylmethyl esters of selected bio-affecting carboxylic acids
US4346059A (en) 1981-03-03 1982-08-24 Donald Spector Aroma-generating lamp structure
DE3116951C2 (en) * 1981-04-29 1984-12-20 Drägerwerk AG, 2400 Lübeck Device for adding liquid anesthetics to the breathing gas to be supplied to the patient
JPS5876038A (en) 1981-10-28 1983-05-09 高森 正之 Evaporation apparatus of insecticide or aromatic agent
GB2122903B (en) 1982-06-22 1986-11-05 Masayuki Takamori Vaporizers for vaporisable substances and support media for substances usable therewith
US4556539A (en) 1982-08-27 1985-12-03 Donald Spector Disc-playing aroma generator
US4508726A (en) 1982-09-16 1985-04-02 The Upjohn Company Treatment of panic disorders with alprazolam
US4474191A (en) 1982-09-30 1984-10-02 Steiner Pierre G Tar-free smoking devices
AT398259B (en) 1982-09-30 1994-11-25 Dainippon Jochugiku Kk THERMAL SMOKER FOR A CHEMICAL PREPARATION
US4523589A (en) 1983-06-29 1985-06-18 Krauser Robert S Method and apparatus for treating ailments
US5038769A (en) 1983-06-29 1991-08-13 Krauser Robert S Method and apparatus for treating ailments
DE3326089A1 (en) 1983-07-20 1985-02-07 Gödecke AG, 1000 Berlin INHALATION-INTENDED PHARMACEUTICAL FORM OF CALCIUM ANTAGONISTS
DE3476197D1 (en) 1983-08-01 1989-02-23 Mclean Hospital Corp Gaba esters and gaba analogue esters
US4588721A (en) * 1983-09-12 1986-05-13 The Upjohn Company Treatment of negative symptoms of schizophrenia
DE3478900D1 (en) 1983-11-08 1989-08-17 Bunnell Life Systems Inc Humidifier, particularly for pulmonary assistance systems
FI68988C (en) * 1984-01-04 1985-12-10 Rauma Repola Oy FLISSIKT VARS SIKTKORG DELATS I TVAO KORGSEKTORER
GB8405190D0 (en) 1984-02-28 1984-04-04 British Petroleum Co Plc Thermoplastic elastomer composition
US4627963A (en) 1984-02-29 1986-12-09 Lad Technology, Inc. Heat activated dispenser and method of dispensing a vapor therefrom
US4683231A (en) 1984-03-02 1987-07-28 Research Foundation For Mental Hygiene, Inc. Method of preventing withdrawal symptoms associated with the cessation or reduction of tobacco smoking
DE3414640A1 (en) * 1984-04-18 1985-10-24 W. Schlafhorst & Co, 4050 Mönchengladbach ROTATIONAL SHAFT
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4647428A (en) * 1984-06-04 1987-03-03 Gyulay Joseph M Air freshener method
US4755508A (en) 1984-06-26 1988-07-05 Merck & Co., Inc. Benzodiazepine analogs and use as antogonists of gastrin and cholecystokinin
US5067499A (en) 1984-09-14 1991-11-26 R. J. Reynolds Tobacco Company Smoking article
US5042509A (en) 1984-09-14 1991-08-27 R. J. Reynolds Tobacco Company Method for making aerosol generating cartridge
US4793365A (en) 1984-09-14 1988-12-27 R. J. Reynolds Tobacco Company Smoking article
US4647433A (en) 1984-10-01 1987-03-03 Donald Spector Long-life aroma-generating capsule
GB8501015D0 (en) 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US4800903A (en) 1985-05-24 1989-01-31 Ray Jon P Nicotine dispenser with polymeric reservoir of nicotine
US4722334A (en) 1985-07-16 1988-02-02 Transpirator Technologies, Inc. Method and apparatus for pulmonary and cardiovascular conditioning of racehorses and competition animals
US5060666A (en) 1985-10-28 1991-10-29 R. J. Reynolds Tobacco Company Smoking article with tobacco jacket
US4793366A (en) 1985-11-12 1988-12-27 Hill Ira D Nicotine dispensing device and methods of making the same
JPS62204756A (en) * 1986-03-04 1987-09-09 大研医工株式会社 Drug volatilizing method and apparatus
JP2573275B2 (en) 1986-03-10 1997-01-22 ブルグハルト,クルト Pharmaceutical preparations and methods for their production
US4708151A (en) 1986-03-14 1987-11-24 R. J. Reynolds Tobacco Company Pipe with replaceable cartridge
US4765347A (en) 1986-05-09 1988-08-23 R. J. Reynolds Tobacco Company Aerosol flavor delivery system
US4771795A (en) 1986-05-15 1988-09-20 R. J. Reynolds Tobacco Company Smoking article with dual burn rate fuel element
US4917120A (en) 1986-05-21 1990-04-17 Advanced Tobacco Products, Inc. Nicotine impact modification
US4774971A (en) 1986-06-03 1988-10-04 Vieten Michael J Cigarette substitute
US4801411A (en) 1986-06-05 1989-01-31 Southwest Research Institute Method and apparatus for producing monosize ceramic particles
US4968885A (en) 1987-03-06 1990-11-06 Extrel Corporation Method and apparatus for introduction of liquid effluent into mass spectrometer and other gas-phase or particle detectors
HU201685B (en) 1987-04-23 1990-12-28 Chinoin Gyogyszer Es Vegyeszet For producing pharmaceutical compositions for inhalation and compositions for scenting air containing volatile active component in cyclodextrine inclusion, and air-scenting composition
US4889850A (en) 1987-05-11 1989-12-26 Thornfeldt Carl R Treatment of colic and teething
US5017575A (en) * 1987-06-09 1991-05-21 Golwyn Daniel H Treatment of immunologically based disorders, specifically Crohn's disease
US4935624A (en) * 1987-09-30 1990-06-19 Cornell Research Foundation, Inc. Thermal-assisted electrospray interface (TAESI) for LC/MS
US5072726A (en) 1987-10-09 1991-12-17 University Of Pittsburgh Of The Commonwealth System Of Higher Education Vaporizer for inhalation anesthetics during high-frequency jet ventilation and associated method
US4911157A (en) * 1988-01-07 1990-03-27 Pegasus Research Corporation Self-regulating, heated nebulizer system
JPH01221313A (en) 1988-02-29 1989-09-04 Hayashi Teruaki Sublimation-releasable medicine composition and releasing system thereof
DE3815221C2 (en) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Use of a retinol and / or retinoic acid ester-containing pharmaceutical preparation for inhalation for acting on the mucous membranes of the tracheo-bronchial tract, including the lung alveoli
US5137034A (en) 1988-05-16 1992-08-11 R. J. Reynolds Tobacco Company Smoking article with improved means for delivering flavorants
US4881556A (en) 1988-06-06 1989-11-21 R. J. Reynolds Tobacco Company Low CO smoking article
US5264433A (en) 1988-07-07 1993-11-23 Fujisawa Pharmaceutical Co., Ltd. Benzodiazepine derivatives
CH678151A5 (en) 1988-07-13 1991-08-15 Heinz Hermann Weick Self-medication nasal dispenser
US5345951A (en) 1988-07-22 1994-09-13 Philip Morris Incorporated Smoking article
US4852561A (en) 1988-07-27 1989-08-01 Sperry C R Inhalation device
EP0358114A3 (en) 1988-09-08 1990-11-14 R.J. Reynolds Tobacco Company Aerosol delivery articles utilizing electrical energy
USRE36744E (en) 1988-09-16 2000-06-20 Ribogene, Inc. Nasal administration of benzodiazepine hypnotics
US4950664A (en) 1988-09-16 1990-08-21 Rugby-Darby Group Companies, Inc. Nasal administration of benzodiazepine hypnotics
US4917830A (en) 1988-09-19 1990-04-17 The United States Of America As Represented By The United States Department Of Energy Monodisperse aerosol generator
US4963289A (en) 1988-09-19 1990-10-16 The United States Of America As Represented By The United States Department Of Energy Method for producing monodisperse aerosols
HU200105B (en) 1988-10-04 1990-04-28 Ferenc Inkovics Electrically actuated inhaler of uniform medicine feeding
US4984158A (en) 1988-10-14 1991-01-08 Hillsman Dean Metered dose inhaler biofeedback training and evaluation system
US4906476A (en) 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US4959380A (en) 1988-12-19 1990-09-25 Wilson Jordan E Method of treating people to stop smoking and composition
US4881541A (en) 1988-12-21 1989-11-21 The Regents Of The University Of California Vaporizer for an anesthetic having a vapor pressure about one atmosphere
GB8900267D0 (en) 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
US4892109A (en) * 1989-03-08 1990-01-09 Brown & Williamson Tobacco Corporation Simulated smoking article
DE3908161A1 (en) 1989-03-13 1990-09-27 Bat Cigarettenfab Gmbh Smokable article
GB8909891D0 (en) 1989-04-28 1989-06-14 Riker Laboratories Inc Device
ATE224748T1 (en) 1989-04-28 2002-10-15 Riker Laboratories Inc INHALATION DEVICE FOR DRY POWDER
KR920700648A (en) 1989-05-05 1992-08-10 오닐 크리스토퍼 Increased fertility
US6313176B1 (en) 1989-10-17 2001-11-06 Everett J. Ellinwood, Jr. Dosing method of administering deprenyl via intraoral administration or inhalation administration
US6048857A (en) 1989-10-17 2000-04-11 Ellinwood, Jr.; Everett H. Dosing method of administering medicaments via inhalation administration
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5269327A (en) 1989-12-01 1993-12-14 Philip Morris Incorporated Electrical smoking article
US5093894A (en) 1989-12-01 1992-03-03 Philip Morris Incorporated Electrically-powered linear heating element
US5060671A (en) 1989-12-01 1991-10-29 Philip Morris Incorporated Flavor generating article
US5144962A (en) 1989-12-01 1992-09-08 Philip Morris Incorporated Flavor-delivery article
US5408574A (en) * 1989-12-01 1995-04-18 Philip Morris Incorporated Flat ceramic heater having discrete heating zones
AU6909091A (en) 1989-12-05 1991-06-26 Ramsey Foundation Neurologic agents for nasal administration to the brain
US5109180A (en) * 1989-12-14 1992-04-28 Phillips Petroleum Company Apparatus providing a shatter-resistant electric lamp
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
GB9000042D0 (en) * 1990-01-03 1990-03-07 Ralph John F Decorative wall covering applied to steel radiators
GB2239807A (en) * 1990-01-09 1991-07-17 Boc Group Plc Anaesthetic vaporiser
US5376386A (en) 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
US5156170A (en) 1990-02-27 1992-10-20 R. J. Reynolds Tobacco Company Cigarette
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5118494A (en) 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5366770A (en) 1990-04-17 1994-11-22 Xingwu Wang Aerosol-plasma deposition of films for electronic cells
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5192548A (en) 1990-04-30 1993-03-09 Riker Laboratoires, Inc. Device
AU646871B2 (en) 1990-06-07 1994-03-10 Astrazeneca Uk Limited Therapeutic heterocyclic compounds
US5167242A (en) 1990-06-08 1992-12-01 Kabi Pharmacia Aktiebolaq Nicotine-impermeable container and method of fabricating the same
SE9002052D0 (en) 1990-06-08 1990-06-08 Pharmacia Ab SMOKING COMPOSITION
US5455043A (en) 1990-06-13 1995-10-03 Fischel-Ghodsian; Fariba Device for controlled release of vaporous medications through nasal route
US5126123A (en) 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
ES2073685T5 (en) * 1990-08-02 2002-03-01 Datex Ohmeda Inc ANESTHETIC VAPORIZER.
US5060667A (en) 1990-08-16 1991-10-29 Brown & Williamson Tobacco Corporation Smoking article
US5292499A (en) 1990-09-11 1994-03-08 University Of Wales College Of Cardiff Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
US5166202A (en) 1990-09-19 1992-11-24 Trustees Of The University Of Pennsylvania Method for the treatment of panic disorder
US5175152A (en) 1990-09-28 1992-12-29 Singh Nikhilesh N Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
NO904226D0 (en) 1990-09-28 1990-09-28 Forsvarets Forsknings MOISTURE DEVICES.
US5179966A (en) * 1990-11-19 1993-01-19 Philip Morris Incorporated Flavor generating article
US5095921A (en) * 1990-11-19 1992-03-17 Philip Morris Incorporated Flavor generating article
US5519019A (en) 1990-12-21 1996-05-21 Gyogyszerkutato Intezet N-acyl-2,3-benzoidazepine derivatives, pharmaceutical compositions containing them and process for preparing same
HU219778B (en) 1990-12-21 2001-07-30 Gyógyszerkutató Intézet Közös Vállalat Process for producing n-acyl-2,3-benzodiazepine derivatives, their acid additional salts and pharmaceutical compositions containing them and a grop of the compounds and pharmaceutical compositions containing them
FR2671487B1 (en) 1991-01-14 1993-03-19 Oreal USE OF A GROWTH FACTOR IN A SLIMMING COMPOSITION.
US5394866A (en) 1991-03-05 1995-03-07 Aradigm Corporation Automatic aerosol medication delivery system and methods
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
EP0683890B1 (en) 1991-03-05 2002-04-03 Aradigm Corporation Method and device for correcting the drift offset of a pressure sensor of a flowmeter
US5226411A (en) 1991-03-07 1993-07-13 Walter Levine Aerosol nebulizer heater
US5479948A (en) * 1993-08-10 1996-01-02 Philip Morris Incorporated Electrical smoking article having continuous tobacco flavor web and flavor cassette therefor
US5249586A (en) 1991-03-11 1993-10-05 Philip Morris Incorporated Electrical smoking
US5505214A (en) 1991-03-11 1996-04-09 Philip Morris Incorporated Electrical smoking article and method for making same
US5186164A (en) 1991-03-15 1993-02-16 Puthalath Raghuprasad Mist inhaler
US5993805A (en) 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US5817656A (en) 1991-04-23 1998-10-06 Eli Lilly And Company Mental disorders
US5627178A (en) 1991-04-23 1997-05-06 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5605897A (en) 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
US5938117A (en) 1991-04-24 1999-08-17 Aerogen, Inc. Methods and apparatus for dispensing liquids as an atomized spray
US5164740A (en) 1991-04-24 1992-11-17 Yehuda Ivri High frequency printing mechanism
GB9109021D0 (en) 1991-04-26 1991-06-12 Boc Group Plc Dosing pump
GB9109442D0 (en) * 1991-05-01 1991-06-26 Volex Group Plc Apparatus for emitting a chemical agent
US5160664A (en) * 1991-05-31 1992-11-03 Msp Corporation High output monodisperse aerosol generator
US5261424A (en) 1991-05-31 1993-11-16 Philip Morris Incorporated Control device for flavor-generating article
US5149538A (en) 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5177071A (en) 1991-06-17 1993-01-05 Merck & Co., Inc. 1,4-benzodiazepines with 6-membered heterocyclic rings to treat panic and anxiety disorder
CA2069687A1 (en) 1991-06-28 1992-12-29 Chandra Kumar Banerjee Tobacco smoking article with electrochemical heat source
US5285798A (en) * 1991-06-28 1994-02-15 R. J. Reynolds Tobacco Company Tobacco smoking article with electrochemical heat source
CN1103609C (en) * 1991-08-07 2003-03-26 伊万·菲利普·吉勒·佩森蒂 Inhalation device
US5184133A (en) * 1991-11-26 1993-02-02 Texas Instruments Incorporated ISAR imaging radar system
US5457100A (en) 1991-12-02 1995-10-10 Daniel; David G. Method for treatment of recurrent paroxysmal neuropsychiatric
US5363842A (en) 1991-12-20 1994-11-15 Circadian, Inc. Intelligent inhaler providing feedback to both patient and medical professional
GB9200047D0 (en) 1992-01-03 1992-02-26 Univ Alberta Nicotine-containing nasal spray
US5229120A (en) 1992-02-05 1993-07-20 Devincent James F Treatment for cocaine abuse
US5639441A (en) 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
DK64592D0 (en) 1992-05-14 1992-05-14 Carlbiotech Ltd As PEPTIDES FOR THERAPEUTIC TREATMENT
US5584701A (en) 1992-05-13 1996-12-17 University Of Florida Research Foundation, Incorporated Self regulating lung for simulated medical procedures
US5391081A (en) 1992-05-13 1995-02-21 University Of Florida Research Foundation, Incorporated Method and apparatus for simulating neuromuscular stimulation during medical surgery
US5525329A (en) 1992-05-21 1996-06-11 The Johns Hopkins University Inhibition of phosphodiesterase in olfactory mucosa
US5607691A (en) 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
AU660824B2 (en) 1992-06-12 1995-07-06 Teijin Limited Pharmaceutical preparation for intra-airway administration
US5622944A (en) 1992-06-12 1997-04-22 Affymax Technologies N.V. Testosterone prodrugs for improved drug delivery
US5284133A (en) 1992-07-23 1994-02-08 Armstrong Pharmaceuticals, Inc. Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means
US5322075A (en) 1992-09-10 1994-06-21 Philip Morris Incorporated Heater for an electric flavor-generating article
US5613505A (en) * 1992-09-11 1997-03-25 Philip Morris Incorporated Inductive heating systems for smoking articles
US5333106A (en) 1992-10-09 1994-07-26 Circadian, Inc. Apparatus and visual display method for training in the power use of aerosol pharmaceutical inhalers
WO1994009842A1 (en) * 1992-10-28 1994-05-11 Rosen Charles A Method and devices for delivering drugs by inhalation
US5888477A (en) 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US6024090A (en) 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US5743250A (en) 1993-01-29 1998-04-28 Aradigm Corporation Insulin delivery enhanced by coached breathing
US5364838A (en) 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
US5724957A (en) 1993-01-29 1998-03-10 Aradigm Corporation Intrapulmonary delivery of narcotics
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5970973A (en) 1993-01-29 1999-10-26 Aradigm Corporation Method of delivering insulin lispro
US6098620A (en) 1993-01-29 2000-08-08 Aradigm Corporation Device for aerosolizing narcotics
US5694919A (en) 1993-01-29 1997-12-09 Aradigm Corporation Lockout device for controlled release of drug from patient-activated dispenser
US5372148A (en) 1993-02-24 1994-12-13 Philip Morris Incorporated Method and apparatus for controlling the supply of energy to a heating load in a smoking article
US5468936A (en) 1993-03-23 1995-11-21 Philip Morris Incorporated Heater having a multiple-layer ceramic substrate and method of fabrication
GB9310412D0 (en) 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
CN1082365A (en) 1993-05-25 1994-02-23 潘昆年 Nutrient health-protecting cigarette
AU7227494A (en) 1993-06-03 1995-01-03 Barthold Von Schrader Inhalator
US5666977A (en) 1993-06-10 1997-09-16 Philip Morris Incorporated Electrical smoking article using liquid tobacco flavor medium delivery system
DE4328243C1 (en) 1993-08-19 1995-03-09 Sven Mielordt Smoke or inhalation device
US5456247A (en) 1993-08-26 1995-10-10 Iowa State University Research Foundation, Inc. Method for delivering drugs soluble in a vaporization vehicle
US5462740A (en) 1993-09-17 1995-10-31 Athena Neurosciences, Inc. Rectally-administered, epileptic-seizure-inhibiting composition
US5400969A (en) * 1993-09-20 1995-03-28 Keene; Christopher M. Liquid vaporizer and diffuser
SE9303574D0 (en) 1993-11-01 1993-11-01 Kabi Pharmacia Ab Composition for drug delivery and method of manufacturing thereof
MA23420A1 (en) 1994-01-07 1995-10-01 Smithkline Beecham Corp BICYCLIC FIBRINOGEN ANTAGONISTS.
US6143746A (en) 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9401894D0 (en) 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
US5522008A (en) 1994-03-16 1996-05-28 Bernard; Costello J. Device for heating and vaporizing a vaporizable module
US5451408A (en) 1994-03-23 1995-09-19 Liposome Pain Management, Ltd. Pain management with liposome-encapsulated analgesic drugs
BR9507236A (en) 1994-03-30 1997-09-16 Procter & Gamble Combination cleansing and moistening bar composition
US6102036A (en) 1994-04-12 2000-08-15 Smoke-Stop Breath activated inhaler
JP3911290B2 (en) 1994-05-13 2007-05-09 アラダイム コーポレーション Anesthesia prescription with aerosol
US5457101A (en) 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
WO1996000069A1 (en) 1994-06-23 1996-01-04 The Procter & Gamble Company Treatment of nicotine craving and/or smoking withdrawal symptoms with a solid or semi-solid composition containing nicotine and caffeine or xanthine, especially for nasal administration
MA23588A1 (en) 1994-06-23 1995-12-31 Procter & Gamble TREATMENT OF NEED FOR NICOTINE AND / OR SMOKING-RELATED SYNDROME
MA23587A1 (en) 1994-06-23 1995-12-31 Procter & Gamble TREATMENT OF NEED FOR NICOTINE AND / OR SMOKING-RELATED SYNDROME
CA2152684A1 (en) 1994-07-01 1996-01-02 Richard Anthony Henry Aerosol delivery of midazolam
DE4425255A1 (en) 1994-07-16 1996-01-18 Asta Medica Ag Formulation for inhalation application
US5456677A (en) 1994-08-22 1995-10-10 Spector; John E. Method for oral spray administration of caffeine
EP0777657A1 (en) 1994-08-22 1997-06-11 Smithkline Beecham Corporation Bicyclic compounds
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5537507A (en) 1994-09-28 1996-07-16 Advanced Ceramics Corporation Coated flash evaporator heater
WO1996010663A1 (en) 1994-09-30 1996-04-11 M & J Fibretech A/S A plant and a process for dry-producing a web-formed product
WO1996011689A1 (en) 1994-10-14 1996-04-25 Glaxo Wellcome Spa Use of cck-b receptor antagonists for the treatment of sleep disorders
JP3748890B2 (en) 1994-10-28 2006-02-22 アラダイム コーポレーション Disposable container, disposable package, drug delivery device, and method for producing aerosol for use in aerosolized spray of respiratory medication
US5767117A (en) 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
US5540959A (en) 1995-02-21 1996-07-30 Howard J. Greenwald Process for preparing a coated substrate
DE19507410C2 (en) 1995-03-03 1997-05-22 Gsf Forschungszentrum Umwelt Method and device for producing aerosols
US5565148A (en) 1995-03-16 1996-10-15 Minnesota Mining And Manufacturing Company Device for selectively providing a multiplicity of aromas
JPH11502845A (en) 1995-03-31 1999-03-09 アラディグム コーポレーション Pulmonary delivery of hematopoietic agents
US6014970A (en) 1998-06-11 2000-01-18 Aerogen, Inc. Methods and apparatus for storing chemical compounds in a portable inhaler
US5586550A (en) 1995-08-31 1996-12-24 Fluid Propulsion Technologies, Inc. Apparatus and methods for the delivery of therapeutic liquids to the respiratory system
TR199701167T1 (en) 1995-04-14 1998-03-21 Glaxo Wellcome Inc. Metered dose inhaler for albuterol.
EP1366777B1 (en) 1995-04-14 2005-06-15 SmithKline Beecham Corporation Metered dose inhaler for salmeterol
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
ATE258813T1 (en) 1995-04-14 2004-02-15 Smithkline Beecham Corp DEVICE FOR THE DOSED INHALATION OF BECLOMETHASONE DIPROPRIONATE
US5725756A (en) 1995-04-18 1998-03-10 Center For Research, Inc. In situ mitigation of coke buildup in porous catalysts with supercritical reaction media
US5690809A (en) 1995-04-18 1997-11-25 Center For Research, Inc. In situ mitigation of coke buildup in porous catalysts by pretreatment of hydrocarbon feed to reduce peroxides and oxygen impurities
US5776928A (en) 1995-04-21 1998-07-07 Eli Lilly And Company Method for treating dyskinesias with olanzapine
FR2733594B1 (en) * 1995-04-28 1997-06-06 France Etat DEVICE FOR THE SAMPLING OF GASEOUS SUBSTANCES, LIQUIDS, AEROSOLS OR EVEN OF POWDERY MATERIALS, FOR THEIR IN SITU ANALYSIS
US5809997A (en) 1995-05-18 1998-09-22 Medtrac Technologies, Inc. Electronic medication chronolog device
DE19519056A1 (en) 1995-05-24 1997-01-16 Klinge Co Chem Pharm Fab Use of antidepressants for the treatment of asthma and / or respiratory diseases by inhalation
GB9512708D0 (en) 1995-06-22 1995-08-23 Reckitt & Colman Inc Improvements in or relating to organic compounds
US6245347B1 (en) 1995-07-28 2001-06-12 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
US6209538B1 (en) 1995-08-02 2001-04-03 Robert A. Casper Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament
US5591409A (en) 1995-08-15 1997-01-07 Watkins; Carl J. Providing aromas
SE9503141D0 (en) 1995-09-12 1995-09-12 Siemens Elema Ab Anesthesia apparatus
US6013050A (en) 1995-10-20 2000-01-11 Powderject Research Limited Particle delivery
AU7669496A (en) 1995-11-03 1997-05-22 University Of Kentucky Method for the intranasal administration of l-dopa prodrugs
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US5564442A (en) 1995-11-22 1996-10-15 Angus Collingwood MacDonald Battery powered nicotine vaporizer
DK0870497T3 (en) 1995-12-14 2004-05-24 Taisho Pharmaceutical Co Ltd aerosol
CA2240836A1 (en) 1995-12-21 1997-07-03 Pierre Van Tran Method for treating dermatitis
CA2245079A1 (en) 1996-02-05 1997-08-07 Fred Silverstein Ventilation imaging using a fine particle aerosol generator
US5829436A (en) 1996-02-05 1998-11-03 Aradigm Corporation Ventilation imaging using a fine particle aerosol generator
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
DE19606107C1 (en) * 1996-02-19 1997-02-13 Martin Umwelt & Energietech Firing grate, in particular for waste incineration plants
GB9604329D0 (en) 1996-02-29 1996-05-01 Ici Plc Electrostatic spraying
AU709384B2 (en) 1996-03-01 1999-08-26 University Of Kansas, The Methods and apparatus for particle precipitation and coating using near-critical and supercritical antisolvents
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
WO1997033581A1 (en) 1996-03-13 1997-09-18 Yale University Smoking cessation treatments using naltrexone and related compounds
GB9606188D0 (en) 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
US5944012A (en) 1996-03-25 1999-08-31 Pera; Ivo E. Method for dispensing antioxidant vitamins by inhalation background of the invention
GB9606677D0 (en) 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
US5875776A (en) 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
GB2312848B (en) 1996-04-26 1999-11-17 Bespak Plc Controlled flow inhalers
HUP9901575A3 (en) 1996-04-29 1999-11-29 Dura Pharmaceuticals Inc San D Methods of dry powder inhalation
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5929093A (en) 1996-06-13 1999-07-27 Mayo Foundation For Medical Education And Research Bifunctional acetylcholinesterase reactivators
CN1106812C (en) * 1996-06-17 2003-04-30 日本烟业产业株式会社 Flavor producing article
CN1113621C (en) 1996-06-17 2003-07-09 日本烟业产业株式会社 Flavor generating product and flavor generating tool
GB9613015D0 (en) 1996-06-21 1996-08-28 Reckitt & Colman Inc Device
US6089857A (en) 1996-06-21 2000-07-18 Japan Tobacco, Inc. Heater for generating flavor and flavor generation appliance
AU3400797A (en) 1996-06-27 1998-01-14 Merck & Co., Inc. A method for treating meniere's disease
IL127956A0 (en) 1996-07-11 1999-11-30 Farmarc Nederland Bv Inclusion complex containing indole selective serotonin agonist
US6004516A (en) 1996-08-06 1999-12-21 Illinois Institute Of Technology Apparatus for generating odor upon electronic signal demand
US6325475B1 (en) 1996-09-06 2001-12-04 Microfab Technologies Inc. Devices for presenting airborne materials to the nose
PT951280E (en) 1996-10-03 2004-05-31 Hermes Biosciences Inc HYDROPHILIC MICROPARTICLES AND METHODS FOR THEIR PREPARATION
US5934289A (en) 1996-10-22 1999-08-10 Philip Morris Incorporated Electronic smoking system
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US5906202A (en) 1996-11-21 1999-05-25 Aradigm Corporation Device and method for directing aerosolized mist to a specific area of the respiratory tract
US6694975B2 (en) * 1996-11-21 2004-02-24 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US5878752A (en) 1996-11-25 1999-03-09 Philip Morris Incorporated Method and apparatus for using, cleaning, and maintaining electrical heat sources and lighters useful in smoking systems and other apparatuses
US5744469A (en) 1996-11-26 1998-04-28 Eli Lilly And Company Method for treating dermatitis
CA2222830C (en) * 1996-12-02 2004-03-30 Fisher & Paykel Limited Humidifier sleep apnea treatment apparatus
CA2275889C (en) 1996-12-30 2008-03-18 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
ATE287257T1 (en) 1997-01-16 2005-02-15 Massachusetts Inst Technology PREPARATION OF PARTICLE-CONTAINING MEDICINAL PRODUCTS FOR INHALATION
DK1014943T3 (en) 1997-02-05 2002-10-14 Jago Res Ag Medical aerosol formulations
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US6192882B1 (en) 1997-02-24 2001-02-27 Aradigm Corporation Formulation and devices for monitoring the efficacy of the delivery of aerosols
US5829435A (en) 1997-02-24 1998-11-03 Aradigm Corporation Prefilter for prevention of clogging of a nozzle in the generation of an aerosol and prevention of administration of undesirable particles
US6051257A (en) 1997-02-24 2000-04-18 Superior Micropowders, Llc Powder batch of pharmaceutically-active particles and methods for making same
US5837713A (en) 1997-02-26 1998-11-17 Mayo Foundation For Medical Education And Research Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids
HU219329B (en) 1997-04-21 2001-03-28 Radelkis Elektroanalitikai Mue Ph-electrode based on glass material
US5769621A (en) * 1997-05-23 1998-06-23 The Regents Of The University Of California Laser ablation based fuel ignition
US5907075A (en) 1997-06-11 1999-05-25 The University Of Kansas Solid acid supercritical alkylation reactions using carbon dioxide and/or other co-solvents
US5906811A (en) 1997-06-27 1999-05-25 Thione International, Inc. Intra-oral antioxidant preparations
US5928520A (en) 1997-07-16 1999-07-27 Abanaki Corporation Method and apparatus for extracting ground water contaiminants
KR100289448B1 (en) 1997-07-23 2001-05-02 미즈노 마사루 Flavor generator
HUP9701284A3 (en) 1997-07-24 2005-11-28 Egyt Gyogyszervegyeszeti Gyar Use of 2,3-benzodiazepine derivatives for producing pharmaceutical compositions for treating and prophylacting illnesses and conditions connected with the endogene opioide system
US5874841A (en) * 1997-07-28 1999-02-23 Philips Electronics North America Corporation Sample-and-hold circuit for a switched-mode power supply
US6090212A (en) * 1997-08-15 2000-07-18 Micro C Technologies, Inc. Substrate platform for a semiconductor substrate during rapid high temperature processing and method of supporting a substrate
US5855564A (en) 1997-08-20 1999-01-05 Aradigm Corporation Aerosol extrusion mechanism
US6250301B1 (en) 1997-08-28 2001-06-26 Hortal Harm B.V. Vaporizer for inhalation and method for extraction of active ingredients from a crude natural product or other matrix
CN1176075A (en) 1997-08-29 1998-03-18 宋国合 Combustion-less innoxious cigarette and its preparation
US6138683A (en) 1997-09-19 2000-10-31 Thione International, Inc. Smokeless tobacco products containing antioxidants
ATE239447T1 (en) 1997-09-29 2003-05-15 Inhale Therapeutic Syst STABILIZED PREPARATIONS USABLE IN NEBULIZERS
US6390453B1 (en) * 1997-10-22 2002-05-21 Microfab Technologies, Inc. Method and apparatus for delivery of fragrances and vapors to the nose
UA46166C2 (en) 1997-11-12 2002-05-15 Баєр Акцієнгезельшафт 2-Phenyl-substituted imidazotriazinones as phosphodiesterase inhibitors, methods for their preparation and medicaments based on them
KR20010034406A (en) 1998-01-27 2001-04-25 아메리칸 사이아나미드 컴파니 2,3,4,5-Tetrahydro-1H[1,4]-benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors
US6044777A (en) 1998-02-09 2000-04-04 Walsh; Michael J. Composite metal safe and method of making
US6158431A (en) 1998-02-13 2000-12-12 Tsi Incorporated Portable systems and methods for delivery of therapeutic material to the pulmonary system
US5996589A (en) * 1998-03-03 1999-12-07 Brown & Williamson Tobacco Corporation Aerosol-delivery smoking article
CA2322193C (en) 1998-03-05 2006-10-24 Batelle Memorial Institute Pulmonary dosing system and method
EP1080720A4 (en) 1998-03-05 2002-06-05 Nippon Shinyaku Co Ltd Fat emulsions for inhalational administration
IL139008A0 (en) 1998-04-14 2001-11-25 Gen Hospital Corp Methods for treating neuropsychiatric disorders
WO1999055362A1 (en) * 1998-04-29 1999-11-04 Genentech, Inc. Spray dried formulations of igf-i
GB9810559D0 (en) 1998-05-15 1998-07-15 Bradford Particle Design Ltd Method and apparatus for particle formation
WO1999064094A1 (en) 1998-06-12 1999-12-16 Aradigm Corporation Methods of delivering aerosolized polynucleotides to the respiratory tract
US6095153A (en) 1998-06-19 2000-08-01 Kessler; Stephen B. Vaporization of volatile materials
TWI223598B (en) 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
WO2000000215A1 (en) 1998-06-29 2000-01-06 Inhale Therapeutic Systems, Inc. Particulate delivery systems and methods of use
GB9814172D0 (en) 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
US6090403A (en) 1998-08-17 2000-07-18 Lectec Corporation Inhalation therapy decongestant with foraminous carrier
CA2346029A1 (en) 1998-10-02 2000-04-13 Anthony R. Imondi Inhalation chemotherapy for prevention and treatment of metastatic tumors in the lung
US6509005B1 (en) * 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
DE19854012C2 (en) 1998-11-12 2001-05-10 Reemtsma H F & Ph Inhalable aerosol delivery system
JP2002529393A (en) 1998-11-12 2002-09-10 フランク ジー. ピルキーウィッツ, Inhalation system
DE19854007C2 (en) 1998-11-12 2001-05-17 Reemtsma H F & Ph Inhalable aerosol delivery system
CA2347856C (en) 1998-11-13 2009-02-17 Jago Research Ag Dry powder for inhalation
US6070575A (en) 1998-11-16 2000-06-06 Aradigm Corporation Aerosol-forming porous membrane with certain pore structure
JP2002529212A (en) 1998-11-16 2002-09-10 アラダイム コーポレーション Method for producing porous membranes with unique pore structure for aerosolized delivery of drugs
US6113795A (en) 1998-11-17 2000-09-05 The University Of Kansas Process and apparatus for size selective separation of micro- and nano-particles
JP3506618B2 (en) 1998-11-18 2004-03-15 ウシオ電機株式会社 Incandescent light bulb for yellow light emission
ATE251447T1 (en) 1998-12-11 2003-10-15 Pharmachemie Bv PHARMACEUTICAL PREPARATIONS FOR INHALING AN OPIOID
EP1313426A2 (en) 1998-12-24 2003-05-28 Bristol-Myers Squibb Pharma Company Succinoylamino benzodiazepines as inhibitors of a-beta protein production
EP1031347B1 (en) 1999-01-27 2002-04-17 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
AR022423A1 (en) 1999-01-27 2002-09-04 American Cyanamid Co COMPOUNDS DERIVED FROM ACIDS 2,3,4,5-TETRAHIDRO-1H- [1,4] BENZODIAZEPINA-3-HYDROXAMICS, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM, AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
US6376550B1 (en) * 1999-02-09 2002-04-23 Asta Medica Ag Pharmaceutical compositions containing tramadol for migraine
WO2000047203A1 (en) 1999-02-12 2000-08-17 Mqs, Inc. Formulation and system for intra-oral delivery of pharmaceutical agents
US6053176A (en) * 1999-02-23 2000-04-25 Philip Morris Incorporated Heater and method for efficiently generating an aerosol from an indexing substrate
WO2000051491A1 (en) 1999-03-05 2000-09-08 Battelle Memorial Institute Method for safely and effectively administering a drug by inhalation
JP2002543092A (en) 1999-04-27 2002-12-17 イーライ・リリー・アンド・カンパニー Insulin crystals for pulmonary administration
EP1143946B1 (en) 1999-04-30 2004-01-28 The Regents Of The University Of Michigan Use of benzodiazepines for treating autoimmune diseases induced by apoptosis
BR0010262A (en) 1999-05-03 2002-01-15 Battelle Memorial Institute Composition to form an aerosol, process for preparing and aerosolizing a composition, and aerosol generating device
US6428769B1 (en) 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
US6309986B1 (en) 1999-05-07 2001-10-30 S. C. Johnson & Son, Inc. Mat for dispensing volatile materials
IL146659A0 (en) 1999-05-27 2002-07-25 Acusphere Inc Porous drug matrices and method of manufacture thereof
ES2424713T4 (en) 1999-06-11 2014-01-23 Aradigm Corporation Method of producing a spray
US20020061281A1 (en) 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
JP4999245B2 (en) 1999-07-16 2012-08-15 アラディグム コーポレイション System for achieving quit smoking
US6593292B1 (en) 1999-08-24 2003-07-15 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
CA2383798A1 (en) 1999-09-07 2001-03-15 Conjuchem Inc. Pulmonary delivery for bioconjugation
DE60032003T2 (en) 1999-09-15 2007-06-06 Aradigm Corp., Hayward PORE STRUCTURES FOR LOW PRESSURE OXINATION
RU2259360C2 (en) 1999-10-15 2005-08-27 Ф.Хоффманн-Ля Рош Аг Derivatives of benzodiazepine and medicinal agent comprising thereof
ES2343124T3 (en) 1999-10-29 2010-07-23 Novartis Ag DRY POWDER COMPOSITIONS WITH IMPROVED DISPERSABILITY.
WO2001041732A1 (en) 1999-12-06 2001-06-14 Gore Stanley L Compositions and methods for intranasal delivery of active agents to the brain
DE19961300A1 (en) 1999-12-18 2001-06-21 Asta Medica Ag Storage system for medicinal products in powder form and inhaler equipped with them
DE10001035A1 (en) * 2000-01-13 2001-07-26 Bayer Ag Active ingredient chip with integrated heating element
ATE392885T1 (en) 2000-02-28 2008-05-15 Pharmakodex Ltd ADMINISTRATION SYSTEMS FOR ORAL MEDICATIONS
WO2001070054A1 (en) 2000-03-23 2001-09-27 Philip Morris Products Inc. Electrical smoking system and method
US6632047B2 (en) 2000-04-14 2003-10-14 Board Of Regents, The University Of Texas System Heater element for use in an in situ thermal desorption soil remediation system
JP2001299916A (en) 2000-04-18 2001-10-30 Kao Corp Mask-shaped inhalator
WO2001095902A1 (en) 2000-06-15 2001-12-20 Respiratorius Ab A composition comprising a combination of receptor agonists and antagonists
GB0015981D0 (en) 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
FR2812545B1 (en) 2000-08-03 2003-03-28 Air Liquide Sante Int INHALABLE DRUG AEROSOL FOR TREATMENT OR PREVENTION OF SWEETNESS
AU2002246500A1 (en) 2000-10-27 2002-07-30 Emlin Biosciences Thermal vaporizing device for drug delivery
US20030121906A1 (en) 2000-11-29 2003-07-03 Abbott Richard C. Resistive heaters and uses thereof
US6681998B2 (en) * 2000-12-22 2004-01-27 Chrysalis Technologies Incorporated Aerosol generator having inductive heater and method of use thereof
US6701921B2 (en) 2000-12-22 2004-03-09 Chrysalis Technologies Incorporated Aerosol generator having heater in multilayered composite and method of use thereof
US6799572B2 (en) 2000-12-22 2004-10-05 Chrysalis Technologies Incorporated Disposable aerosol generator system and methods for administering the aerosol
US6491233B2 (en) 2000-12-22 2002-12-10 Chrysalis Technologies Incorporated Vapor driven aerosol generator and method of use thereof
US6501052B2 (en) 2000-12-22 2002-12-31 Chrysalis Technologies Incorporated Aerosol generator having multiple heating zones and methods of use thereof
US6443152B1 (en) 2001-01-12 2002-09-03 Becton Dickinson And Company Medicament respiratory delivery device
FI20010115A0 (en) 2001-01-18 2001-01-18 Orion Corp A process for preparing nanoparticles
US6680668B2 (en) 2001-01-19 2004-01-20 Vishay Intertechnology, Inc. Fast heat rise resistor using resistive foil
US20020176841A1 (en) 2001-03-19 2002-11-28 Praecis Pharmaceuticals Inc. Pharmaceutical formulations for sustained release
US20030023638A1 (en) * 2001-05-02 2003-01-30 Weight Christopher F. Method and apparatus for processing content
US7645442B2 (en) * 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
DK1389096T3 (en) 2001-05-24 2009-06-22 Alexza Pharmaceuticals Inc Administration of opiates through an inhalation route
US20080038363A1 (en) * 2001-05-24 2008-02-14 Zaffaroni Alejandro C Aerosol delivery system and uses thereof
US20030118512A1 (en) 2001-10-30 2003-06-26 Shen William W. Volatilization of a drug from an inclusion complex
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
US7585493B2 (en) * 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
JP4680498B2 (en) * 2001-07-31 2011-05-11 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム Method and apparatus for generating evaporated liquid
US6568390B2 (en) 2001-09-21 2003-05-27 Chrysalis Technologies Incorporated Dual capillary fluid vaporizing device
US6648950B2 (en) 2001-10-15 2003-11-18 Hewlett-Packard Development Company, L.P. Electro-thermal odor-releasing inks and methods for releasing odors from the same
US6779520B2 (en) 2001-10-30 2004-08-24 Iep Pharmaceutical Devices Inc. Breath actuated dry powder inhaler
GB0126150D0 (en) 2001-10-31 2002-01-02 Gw Pharma Ltd A device method and resistive element for vaporising a substance
WO2003045484A2 (en) 2001-11-21 2003-06-05 Alexza Molecular Delivery Corporation Open-celled substrates for drug delivery
US6681769B2 (en) * 2001-12-06 2004-01-27 Crysalis Technologies Incorporated Aerosol generator having a multiple path heater arrangement and method of use thereof
US20030106551A1 (en) 2001-12-06 2003-06-12 Sprinkel F. Murphy Resistive heater formed inside a fluid passage of a fluid vaporizing device
CN1176075C (en) 2001-12-07 2004-11-17 北京燕山石油化工公司研究院 Pyrrole derivative preparation method
AU2002361742A1 (en) 2001-12-18 2003-06-30 Alexza Molecular Delivery Corporation Parental analgesic formulations comprising fentanyl and a cannabinoid receptor agonist
US6772756B2 (en) 2002-02-09 2004-08-10 Advanced Inhalation Revolutions Inc. Method and system for vaporization of a substance
US6961515B2 (en) 2002-02-15 2005-11-01 Dekko Technologies, Inc. PTC heater with flexible printed circuit board
US6728478B2 (en) 2002-02-21 2004-04-27 Dekko Heating Technologies, Inc. Heated chemical delivery system
US20060193788A1 (en) 2002-11-26 2006-08-31 Hale Ron L Acute treatment of headache with phenothiazine antipsychotics
MXPA04012161A (en) 2002-06-06 2005-04-19 Johnson & Son Inc S C Localized surface volatilization.
WO2004022128A2 (en) * 2002-09-06 2004-03-18 Chrysalis Technologies Incorporated Liquid aerosol formulations and aerosol generating devices and methods for generating aerosols
US6772757B2 (en) 2002-10-25 2004-08-10 Chrysalis Technologies Incorporated Concentric controlled temperature profile fluid vaporizing device
CA2507159A1 (en) 2002-11-26 2004-06-10 Alexza Molecular Delivery Corporation Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain
JP2006514633A (en) 2002-11-26 2006-05-11 アレックザ ファーマシューティカルズ, インコーポレイテッド Treatment of headache with antipsychotics delivered by inhalation
US7913688B2 (en) * 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
CA2526475A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
JP4869927B2 (en) 2003-08-04 2012-02-08 アレックザ ファーマシューティカルズ, インコーポレイテッド Substrates and preparation methods and uses for drug delivery devices
US20050037506A1 (en) 2003-08-04 2005-02-17 Alexza Molecular Delivery Corporation Methods of determining film thicknesses for an aerosol delivery article
WO2005061033A1 (en) 2003-12-15 2005-07-07 Alexza Pharmaceuticals, Inc. Treatment of breakthrough pain by drug aerosol inhalation
WO2005059804A2 (en) 2003-12-16 2005-06-30 Alexza Pharmaceuticals, Inc. Methods for monitoring severity of panic attacks and other rapidly evolving medical events in real-time
US7402777B2 (en) 2004-05-20 2008-07-22 Alexza Pharmaceuticals, Inc. Stable initiator compositions and igniters
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US20060032496A1 (en) 2004-08-12 2006-02-16 Alexza Molecular Delivery Corporation Inhalation actuated percussive ignition system
US20100006092A1 (en) * 2004-08-12 2010-01-14 Alexza Pharmaceuticals, Inc. Aerosol Drug Delivery Device Incorporating Percussively Activated Heat Packages
EP2246086A3 (en) 2004-08-12 2012-11-21 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heating unit
EP1809240A4 (en) 2004-10-12 2010-06-16 Alexza Pharmaceuticals Inc Cardiac safe, rapid medication delivery
WO2007079118A1 (en) 2005-12-29 2007-07-12 Molex Incorporated Heating element connector assembly with press-fit terminals
WO2008080170A1 (en) 2006-12-22 2008-07-03 Alexza Pharmaceuticals, Inc. Mixed drug aerosol compositiions
US7513781B2 (en) 2006-12-27 2009-04-07 Molex Incorporated Heating element connector assembly with insert molded strips
ES2594867T3 (en) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US20080306285A1 (en) 2007-04-27 2008-12-11 Alexza Pharmaceuticals, Inc. Heat-Labile Prodrugs
WO2009089550A1 (en) 2008-01-11 2009-07-16 Alexza Pharmaceuticals, Inc. Metal coordination complexes of volatile drugs
US20100065052A1 (en) 2008-09-16 2010-03-18 Alexza Pharmaceuticals, Inc. Heating Units
US7834295B2 (en) 2008-09-16 2010-11-16 Alexza Pharmaceuticals, Inc. Printable igniters
US20100068155A1 (en) 2008-09-16 2010-03-18 Alexza Pharmaceuticals, Inc. Reactant Formulations and Methods for Controlled Heating
US20100300433A1 (en) 2009-05-28 2010-12-02 Alexza Pharmaceuticals, Inc. Substrates for Enhancing Purity or Yield of Compounds Forming a Condensation Aerosol
US20100181387A1 (en) 2009-12-01 2010-07-22 Zaffaroni Alejandro C Aerosol delivery system and uses thereof
US20120048963A1 (en) 2010-08-26 2012-03-01 Alexza Pharmaceuticals, Inc. Heat Units Using a Solid Fuel Capable of Undergoing an Exothermic Metal Oxidation-Reduction Reaction Propagated without an Igniter
EP3838316B1 (en) 2013-07-11 2024-04-03 Alexza Pharmaceuticals, Inc. Drug delivery and drug cessation system

Patent Citations (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560607A (en) * 1962-11-30 1971-02-02 Fisons Pharmaceuticals Ltd Aerosol formulations of finely divided solid medicaments with anionic surface-active agents
US3949743A (en) * 1973-03-19 1976-04-13 Schick Incorporated Medicated vapor production method and apparatus
US4141369A (en) * 1977-01-24 1979-02-27 Burruss Robert P Noncombustion system for the utilization of tobacco and other smoking materials
US4566451A (en) * 1982-07-02 1986-01-28 Plantorgan Werk Heinrich G. E. Christensen Kg Vapor inhalation device
US4753758A (en) * 1983-05-19 1988-06-28 Intertech Resources Inc. Respiratory humidifier
US4854331A (en) * 1984-09-14 1989-08-08 R. J. Reynolds Tobacco Company Smoking article
US5027836A (en) * 1984-12-21 1991-07-02 R. J. Reynolds Tobacco Company Insulated smoking article
US5119834A (en) * 1985-04-15 1992-06-09 R. J. Reynolds Tobacco Company Smoking article with improved substrate
US4928714A (en) * 1985-04-15 1990-05-29 R. J. Reynolds Tobacco Company Smoking article with embedded substrate
US4895719A (en) * 1985-05-22 1990-01-23 Liposome Technology, Inc. Method and apparatus for administering dehydrated liposomes by inhalation
US5020548A (en) * 1985-08-26 1991-06-04 R. J. Reynolds Tobacco Company Smoking article with improved fuel element
US4989619A (en) * 1985-08-26 1991-02-05 R. J. Reynolds Tobacco Company Smoking article with improved fuel element
US5105831A (en) * 1985-10-23 1992-04-21 R. J. Reynolds Tobacco Company Smoking article with conductive aerosol chamber
US5033483A (en) * 1985-10-28 1991-07-23 R. J. Reynolds Tobacco Company Smoking article with tobacco jacket
US4756318A (en) * 1985-10-28 1988-07-12 R. J. Reynolds Tobacco Company Smoking article with tobacco jacket
US4735217A (en) * 1986-08-21 1988-04-05 The Procter & Gamble Company Dosing device to provide vaporized medicament to the lungs as a fine aerosol
US4858630A (en) * 1986-12-08 1989-08-22 R. J. Reynolds Tobacco Company Smoking article with improved aerosol forming substrate
US5133368A (en) * 1986-12-12 1992-07-28 R. J. Reynolds Tobacco Company Impact modifying agent for use with smoking articles
US4734560A (en) * 1987-01-20 1988-03-29 Medical Enterprises, Ltd. Vaporizing unit
US4819665A (en) * 1987-01-23 1989-04-11 R. J. Reynolds Tobacco Company Aerosol delivery article
US4924883A (en) * 1987-03-06 1990-05-15 R. J. Reynolds Tobacco Company Smoking article
US4848374A (en) * 1987-06-11 1989-07-18 Chard Brian C Smoking device
US5019122A (en) * 1987-08-21 1991-05-28 R. J. Reynolds Tobacco Company Smoking article with an enclosed heat conductive capsule containing an aerosol forming substance
US4906417A (en) * 1988-02-08 1990-03-06 Associated Mills Inc. Humidifier
US4853517A (en) * 1988-03-28 1989-08-01 John G. Bowen Vaporizing unit
US4922901A (en) * 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US4947875A (en) * 1988-09-08 1990-08-14 R. J. Reynolds Tobacco Company Flavor delivery articles utilizing electrical energy
US4947874A (en) * 1988-09-08 1990-08-14 R. J. Reynolds Tobacco Company Smoking articles utilizing electrical energy
US5511726A (en) * 1988-09-23 1996-04-30 Battelle Memorial Institute Nebulizer device
US4917119A (en) * 1988-11-30 1990-04-17 R. J. Reynolds Tobacco Company Drug delivery article
US4941483A (en) * 1989-09-18 1990-07-17 R. J. Reynolds Tobacco Company Aerosol delivery article
US5224498A (en) * 1989-12-01 1993-07-06 Philip Morris Incorporated Electrically-powered heating element
US5099861A (en) * 1990-02-27 1992-03-31 R. J. Reynolds Tobacco Company Aerosol delivery article
US6051566A (en) * 1991-02-09 2000-04-18 B.S.D. Bio Science Development Snc Di Omini C. & Zuccari G. Anti-reactive anti-asthmatic activity of non-steroidal anti-inflammatory drugs by inhalation
US5915378A (en) * 1993-01-29 1999-06-29 Aradigm Corporation Creating an aerosolized formulation of insulin
US5735263A (en) * 1993-01-29 1998-04-07 Aradigm Corporation Lockout device for controlled release of drug from patient-activated dispenser
US5894841A (en) * 1993-06-29 1999-04-20 Ponwell Enterprises Limited Dispenser
US5388574A (en) * 1993-07-29 1995-02-14 Ingebrethsen; Bradley J. Aerosol delivery article
US5605146A (en) * 1993-11-29 1997-02-25 Instrumentarium Oy Method and an arrangement in connection with vaporizing an anaesthetic
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US6264922B1 (en) * 1995-02-24 2001-07-24 Elan Pharma International Ltd. Nebulized aerosols containing nanoparticle dispersions
US5738865A (en) * 1995-04-07 1998-04-14 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US5758637A (en) * 1995-08-31 1998-06-02 Aerogen, Inc. Liquid dispensing apparatus and methods
US5649554A (en) * 1995-10-16 1997-07-22 Philip Morris Incorporated Electrical lighter with a rotatable tobacco supply
US6041777A (en) * 1995-12-01 2000-03-28 Alliance Pharmaceutical Corp. Methods and apparatus for closed-circuit ventilation therapy
US5918595A (en) * 1995-12-21 1999-07-06 Siemens-Elema Ab Method for vaporizing an anesthetic liquid and vaporizer operating according to the method
US5743251A (en) * 1996-05-15 1998-04-28 Philip Morris Incorporated Aerosol and a method and apparatus for generating an aerosol
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US20020037828A1 (en) * 1997-10-28 2002-03-28 Wilson Leland F. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US20020086852A1 (en) * 1998-05-14 2002-07-04 Cantor Jerome O. Method for treating respiratory disorders associated with pulmonary elastic fiber injury
US6060212A (en) * 1998-06-11 2000-05-09 Clariant Finance (Bvi) Limited 193 nm positive-working photoresist composition
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6234167B1 (en) * 1998-10-14 2001-05-22 Chrysalis Technologies, Incorporated Aerosol generator and methods of making and using an aerosol generator
US6255334B1 (en) * 1998-10-30 2001-07-03 Pfizer Inc 5HT 1 receptor agonists and metoclopramide for the treatment of migraine
US6591839B2 (en) * 1999-02-17 2003-07-15 Dieter Meyer Filter material for reducing harmful substances in tobacco smoke
US6506762B1 (en) * 1999-09-30 2003-01-14 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
US20040016427A1 (en) * 2000-04-27 2004-01-29 Byron Peter R. Method and apparatus for generating an aerosol
US20020058009A1 (en) * 2000-09-19 2002-05-16 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6514482B1 (en) * 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US20030004142A1 (en) * 2001-04-18 2003-01-02 Prior Christopher P. Use of NSAIDs for prevention and treatment of cellular abnormalities of the lung or bronchial pathway
US20030017120A1 (en) * 2001-05-24 2003-01-23 Rabinowitz Joshua D. Delivery of erectile dysfunction drugs through an inhalation route
US20030032638A1 (en) * 2001-05-24 2003-02-13 Kim John J. Delivery of benzodiazepines through an inhalation route
US20030012738A1 (en) * 2001-05-24 2003-01-16 Rabinowitz Joshua D. Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US20030012740A1 (en) * 2001-05-24 2003-01-16 Rabinowitz Joshua D. Delivery of compounds for the treatment of parkinsons through an inhalation route
US20030012737A1 (en) * 2001-05-24 2003-01-16 Rabinowitz Joshua D. Delivery of diphenhydramine through an inhalation route
US20030017119A1 (en) * 2001-05-24 2003-01-23 Rabinowitz Joshua D. Delivery of opioids through an inhalation route
US20030017116A1 (en) * 2001-05-24 2003-01-23 Rabinowitz Joshua D. Delivery of sedative-hypnotics through an inhalation route
US20030017115A1 (en) * 2001-05-24 2003-01-23 Rabinowitz Joshua D. Delivery of drug esters through an inhalation route
US20030017117A1 (en) * 2001-05-24 2003-01-23 Rabinowitz Joshua D. Delivery of analgesics through an inhalation route
US20030015190A1 (en) * 2001-05-24 2003-01-23 Rabinowitz Joshua D. Delivery of compounds for the treatment of migraine through an inhalation route
US20030017118A1 (en) * 2001-05-24 2003-01-23 Rabinowitz Joshua D. Delivery of antipsychotics through an inhalation route
US20030015189A1 (en) * 2001-05-24 2003-01-23 Rabinowitz Joshua D. Delivery of antihistamines through an inhalation route
US20040127481A1 (en) * 2001-05-24 2004-07-01 Alexza Molecular Delivery Corporation Delivery of anti-migraine compounds through an inhalation route
US20030005924A1 (en) * 2001-05-24 2003-01-09 Rabinowitz Joshua D. Delivery of beta-blockers through an inhalation route
US20030017114A1 (en) * 2001-05-24 2003-01-23 Rabinowitz Joshua D. Delivery of physiologically active compounds through an inhalation route
US20030021753A1 (en) * 2001-05-24 2003-01-30 Rabinowitz Joshua D. Delivery of antiemetics through an inhalation route
US20030021754A1 (en) * 2001-05-24 2003-01-30 Rabinowitz Joshua D. Delivery of anti-migraine compounds through an inhalation route
US20030021755A1 (en) * 2001-05-24 2003-01-30 Hale Ron L. Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route
US20030005925A1 (en) * 2001-05-24 2003-01-09 Hale Ron L. Delivery of rizatriptan or zolmitriptan through an inhalation route
US20030007933A1 (en) * 2001-05-24 2003-01-09 Rabinowitz Joshua D. Delivery of muscle relaxants through an inhalation route
US20040126328A1 (en) * 2001-05-24 2004-07-01 Alexza Molecular Delivery Corporation Delivery of compounds for the treatment of migraine through an inhalation route
US20040126326A1 (en) * 2001-05-24 2004-07-01 Alexza Molecular Delivery Corporation Delivery of antidepressants through an inhalation route
US20040126327A1 (en) * 2001-05-24 2004-07-01 Alexza Molecular Delivery Corporation Delivery of nonsteroidal antiinflammatory drugs through an inhalation route
US20030007934A1 (en) * 2001-05-24 2003-01-09 Rabinowitz Joshua D. Delivery of stimulants through an inhalation route
US20040126329A1 (en) * 2001-05-24 2004-07-01 Alexza Molecular Delivery Corporation Delivery of analgesics through an inhalation route
US20040127490A1 (en) * 2001-05-24 2004-07-01 Alexza Molecular Delivery Corporation Delivery of alprazolam, estazolam midazolam or triazolam through an inhalation route
US20040099269A1 (en) * 2001-05-24 2004-05-27 Alexza Molecular Delivery Corporation Drug condensation aerosols and kits
US20030000518A1 (en) * 2001-05-24 2003-01-02 Rabinowitz Joshua D. Delivery of nonsteroidal antiinflammatory drugs through an inhalation route
US20030062042A1 (en) * 2001-06-05 2003-04-03 Wensley Martin J. Aerosol generating method and device
US20030035776A1 (en) * 2001-06-05 2003-02-20 Hodges Craig C. Delivery of aerosols containing small particles through an inhalation route
US20030015196A1 (en) * 2001-06-05 2003-01-23 Hodges Craig C. Aerosol forming device for use in inhalation therapy
US20030091511A1 (en) * 2001-11-09 2003-05-15 Rabinowitz Joshua D. Delivery of diazepam through an inhalation route
US20030138382A1 (en) * 2001-11-21 2003-07-24 Rabinowitz Joshua D. Delivery of caffeine through an inhalation route
US6701922B2 (en) * 2001-12-20 2004-03-09 Chrysalis Technologies Incorporated Mouthpiece entrainment airflow control for aerosol generators
US20040009128A1 (en) * 2002-05-13 2004-01-15 Rabinowitz Joshua D Delivery of drug amines through an inhalation route
US20040010148A1 (en) * 2002-06-06 2004-01-15 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US20040105819A1 (en) * 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Respiratory drug condensation aerosols and methods of making and using them
US20040105818A1 (en) * 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them

Cited By (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US20040185002A1 (en) * 2001-05-24 2004-09-23 Alexza Molecular Delivery Corporation Delivery of physiologically active compounds through an inhalation route
US20040156791A1 (en) * 2001-05-24 2004-08-12 Alexza Molecular Delivery Corporation Delivery of antipsychotics through an inhalation route
US20040161385A1 (en) * 2001-05-24 2004-08-19 Alexza Molecular Delivery Corporation Delivery of beta-blockers through an inhalation route
US20040184998A1 (en) * 2001-05-24 2004-09-23 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US20040184996A1 (en) * 2001-05-24 2004-09-23 Alexza Molecular Delivery Corporation Delivery of nonsteroidal antiinflammatory drugs through an inhalation route
US7988952B2 (en) 2001-05-24 2011-08-02 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
US20040228807A1 (en) * 2001-05-24 2004-11-18 Alexza Molecular Delivery Corporation Delivery of sedative-hypnotics through an inhalation route
US8173107B2 (en) 2001-05-24 2012-05-08 Alexza Pharmaceuticals, Inc. Delivery of antipsychotics through an inhalation route
US20050075273A1 (en) * 2001-05-24 2005-04-07 Alexza Molecular Delivery Corporation Delivery of opioids through an inhalation route
US8235037B2 (en) 2001-05-24 2012-08-07 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US20050089479A1 (en) * 2001-05-24 2005-04-28 Alexza Molecular Delivery Corporation Delivery of sedative-hypnotics through an inhalation route
US20090246147A1 (en) * 2001-05-24 2009-10-01 Alexza Pharmaceuticals, Inc. Delivery Of Antipsychotics Through An Inhalation Route
US20060153779A1 (en) * 2001-05-24 2006-07-13 Alexza Pharmaceuticals, Inc. Delivery of stimulants through an inhalation route
US9211382B2 (en) 2001-05-24 2015-12-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US20060216243A1 (en) * 2001-05-24 2006-09-28 Alexza Pharmaceuticals, Inc. Delivery of Beta-Blockers Through An Inhalation Route
US20060216244A1 (en) * 2001-05-24 2006-09-28 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of parkinson's through an inhalation route
US20060233718A1 (en) * 2001-05-24 2006-10-19 Alexza Pharmaceuticals, Inc. Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US20060239936A1 (en) * 2001-05-24 2006-10-26 Alexza Pharmaceuticals, Inc. Delivery of anti-migraine compounds through an inhalation route
US20060246012A1 (en) * 2001-05-24 2006-11-02 Alexza Pharmaceuticals, Inc. Delivery of physiologically active compounds through an inhalation route
US20060251588A1 (en) * 2001-05-24 2006-11-09 Alexza Pharmaceuticals, Inc. Delivery of erectile dysfunction drugs through an inhalation route
US20060251587A1 (en) * 2001-05-24 2006-11-09 Alexza Pharmaceuticals, Inc. Delivery of analgesics through an inhalation route
US20060257329A1 (en) * 2001-05-24 2006-11-16 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
US9440034B2 (en) 2001-05-24 2016-09-13 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US20060269487A1 (en) * 2001-05-24 2006-11-30 Alexza Pharmaceuticals, Inc. Delivery of nonsteroidal antiinflammatory drugs through an inhalation route
US20070178052A1 (en) * 2001-05-24 2007-08-02 Alexza Pharmaceuticals, Inc. Delivery of opioids through an inhalation route
US10350157B2 (en) 2001-05-24 2019-07-16 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US20070014737A1 (en) * 2001-05-24 2007-01-18 Alexza Pharmaceuticals, Inc. Delivery of muscle relaxants through an inhalation route
US20060286043A1 (en) * 2001-05-24 2006-12-21 Alexza Pharmaceuticals, Inc. Delivery of antihistamines through an inhalation route
US20060280692A1 (en) * 2001-05-24 2006-12-14 Alexza Pharmaceuticals, Inc. Delivery of antipsychotics through an inhalation route
US9687487B2 (en) 2001-06-05 2017-06-27 Alexza Pharmaceuticals, Inc. Aerosol forming device for use in inhalation therapy
US9439907B2 (en) 2001-06-05 2016-09-13 Alexza Pharmaceutical, Inc. Method of forming an aerosol for inhalation delivery
US9308208B2 (en) 2001-06-05 2016-04-12 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7942147B2 (en) 2001-06-05 2011-05-17 Alexza Pharmaceuticals, Inc. Aerosol forming device for use in inhalation therapy
US11065400B2 (en) 2001-06-05 2021-07-20 Alexza Pharmaceuticals, Inc. Aerosol forming device for use in inhalation therapy
US8955512B2 (en) 2001-06-05 2015-02-17 Alexza Pharmaceuticals, Inc. Method of forming an aerosol for inhalation delivery
US8074644B2 (en) 2001-06-05 2011-12-13 Alexza Pharmaceuticals, Inc. Method of forming an aerosol for inhalation delivery
US20060257328A1 (en) * 2001-11-21 2006-11-16 Alexza Pharmaceuticals, Inc. Delivery of caffeine through an inhalation route
US20040009128A1 (en) * 2002-05-13 2004-01-15 Rabinowitz Joshua D Delivery of drug amines through an inhalation route
US8003080B2 (en) 2002-05-13 2011-08-23 Alexza Pharmaceuticals, Inc. Delivery of drug amines through an inhalation route
US7987846B2 (en) 2002-05-13 2011-08-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US20100055048A1 (en) * 2002-05-20 2010-03-04 Alexza Pharmaceuticals, Inc. Acute treatment of headache with phenothiazine antipsychotics
US20090062254A1 (en) * 2002-11-26 2009-03-05 Alexza Pharmaceuticals, Inc. Acute Treatment of Headache with Phenothiazine Antipsychotics
US20090258075A1 (en) * 2002-11-26 2009-10-15 Alexza Pharmaceuticals, Inc. Respiratory Drug Condensation Aerosols and Methods of Making and Using Them
US7981401B2 (en) 2002-11-26 2011-07-19 Alexza Pharmaceuticals, Inc. Diuretic aerosols and methods of making and using them
US8288372B2 (en) 2002-11-26 2012-10-16 Alexza Pharmaceuticals, Inc. Method for treating headache with loxapine
US8506935B2 (en) 2002-11-26 2013-08-13 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
US20040102434A1 (en) * 2002-11-26 2004-05-27 Alexza Molecular Delivery Corporation Method for treating pain with loxapine and amoxapine
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
US20050079166A1 (en) * 2003-05-21 2005-04-14 Alexza Molecular Delivery Corporation Self-contained heating unit and drug-supply unit employing same
US8387612B2 (en) 2003-05-21 2013-03-05 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US8991387B2 (en) 2003-05-21 2015-03-31 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US9370629B2 (en) 2003-05-21 2016-06-21 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US20050034723A1 (en) * 2003-08-04 2005-02-17 Bryson Bennett Substrates for drug delivery device and methods of preparing and use
US7923662B2 (en) 2004-05-20 2011-04-12 Alexza Pharmaceuticals, Inc. Stable initiator compositions and igniters
US20050258159A1 (en) * 2004-05-20 2005-11-24 Alexza Molecular Delivery Corporation Stable initiator compositions and igniters
US8333197B2 (en) 2004-06-03 2012-12-18 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US8628796B2 (en) 2004-12-09 2014-01-14 Insys Therapeutics, Inc. Room-temperature stable dronabinol formulations
US20060160888A1 (en) * 2004-12-09 2006-07-20 Insys Therapeutics, Inc. Room-temperature stable dronabinol formulations
US20070083677A1 (en) * 2005-05-18 2007-04-12 Nektar Therapeutics Valves, devices, and methods for endobronchial therapy
WO2007030162A2 (en) 2005-05-18 2007-03-15 Nektar Therapeutics Valves, devices, and methods for endobronchial therapy
US20100126502A1 (en) * 2005-08-23 2010-05-27 Aerogen, Inc. Self-sealing t-piece and valved t-piece
US20070207207A1 (en) * 2006-01-06 2007-09-06 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8252328B2 (en) 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US10507180B2 (en) 2006-01-06 2019-12-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US10342762B2 (en) 2006-01-06 2019-07-09 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US10245228B2 (en) 2006-01-06 2019-04-02 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9744129B2 (en) 2006-01-06 2017-08-29 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US20080268023A1 (en) * 2006-01-06 2008-10-30 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8231900B2 (en) 2006-01-06 2012-07-31 Acelrx Pharmaceutical, Inc. Small-volume oral transmucosal dosage
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9320710B2 (en) 2006-01-06 2016-04-26 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9289583B2 (en) 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8778393B2 (en) 2006-01-06 2014-07-15 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8778394B2 (en) 2006-01-06 2014-07-15 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8865211B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US20090131479A1 (en) * 2006-01-06 2009-05-21 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage
WO2007145868A1 (en) * 2006-06-07 2007-12-21 Wyeth Treating cystic fibrosis with antibiotics via an aerosol drug
US20070286818A1 (en) * 2006-06-07 2007-12-13 Wyeth Treating cystic fibrosis with antibiotics via an aerosol drug
US20070299687A1 (en) * 2006-06-23 2007-12-27 Pamela Palmer Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed
US20080112895A1 (en) * 2006-08-04 2008-05-15 Insys Therapeutics Inc. Aqueous dronabinol formulations
US20080299048A1 (en) * 2006-12-22 2008-12-04 Alexza Pharmaceuticals, Inc. Mixed drug aerosol compositions
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US10625033B2 (en) 2007-03-09 2020-04-21 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US11642473B2 (en) 2007-03-09 2023-05-09 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US20090181080A1 (en) * 2007-08-06 2009-07-16 Insys Therapeutics Inc. Oral cannabinnoid liquid formulations and methods of treatment
US20100065052A1 (en) * 2008-09-16 2010-03-18 Alexza Pharmaceuticals, Inc. Heating Units
US7834295B2 (en) 2008-09-16 2010-11-16 Alexza Pharmaceuticals, Inc. Printable igniters
US20110166063A1 (en) * 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of therapeutic peptides
US20110171312A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Modified therapeutic peptides, methods of their preparation and use
US9682153B2 (en) 2008-09-19 2017-06-20 Nektar Therapeutics Polymer conjugates of therapeutic peptides
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
US20100196286A1 (en) * 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US9161912B2 (en) 2008-12-23 2015-10-20 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US20100192945A1 (en) * 2008-12-23 2010-08-05 Robert Owen Cook Inhalation devices and related methods for administration of sedative hypnotic compounds
US20100300433A1 (en) * 2009-05-28 2010-12-02 Alexza Pharmaceuticals, Inc. Substrates for Enhancing Purity or Yield of Compounds Forming a Condensation Aerosol
US10786635B2 (en) 2010-08-26 2020-09-29 Alexza Pharmaceuticals, Inc. Heat units using a solid fuel capable of undergoing an exothermic metal oxidation-reduction reaction propagated without an igniter
US11839714B2 (en) 2010-08-26 2023-12-12 Alexza Pharmaceuticals, Inc. Heat units using a solid fuel capable of undergoing an exothermic metal oxidation-reduction reaction propagated without an igniter
US11484668B2 (en) 2010-08-26 2022-11-01 Alexza Pharmauceticals, Inc. Heat units using a solid fuel capable of undergoing an exothermic metal oxidation-reduction reaction propagated without an igniter
US10328229B2 (en) 2013-03-15 2019-06-25 Trudell Medical International Ventilator circuit, adapter for use in ventilator circuit and methods for the use thereof
US9642980B2 (en) 2013-03-15 2017-05-09 Trudell Medical International Ventilator circuit, adapter for use in ventilator circuit and methods for the use thereof
US11458130B2 (en) 2013-07-11 2022-10-04 Alexza Pharmaceuticals, Inc. Nicotine salt with meta-salicylic acid and applications therein
US10166224B2 (en) 2013-07-11 2019-01-01 Alexza Pharmaceuticals, Inc. Nicotine salt with meta-salicylic acid and applications therein
US9724341B2 (en) 2013-07-11 2017-08-08 Alexza Pharmaceuticals, Inc. Nicotine salt with meta-salicylic acid
US20160354561A1 (en) * 2014-02-11 2016-12-08 Timothy McCullough Methods and drug delivery devices using cannabis
US9380813B2 (en) * 2014-02-11 2016-07-05 Timothy McCullough Drug delivery system and method
US9220294B2 (en) 2014-02-11 2015-12-29 Timothy McCullough Methods and devices using cannabis vapors
US10821240B2 (en) * 2014-02-11 2020-11-03 Vapor Cartridge Technology Llc Methods and drug delivery devices using cannabis
WO2015123317A1 (en) * 2014-02-11 2015-08-20 Mccullough Timothy Methods and drug delivery devices using cannabis
US20150223523A1 (en) * 2014-02-11 2015-08-13 Timothy McCullough Drug delivery system and method
US11395891B2 (en) 2014-02-11 2022-07-26 Vapor Cartridge Technology Llc Methods and delivery devices using herbal extracts
US10661036B2 (en) 2014-02-11 2020-05-26 Timothy McCullough Methods and delivery devices using herbal extracts
US10034990B2 (en) 2014-02-11 2018-07-31 Vapor Cartridge Technology Llc Drug delivery system and method
US9408986B2 (en) * 2014-02-11 2016-08-09 Timothy McCullough Methods and devices using cannabis vapors
US11511054B2 (en) 2015-03-11 2022-11-29 Alexza Pharmaceuticals, Inc. Use of antistatic materials in the airway for thermal aerosol condensation process
US11241383B2 (en) 2016-12-09 2022-02-08 Alexza Pharmaceuticals, Inc. Method of treating epilepsy
US11717479B2 (en) 2016-12-09 2023-08-08 Alexza Pharmaceuticals, Inc. Method of treating epilepsy
US11497249B2 (en) 2019-09-16 2022-11-15 Vapor Cartridge Technology Llc Drug delivery system with stackable substrates

Also Published As

Publication number Publication date
HK1068293A1 (en) 2005-04-29
CZ20033223A3 (en) 2004-07-14
HUP0401948A2 (en) 2005-01-28
DE60236430D1 (en) 2010-07-01
WO2002098390A2 (en) 2002-12-12
HUP0401008A2 (en) 2004-08-30
AU2002311923B2 (en) 2007-05-17
IL158954A0 (en) 2004-05-12
CA2646756A1 (en) 2002-12-12
HK1068268A1 (en) 2005-04-29
JP2004532881A (en) 2004-10-28
AU2007207865A1 (en) 2007-09-06
HUP0401948A3 (en) 2008-04-28
PL373836A1 (en) 2005-09-19
EP1392381A1 (en) 2004-03-03
US7766013B2 (en) 2010-08-03
EP1392381B1 (en) 2011-03-30
PL374048A1 (en) 2005-09-19
US20130276779A1 (en) 2013-10-24
US9308208B2 (en) 2016-04-12
US20090229600A1 (en) 2009-09-17
US20140066618A1 (en) 2014-03-06
CN1512900A (en) 2004-07-14
US20110240013A1 (en) 2011-10-06
US20170281884A1 (en) 2017-10-05
JP2005503846A (en) 2005-02-10
CA2447354C (en) 2008-12-02
CA2447210A1 (en) 2002-12-12
US20140060532A1 (en) 2014-03-06
AU2002311926B2 (en) 2007-12-06
JP4510438B2 (en) 2010-07-21
CA2447210C (en) 2007-09-11
EP1392263A2 (en) 2004-03-03
JP2010057950A (en) 2010-03-18
WO2002098389A8 (en) 2006-10-12
MXPA03011269A (en) 2004-03-18
US20150157635A1 (en) 2015-06-11
EP1392242A1 (en) 2004-03-03
US20100294268A1 (en) 2010-11-25
US8955512B2 (en) 2015-02-17
ES2343678T3 (en) 2010-08-06
US20030035776A1 (en) 2003-02-20
US20110240022A1 (en) 2011-10-06
IL158955A0 (en) 2004-05-12
US9439907B2 (en) 2016-09-13
CA2447081C (en) 2010-02-23
ATE503516T1 (en) 2011-04-15
WO2002098496A1 (en) 2002-12-12
US6682716B2 (en) 2004-01-27
US20030062042A1 (en) 2003-04-03
CN1514719A (en) 2004-07-21
US20030015196A1 (en) 2003-01-23
US7942147B2 (en) 2011-05-17
CN100496458C (en) 2009-06-10
NZ529296A (en) 2008-07-31
AU2007231750A1 (en) 2007-11-29
WO2002098389A1 (en) 2002-12-12
NZ529298A (en) 2008-03-28
US9687487B2 (en) 2017-06-27
JP4912566B2 (en) 2012-04-11
US20030051728A1 (en) 2003-03-20
WO2002098390A3 (en) 2003-02-20
AU2007207865B2 (en) 2010-06-03
CN1304067C (en) 2007-03-14
US20030015197A1 (en) 2003-01-23
MXPA03011268A (en) 2004-03-18
CZ20033249A3 (en) 2004-05-12
US11065400B2 (en) 2021-07-20
DE60239604D1 (en) 2011-05-12
CA2447081A1 (en) 2002-12-12
JP2004529724A (en) 2004-09-30
US7537009B2 (en) 2009-05-26
US8074644B2 (en) 2011-12-13
EP1392381B9 (en) 2011-09-14
CA2447354A1 (en) 2002-12-12
ATE468105T1 (en) 2010-06-15
EP1392242B1 (en) 2010-05-19
CA2646756C (en) 2010-10-26
AU2007231750B2 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
US11065400B2 (en) Aerosol forming device for use in inhalation therapy
AU2002311923A1 (en) An aerosol forming device for use in inhalation therapy
AU2002311926A1 (en) Method of forming an aerosol for inhalation delivery
CN100551458C (en) The aerocolloidal forming device that is used for anapnotherapy
AU2002315076A1 (en) Delivery of aerosols containing small particles through an inhalation route

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALEXZA PHARMACEUTICALS, INC., CALIFORNIA

Free format text: CHANGE OF NAME;ASSIGNOR:ALEXZA MOLECULAR DELIVERY CORPORATION;REEL/FRAME:016926/0674

Effective date: 20050720

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION